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 Abstract 
 
The work presented in this thesis aimed at unravelling novel modes of 
antimicrobial action through: i) the study of Staphylococcus aureus defences 
against nitric oxide, an antimicrobial weapon of the innate immune system, namely 
by performing the biochemical characterisation of S. aureus NO-detoxifying 
flavohaemoglobin and analysing the conditions under which the enzyme is 
operative; ii) the identification of the mechanisms beyond the antibacterial activity 
of azole antibiotics towards S. aureus that were shown to include the increase of 
endogenous reactive oxygen species triggered by the binding of imidazoles to 
flavohaemoglobin; and iii) the discovery of a novel type of bactericides, the carbon 
monoxide-releasing molecules, and identification of its potential cellular targets via 
analysis of the transcriptional response of Escherichia coli to CORM-2, a carbon 
monoxide-releasing molecule known to mimic the physiological function of carbon 
monoxide. 
Microbes have the ability to defend themselves against an array of 
antimicrobial products that are generated within phagocytic cells, including nitric 
oxide. Flavohaemoglobins are NO-metabolising enzymes and although it is well 
established that they are involved in nitric oxide detoxification the dioxygen-related 
conditions whither their enzymatic activity is operative remain a matter of debate. 
S. aureus is a pathogen that displays a high level of drug-resistance and has 
the ability to survive inside neutrophils. To address the S. aureus defence 
mechanisms toward nitrosative stress, the flavohaemoglobin gene was disrupted 
and its resistance to nitric oxide evaluated. To unmask the physiological conditions 
that enable S. aureus flavohaemoglobin to metabolise NO, the growth of S. aureus 
flavohaemoglobin null mutant was analysed under different NO/dioxygen 
conditions. The flavohaemoglobin protein was also cloned, expressed and purified 
which allowed the biochemical and spectroscopic characterisation. It was observed 
that: i) the over-expression of S. aureus flavohaemoglobin in the flavorubredoxin 
null mutant of E. coli, a strain susceptible to the deleterious effects of nitric oxide, 
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provides protection to E. coli cells against nitrosative stress under anaerobic 
conditions; ii) the highest induction of the flavohaemoglobin transcription is 
observed when S. aureus is grown under microaerobic conditions; and iii) a S. 
aureus strain deleted in flavohaemoglobin is susceptible to nitrosative stress 
exclusively under microaerobic conditions. These novel data have important 
implications since it shows that under physiological conditions S. aureus 
flavohaemoglobin utilises a NO denitrosylase mechanism. 
S. aureus flavohaemoglobin was also demonstrated to be involved in the 
antimicrobial action of imidazoles antibiotics as the deletion of the 
flavohaemoglobin gene increases the resistance of S. aureus to imidazoles. To 
address the mechanism by which flavohaemoglobin increases S. aureus sensitivity 
to imidazoles, the binding of imidazoles to the purified flavohaemoglobin protein 
was analysed. Spectroscopic studies showed that imidazoles are able to bind the 
ferric and ferrous haem of flavohaemoglobin. Furthermore, the ligation of 
flavohaemoglobin to miconazole, the most active imidazole against S. aureus, leads 
to the amplification of superoxide production by the protein with consequent 
increase of the endogenous content of reactive oxygen species. 
To examine the effect of flavohaemoglobin on the survival of miconazole-
treated S. aureus cells in the presence of nitric oxide, the viability of S. aureus wild 
type and flavohaemoglobin null mutant was analysed after phagocytosis by LPS- 
and INF-γ-activated macrophages. The results showed that miconazole reduces 
the survival of S. aureus wild type, whereas the viability of miconazole-treated S. 
aureus flavohaemoglobin null mutant is higher. When S. aureus wild type and 
flavohaemoglobin null mutant infect macrophages in which the production of nitric 
oxide is inhibited by L-NMMA, similar results were obtained. In fact, the S. aureus 
cells expressing flavohaemoglobin display lower resistance to miconazole when 
compared to cells lacking the flavohaemoglobin gene. 
Based on the higher content of intracellular reactive oxygen species and 
decreased viability of S. aureus cells expressing flavohaemoglobin and treated with 
miconazole, it is proposed that the generation of reactive oxygen species that 
occurs upon binding of imidazoles to flavohaemoglobin is one of the mechanisms 
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by which imidazoles decrease S. aureus survival. The fact that imidazoles inhibit 
the NO denitrosylase activity of flavohaemoglobin shows that the azole ligation to 
flavohaemoglobin also contributes to a lower ability of S. aureus for defence 
against nitrosative stress. 
The carbon monoxide-releasing molecules named CO-RMs were identified as a 
novel group of bactericides. CO-RMs contain a transition metal coordinated to 
carbonyl groups and have the ability of liberating carbon monoxide to the 
biological systems. Several studies indicate that CO-RMs mitigate the beneficial 
effects of carbon monoxide on eukaryotic cells, but their role in bacteria had never 
been evaluated. The work presented herein shows for the first time that CO-RMs 
possess antimicrobial activity against Gram-negative and Gram-positive bacteria, as 
demonstrated by the significant decrease of cell viability of E. coli and S. aureus 
cells treated with CO-RMs. Furthermore, their effectiveness is reinforced towards 
bacteria grown under low levels of dioxygen.  
Inductively coupled plasma mass spectrometry analysis revealed that after 
exposure to CO-RMs, E. coli cells display higher metal content than untreated 
ones, which indicates that CO-RMs are able to accumulate inside the bacterial cells 
where they release carbon monoxide to the cellular targets. 
The antimicrobial effect of CO-RMs was shown to be related to the release of 
carbon monoxide since: i) the antimicrobial effect is abolished when carbon 
monoxide of CO-RMs is sequestered upon addition of haemoglobin to the cultures; 
ii) the inactive form of CO-RMs, a CO depleted form of the compound, does not 
have bactericidal effect; and iii) bacterial viability is lower after treatment with CO 
gas.  
To address the mechanism that underpin the antimicrobial action of CO-RMs 
and to identify the bacterial targets, a transcriptomic analysis of E. coli exposed to 
tricarbonyldichlororuthenium (II) dimer, known as CORM-2, was performed. DNA 
microarray results obtained for E. coli cells grown aerobically showed that CORM-2 
down-regulates the transcription of multiple enzymes of the citric acid cycle and 
up-regulates several methionine-related genes, indicating that the biological 
processes most affected by CORM-2 are the aerobic respiration and the methionine 
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biosynthesis. The phenotypic analysis of E. coli mutant strains in metR, the 
regulator of methionine biosynthesis, and in metI and metN, both described as 
involved in methionine transport confirmed that MetR, MetI and MetN, contribute 
to the lower susceptibility of E. coli toward CORM-2. 
The data obtained for E. coli cells grown anaerobically revealed that upon 
exposure to CORM-2 the transcription of glycolytic enzymes is inhibited while 
several heat-shock proteins, chaperones, and proteases are induced, indicating 
that the pathways more affected by CORM-2 include the glycolysis and the protein 
folding. To address the function of protein homeostasis-related genes in the E. coli 
CORM-2 susceptibility, the phenotype of ibpAB and cpxP null mutant strains was 
analysed in the presence of CORM-2. The results showed that ∆ibpAB and ∆cpxP 
display elevated sensitivity to CORM-2 under anaerobic conditions, which reveal 
that IbpAB and CpxP are involved in the resistance to CORM-2. 
The analysis of the results obtained for cells of E. coli grown aerobically and 
anaerobically revealed a common set of genes regulated by CORM-2. 
Independently of the presence of dioxygen, CORM-2 alters the transcription of 
several regulators namely, frmR, zntR, narP, gadX, soxS and OxyR, which are 
involved in the response to formaldehyde, zinc, nitrate/nitrite, acid and oxidative 
stress, respectively. Phenotypic analysis of the soxS null mutant, a strain that 
exhibits an increase of susceptibility to CORM-2 under aerobic and anaerobic 
conditions, revealed that SoxS plays an important role in protection against CORM-
2 under both oxygen growth conditions. The deletion of oxyR decreases the 
viability of E. coli cells grown aerobically, indicating that OxyR has also a major 
function in protection against CORM-2. These results suggest that CORM-2 may 
participate in the intracellular generation of reactive oxygen species. 
Since it was detected that CORM-2 affects the transcription of several genes 
involved in biofilm production, the evaluation of the total biofilm formed by E. coli 
cells in the presence of CORM-2 was done. The results revealed that CORM-2 does 
increase the biofilm production. To gain insight into the CO-RM-related function of 
biofilm-associated genes, the susceptibility to CORM-2 of bshA and tqsA null 
mutants was analysed. It was observed that the deletion of bshA increases the 
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resistance of E. coli to CORM-2, while the total biofilm formed upon exposure to 
CORM-2 is similar to that of the wild type. The deletion of tqsA decreases the 
sensitivity of E. coli to CORM-2 and abolishes the increase of biofilm formation 
trigged by the presence of CORM-2. Hence, TsqA participates in the formation of 
biofilm induced by CORM-2 and both TsqA and BshA contribute to the sensitivity of 
E. coli cells to CORM-2. 
In conclusion, the results present in this thesis contribute to a better 
understanding of the role of S. aureus flavohaemoglobin as a fundamental 
bacterial enzyme involved in the detoxification of nitric oxide and reveal its 
potential as an antibiotic target, due to its involvement in the antibacterial activity 
of azoles antibiotics. A novel type of bactericides, the carbon monoxide-releasing 
molecules that strongly decrease the viability of Gram-negative and Gram–positive 
bacteria were discovered and several potential bacterial targets that contribute to 
CO-RMs antimicrobial action were identified. Therefore, this thesis addressed new 
strategies to combat the emergence and spread of drug-resistant pathogens, 
which due to the ineffectiveness of currently available antibiotics represents a 
concern for public health. 
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 Resumo 
 
O trabalho apresentado nesta tese teve como objectivo desvendar novos 
modos de acção antibacteriana através: i) do estudo das defesas de 
Staphylococcus aureus contra o óxido nítrico, uma arma antibacteriana usada pelo 
sistema imunitário inato, nomeadamente pela caracterização bioquímica da 
flavohemoglobina de S. aureus e pela análise das condições nas quais a atividade 
da flavohemoglobina opera; ii) da identificação dos mecanismos pelos quais os 
azoles reduzem a viabilidade de S. aureus, os quais incluem o aumento da 
produção endógena de espécies reativas de oxigénio desencadeado pela ligação 
dos imidazoles à flavohemoglobina; e iii) da descoberta de um novo tipo de 
bactericidas, as moléculas libertadoras de monóxido de carbono, e da identificação 
de potenciais alvos celulares através da análise da resposta transcriptional de 
Escherichia coli ao CORM-2, uma molécula libertadora de monóxido de carbono, a 
qual mimetiza as funções fisiológicas do monóxido de carbono. 
Os micróbios têm a capacidade de se defenderem contra uma série de 
produtos com acção antimicrobiana que são gerados dentro das células fagociticas, 
os quais incluem o óxido nítrico. As flavohemoglobinas são enzimas que 
metabolisam o óxido nítrico, e embora esteja bem estabelecido que elas estão 
envolvidas na destoxificação do óxido nítrico, as condições de oxigénio em que a 
sua actividade catalítica opera é uma questão em debate. 
S. aureus é uma bacteria patogénea que exibe um nível alto de resistência 
a antibióticos e tem a capacidade de sobreviver dentro dos neutrófilos. Para 
estudar quais os mecanismos de defesa que S. aureus dispõe para se defender 
contra o stress nitrosativo, o gene da flavohemoglobina foi interrompido e sua 
resistência ao óxido nítrico foi avaliada. Para conhecer as condições fisiológicas nas 
quais a flavohemoglobina de S. aureus consegue metabolizar o óxido nítrico, o 
crescimento de S. aureus foi analisado em diferentes condições de NO/oxigénio. A 
proteína também foi clonada, expressa e purificada de modo a proceder-se à sua 
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caracterização bioquímica. Foi observado que: i) a sobre-expressão da 
flavohemoglobina de S. aureus no mutante da flavorubredoxina de E. coli, uma 
estirpe suscetível aos efeitos nocivos do óxido nítrico, confere protecção às células 
de E. coli contra o stress nitrosativo, em condições anaeróbias; ii) o maior 
aumento da transcrição do gene da flavohemoglobina é observado quando S. 
aureus é crescida em condições microaeróbias; e iii) a estirpe de S. aureus 
deletada no gene da flavohemoglobina é suscetível ao stress nitrosativo 
exclusivamente em condições microaeróbias. Estes novos dados tem importantes 
implicações uma vez que mostram que nas condições fisiológicas a 
flavohemoglobina de S. aureus utiliza o mecanismo de NO denitrosilase. 
Foi ainda demonstrado que a flavohemoglobina de S. aureus está 
envolvida na acção antimicrobiana dos antibióticos imidazoles uma vez que a 
deleção do gene da flavohemoglobina aumenta a resistência de S. aureus aos 
imidazoles. Para descobrir o mecanismo através do qual a flavohemoglobina 
aumenta a sensibilidade de S. aureus aos imidazoles, a ligação dos imidazoles à 
flavohemoglobina foi analisada. Estudos espectroscópicos mostraram que os 
imidazoles ligam-se ao ferro do hemo da proteina no estado férrico e no ferroso. A 
ligação do miconazol, o imidazol mais activo contra S. aureus, leva à amplificação 
da produção de superoxido pela proteína e aumenta consequentemente o 
conteúdo endógeno de espécies reativas de oxigénio em células de S. aureus que 
expressam a flavohemoglobina. 
Para examinar o efeito da flavohemoglobina na sobrevivência das células 
de S. aureus tratadas com o miconazol na presença de óxido nítrico, a viabilidade 
da estirpe selvagem e da estirpe mutada no gene da flavohemoglobina de S. 
aureus foi analisada depois de as bacterias terem sido fagocitadas pelos 
macrofagos, tendo sido estes previamente activados por lipopolissacarídeos e pelo 
interferão-γ. Os resultados mostraram que o miconazol reduz a sobrevivência da 
estirpe selvagem de S. aureus, enquanto que a sobrevivência da estirpe mutada no 
gene da flavohemoglobina é maior. Quando a estirpe selvagem e a estirpe mutada 
no gene da flavohemoglobina de S. aureus infetam os macrofagos, nos quais a 
produção de óxido nítrico foi inibida pelo L-NMMA, resultados semelhantes foram 
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obtidos. De facto, as células de S. aureus que expressam a flavohemoglobina 
apresentam uma menor resistência ao miconazol do que as células que não 
contêm o gene que codifica a flavohemoglobina. 
Baseado no alto conteúdo intracelular de espécies reativas de oxigénio e 
na reduzida viabilidade que as células de S. aureus exibem quando expressam a 
flavohemoglobina e são tratadas com o miconazol, é proposto que a geração de 
espécies reativas de oxigénio que ocorre após a ligação dos imidazoles à 
flavohemoglobina seja um dos mecanismos através dos quais os imidazoles 
diminuem a sobrevivência de S. aureus. Uma vez que os imidazoles inibem a 
actividade de NO denitrosilase da flavohemoglobina, a ligação desses compostos à 
flavohemoglobina, também reduz a defesa de S. aureus contra o stress nitrosativo, 
o que contribui para a diminuição da viabilidade bacteriana. 
As moléculas libertadoras de monóxido de carbono denominadas de CO-
RMs foram identificadas como um novo grupo de bactericidas. Os CO-RMs são 
constituidos por um metal de transição coordenado a grupos carbonil e tem a 
capacidade de libertar monóxido de carbono nos sistemas biológicos. Vários 
estudos mostraram que os CO-RMs mimetizam os efeitos benéficos de monóxido 
de carbono em células eucarióticas, mas o seu papel em bactérias nunca tinha sido 
avaliado. O trabalho apresentado, mostrou, pela primeira vez, que os CO-RMs 
possuem atividade antimicrobiana contra bactérias Gram-negativas e Gram-
positivas, como concluido pela diminuição acentuada da viabilidade das células de 
E. coli e de S. aureus tratadas com os CO-RMs. Além disso, a eficácia dos CO-RMs 
é maior quando as bactérias são crescidas em baixos níveis de oxigénio. 
A determinação do conteúdo de metais nas células de E. coli tratadas com 
os CO-RMs revelou que as células expostas aos CO-RMs apresentam uma maior 
concentração de metais do que as células não tratadas, o que indica que os CO-
RMs podem se acumular dentro das células bacterianas onde libertam o monóxido 
de carbono para os alvos celulares. 
O efeito bactericida dos CO-RMs está relacionado com a libertação de 
monóxido de carbono uma vez que: i) o efeito antimicrobiano é abolido quando o 
monóxido de carbono dos CO-RMs é sequestrado pela adição da hemoglobina às 
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culturas; ii) a forma inactiva dos CO-RMs, um composto que não contém grupos 
CO, não tem efeito bactericida; e iii) a viabilidade bacteriana é reduzida pelo 
tratamento com CO gás. 
Para comprender o mecanismo subjacente à ação antimicrobiana dos CO-
RMs e identificar os seus potenciais alvos, foi efectuada a análise transcriptomica 
de E. coli exposta ao CORM-2. Os resultados obtidos para as células de E. coli 
crescidas aerobicamente mostraram que o CORM-2 reprime a transcrição de 
múltiplas enzimas do ciclo do ácido cítrico e induz vários genes relacionados com a 
metionina, o que indica que os processos biológicos mais afectados por CORM-2 
são a respiração aeróbica e a biossíntese da metionina. A análise fenotípica do 
mutante de E. coli no gene metR, o regulador de biossíntese da metionina, e nos 
genes metI e metN, ambos descritos como sendo genes envolvidos no transporte 
da metionina, confirmaram que o MetR, o MetI e o MetN, contribuiem para a 
redução da susceptibilidade de E. coli ao CORM-2. 
Os dados obtidos para células de E. coli crescidas anaerobicamente e 
expostas ao CORM-2 revelou que a transcrição de enzimas glicolíticas foi repressa 
enquanto que genes codificando para proteínas de choque térmico, chaperões e 
proteases foram induzidos, o que indica que os processos mais afectados pelo 
CORM-2 incluem a glicólise e o enrolamento de proteínas. Para avaliar a função de 
genes relacionados com a homeostase de proteínas na susceptibilidade de E. coli 
ao CORM-2, o fenótipo de estirpes mutadas nos genes ibpAB e cpxP foi analisado 
na presença de CORM-2. Os resultados mostraram que a deleção desses genes 
aumentou a sensibilidade ao CORM-2 em condições anaeróbias, o que revela que o 
IbpAB e o CpxP estão involvidos na resistência ao CORM-2. 
A análise comparativa dos resultados obtidos para células de E. coli 
crescidas aerobica e anaerobicamente revelou um conjunto de genes que são 
comumente regulados pelo CORM-2. Independentemente da presença de oxigénio, 
o CORM-2 alterou a transcrição de vários reguladores nomeadamente, frmR, zntR, 
narP, gadX, soxS e OxyR, os quais estão envolvidos na resposta ao formaldeído, 
zinco, nitrato/nitrito, ácido e ao stress oxidativo, respectivamente. A análise 
fenotípica do mutante no gene soxS, uma estirpe que exibe um aumento da 
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suscetibilidade ao CORM-2 em condições aeróbias e anaeróbias, revelaram que o 
SoxS tem um papel importante na proteção contra CORM-2 em ambas as 
condições de oxigénio usadas no crescimento. A deleção do gene oxyR, diminui a 
viabilidade das células de E. coli crescidas aerobicamente, indicando que o OxyR 
também tem uma função importante na proteção contra o CORM-2. Estes 
resultados sugerem que o CORM-2 poderá participar na geração intracelular de 
espécies reativas de oxigénio. 
Uma vez que também foi detetado que o CORM-2 afeta a transcrição de 
vários genes implicados na produção do biofilme, o biofilme formado em células de 
E. coli na presença de CORM-2 foi avaliado. Os resultados revelaram que CORM-2 
aumenta a produção de biofilme. Para compreender a função dos genes regulados 
pelo CORM-2 e involvidos na formação do biofilme, a susceptibilidade ao CORM-2 
das estirpes mutadas no gene bhsA e no tqsA foi analisada. Observou-se que a 
deleção do gene bshA aumenta a resistência de E. coli ao CORM-2, enquanto que 
o biofilme formado após o tratamento com o CORM-2 foi semelhante ao obtido 
para a estirpe selvagem. A deleção do gene tqsA diminui a sensibilidade de E. coli 
ao CORM-2 e abole o aumento do biofilme induzido pela presença de CORM-2. Por 
isso, TqsA participa na formação de biofilme induzido pelo CORM-2 e tanto TqsA 
como BhsA contribuem para a sensibilidade das células de E. coli ao CORM-2. 
Em conclusão, os resultados apresentados nesta tese contribuiram para 
um melhor conhecimento do papel da flavohemoglobina de S. aureus, uma enzima 
fundamental envolvida na destoxificação do óxido nítrico e revela o seu potencial 
como alvo de antibióticos, devido ao seu envolvimento na atividade antibacteriana 
dos azoles. Um novo tipo de bactericidas, as moléculas libertadoras de monóxido 
de carbono, as quais diminuem a viabilidade de bactérias Gram-negativas e Gram-
positivas foram descobertos e vários potenciais alvos bacterianos que contribuiem 
para a sua ação antimicrobiana foram identificados. Portanto, esta tese contribuiu 
para revelar novas estratégias para combater o aparecimento e desenvolvimento 
de bactérias resistentes a antibióticos o que, devido à ineficácia dos actuais 
antibióticos, representa uma preocupação para a saúde pública. 
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 Abbreviations 
 
∆ Deletion 
ALF 062 Pentacarbonyl bromide 
ALF 021 Bromo(pentacarbonyl)manganese 
ATP Adenosine triphosphate 
BMPO 5-tert-butoxycarbonyl 5-methyl-1-pyrroline N-oxide 
bp Base pair 
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1.1 Staphylococcus aureus  
The name staphylococcus is derived from the Greek term "staphyle" meaning 
"a bunch of grapes". This name refers to its spherical shape (about 1 μm in 
diameter) arranged in pairs, short chains, or bunched in irregular groups which 
resemble a grape-like cluster (Figure 1.1A) [1]. The name aureus had its 
etymological origin in the Latin and means gold. The assigned name is associated 
with bacterium appearance as Staphylococcus aureus form large, round and yellow 
colonies on agar plates (Figure 1.1B) [2]. 
Staphylococci are very common in the environment and are highly resistant to 
hostile conditions, such as heat, desiccation, or salinity. They are readily dispersal 
in dust particles through the air and are often commensals on the skin or mucosa 
of humans and animals [3]. S. aureus is the best-known member of the 
staphylococci genus and is commonly associated with human diseases [4]. S. 
aureus is the only staphylococci that produces the enzyme coagulase, which 
differentiates it from the other species and is also catalase positive which allow to 
distinguished staphylococci from enterococci and streptococci infections [1, 4]. 
A            B 
 
 
FIGURE 1.1 S. aureus. (A) Scanning electron microscope image of S. aureus (D. Scharf, 
http://www.scharfphoto.com). (B) S. aureus colonies (K. Hedetniemi and M. Liao, Furman University; 
ASM MicrobeLibrary.org). 
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S. aureus is a Gram-positive bacterium with a low GC content (~ 33 %) that 
can grow either in oxygenated environments or under low levels of dioxygen, 
being considered as a facultative anaerobe [4]. The most common habitat of S. 
aureus is the upper respiratory tract, especially the nose, throat, and the skin 
surface. Therefore, it is often part of the normal flora of the nasopharynx of 
healthy individuals (about 20 % of the population are long-term carriers of S. 
aureus) [5]. 
S. aureus is the most virulent staphylococci species, been frequently 
associated with pathological conditions ranging from mild skin infections to life-
threatening diseases, including pneumonia, osteomyelitis, meningitis, arthritis, 
toxic shock syndrome and septicemia [4]. S. aureus is also a major veterinary 
pathogen associated with infections of an array of farm animals [6, 7]. 
S. aureus infections can be either acquired in the community and in 
association with health care, since injuries that compromise epithelial integrity, 
cause trauma, the surgical interventions, as well as viral infections can lead to S. 
aureus tissue invasion. Therefore, this pathogen has great importance in human 
medicine and the enhanced virulence that S. aureus has acquired through lateral 
gene transfer results most of the time in antibiotic resistance [8, 9]. In fact, no 
longer after the introduction of the first antibiotic (penicillin), the first staphylococci
resistant strains appear (Table 1.1), 
and by late 1960s more than 80 % of 
both community and hospital-acquired 
staphylococcal isolates were resistant 
to penicillin [10-12]. More importantly 
was the emergency of methicillin- 
resistant S. aureus strains (MRSA). 
Methicillin is a penicillin derivative, 
which was introduced in 1961, and no 
  
TABLE 1.1 Drugs and S. aureus 
resistance occurrence. 
Drug 
Year drug 
introduction 
Years to 
report 
resistance 
Penicillin 1941 1-2 
Methicillin 1961 <1 
Vancomycin 1956 40 
Adapted from [13] 
more than one year had passed until the first case of MRSA was reported (Table 
1.1) [13]. Although methicillin is no longer in use, the term MRSA continues to be 
 Resistance of S. aureus to oxidative and nitrosative stress 
____________________________________________________________________________________ 
 7 
used to describe S. aureus strains resistant to all penicillins. MRSA strains are now 
worldwide spread, having a high impact on human health [14, 15]. 
The antibiotic vancomycin has been used as a drug of "last resort" to the 
treatment of serious, life-threatening infections caused by S. aureus and others 
Gram-positive bacteria [16]. However in 1997, the first report of vancomycin 
intermediate-resistant S. aureus (VISA) was identified in Japan and additional 
cases were subsequently reported in other countries (Table 1.1) [17, 18]. The
occurrence of infections caused by vancomycin-resistant S. aureus (VRSA) is of 
great concern because, in general, these strains are also resistant to the other 
currently available antibiotics [12]. Nevertheless, most of S. aureus soft skin 
infections are susceptible to clindamycin or trimethoprim-sulfamethoxazole oral 
treatment, while intravenous therapies with vancomycin, daptomycin and linezolid 
are required to treat severe S. aureus infections [19]. 
 
TABLE 1.2 S. aureus completed sequenced genomes. 
S. aureus 
Accession 
Number 
Length 
(nt) 
Proteins RNAs Genes 
Relevant 
Characteristics 
NCTC 8325 NC_007795 2821361 2892 77 2969 MSSA 
MSSA476 NC_002953 2799802 2571 104 2715 MSSA 
COL NC_002951 2809422 2612 72 2723 MRSA 
MRSA252 NC_002952 2902619 2650 101 2839 MRSA 
MW2 NC_003923 2820462 2624 80 2704 MRSA 
N315 NC_002745 2814816 2583 79 2664 MRSA 
USA300_FPR3757 NC_007793 2872769 2560 70 2648 MRSA 
USA300_TCH1516 NC_010079 2872915 2654 88 2799 MRSA 
Newman  NC_009641 2878897 2614 73 2687 MRSA 
JH1 NC_009632 2906507 2747 81 2870 VISA 
JH9 NC_009487 2906700 2697 81 2816 VISA 
Mu3 NC_009782 2880168 2690 78 2768 VISA 
Mu50 NC_002758 2878529 2696 77 2774 VISA 
RF122 NC_007622 2742531 2509 76 2663 Bovine pathogen 
ED98 NC_013450 2824404 2661 82 2752 Avian pathogen 
MSSA: Methicillin-sensitive S. aureus  
MRSA: Methicillin-resistant S. aureus 
VISA: Vancomycin-intermediate S. aureus (MIC 8–16 µg/ml [12])  
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The dissemination of multidrug-resistant S. aureus represents a difficult 
therapeutic problem, specially because no vaccine is yet available [12, 20]. To 
date, the genome of 15 S. aureus clinical strains were sequenced and published 
(Table 1.2) [8]. 
 
1.2 Weapons of the innate immunity against invading 
pathogens 
The mammalian immune system is constituted by innate and adaptive 
defence mechanisms and both work together protecting the host cells against 
microbial infections [21]. The innate immunity is mediated by pattern recognition 
receptors (e.g. Toll-like receptors), which bind components of the microbial cell 
wall such as lipopolysaccharides (LPS), peptidoglycans and lipoteichoic acids while 
the adaptive response is mediated by antigen receptors [21]. 
 
TABLE 1.3 Antimicrobial products of human phagocytes. 
Product Neutrophils Macrophage* 
Myeloperoxidase + - 
Lactoferrin + - 
Bacterial permeability increasing factor + - 
Serprocidins  
(elastase, cathepsin G, protease 3, azurocidin) 
+ - 
Phospholipase A2 + - 
Cathelicidin + - 
Lysozyme + - 
Defensins 1-4 + - 
Reactive oxygen species + + 
Reactive nitrogen species + + 
* Monocytes contain some of the antimicrobial proteins of neutrophils before differentiation into macrophages 
Adapted from [22] 
 
The innate immunity is constituted by several components being phagocytes 
(e.g. macrophages and neutrophils) a key element whose primary function is to 
engulf, destroy the pathogens and digest their remains [4, 21]. On encountering 
bacteria, phagocytes engulf microbes into a phagosome, which fuses with 
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intracellular granules, e.g. lysosome, to form a phagolysosome. The first strategy 
of intracellular defence of phagocytes includes pathogen compartmentation and 
the generation of high concentrations of antimicrobials (Table 1.3) in an 
environment with low nutrient availability, low pH (~4.8) and iron limitation [23].  
 
 
FIGURE 1.2 Schematic representation of a phagolysosome generating reactive nitrogen 
and oxygen species. NO synthase (NOS) and NADPH oxidase (Phox) leads to the production of nitric 
oxide (•NO) and superoxide (O2
•-) respectively. Superoxide is dismutated by superoxide dismutase 
(SOD) releasing hydrogen peroxide (H2O2), which in turn is converted into radical hydroxyl (
•OH) and 
hydroxide ion (OH-) by the Fenton reaction or is used by myeloperoxidase (MPO) to synthesise 
hypochlorous acid (HOCl). MPO also catalyses the reduction of nitrite (NO2
-) to nitrogen dioxide (•NO2). 
Superoxide reacts with •NO generating peroxynitrite (OHOO-). Peroxynitrite is decomposed into •OH and 
nitrogen dioxide (•NO2) or react with carbon dioxide (CO2) producing carbonate (CO3
•-) and •NO2. 
•NO 
also reacts with dioxygen (O2) forming nitrogen trioxide (N2O3). Ferroportin (Nramp) pumps Fe
2+ and 
Mg2+ out of the phagosomal lumen and granules release their content (e.g. lysozyme, cathepsins) into 
the phagosome.  
 
The sequestration of iron is an important strategy since iron is essential for 
cell metabolism and protection against oxidative stress [23]. Phagocytes decrease 
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the accessibility of iron by: i) releasing lactoferrin, an iron chelator present in 
granules that sequester iron in the phagosome [24]; ii) down-regulating the 
expression of transferrin receptor and ferritin, which is a high affinity receptor for 
iron and an iron storage protein, respectively [25]; and iii) removing ferrous iron 
from phagosomal lumen to the cytosol through ferroportin, an iron transporter that 
can also act as a manganese efflux pump [26, 27]. Within the phagolysosome 
bacteria are killed by several antimicrobial products (Table 1.3), including reactive 
oxygen (ROS) and reactive nitrogen species (RNS) (Figure 1.2) [28]. ROS and RNS 
are considered essential as antimicrobial agents of the immune system, since the 
simultaneously deletion of the induced nitric oxide synthase and NADPH oxidase 
results in massive death of mice caused by spontaneous infections with commensal 
microorganisms [29].  
 
1.2.1 Oxidative stress 
 
Production of reactive oxygen species 
Oxygen toxicity has been associated with the over-production of superoxide, 
which leads to the production of others reactive oxygen species (Table 1.4) [30]. 
 
TABLE 1.4 Examples of reactive oxygen species. 
Radicals Non-radicals 
Superoxide (O2
•-) Hydrogen peroxide (H2O2) 
Hydroxyl (•OH) Hypochlorous acid (HOCl) 
Peroxyl (ROO•)  
Alkoxyl (RO•)  
Hydroperoxyl (HOO•)  
Adapted from [30]  
 
In phagocytes, the major source of reactive oxygen species is NADPH oxidase 
(Phox). This enzyme catalyses the reduction of dioxygen to superoxide leading to a 
burst of oxidative stress (Equation 1.1) [31, 32]. In resting cells, the Phox subunits 
(gp91, p21, p67, p47, and Rac) are present in phagocytes but are dissociated from 
each other. Upon phagocytosis, the cytosolic components (p67, p47 and Rac) are 
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translocated to the phagosome and assembled in the phagocyte membrane were 
the membrane components are located (gp91 and p21) which facilitated the 
formation of superoxide in the phagosomal lumen [33].  
 
EQUATION 1.1   2 O2 + NADPH  2 O2
- + NADPH+ + H+ 
 
EQUATION 1.2   2 O2
- + 2 H+  O2 + H2O2 
 
EQUATION 1.3   Cl- + H2O2  OCl
- + H2O 
 
Superoxide dismutates spontaneously by reacting with itself (in a pH-
dependent fashion) or enzymatically by superoxide dismutase (SOD), and both 
reactions lead to the formation of hydrogen peroxide and dioxygen (Equation 1.2) 
[32]. In eukaryotes two types of superoxide dismutase have been identified: a 
copper-zinc and a manganese-enzyme; the Cu-Zn superoxide dismutase is 
cytoplasmic and its expression is constitutive while the Mn-SOD is located in the 
mitochondria and is inducible by stress conditions [32]. In neutrophils, but not in 
macrophages, hydrogen peroxide together with chloride is converted into 
hypochlorous acid (Equation 1.3) by myeloperoxidase (MPO).  
Hydroxyl radical, a highly oxidising species is formed by the reaction of 
superoxide with hypochlorous acid (Equation 1.4) or with hydrogen peroxide, a 
reaction described by Haber and Weiss (Equation 1.5) that is catalysed by 
transition metals (e.g. iron). In this reaction, superoxide firstly reduces ferric iron 
to the ferrous state forming dioxygen and subsequently hydrogen peroxide reacts 
with ferrous iron to form hydroxide and the hydroxyl radical while iron is reoxidised 
[34]. The latter reaction is denominated Fenton reaction and is the major source of 
hydroxyl radicals in the biological systems (Equation 1.6). 
 
EQUATION 1.4   HOCl + O2
•-  O2 + Cl
- + •OH 
 
EQUATION 1.5  O2
•- + H2O2  O2 + 
•OH + OH- 
 
EQUATION 1.6   H2O2 + Fe
2+  •OH + OH- + Fe3+ 
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Antimicrobial action of reactive oxygen species: DNA, lipid and 
protein damage 
Several evidences demonstrated the importance of reactive oxygen species in 
pathogen elimination. For example, a Phox-deficient macrophage is unable to 
restrict Salmonella typhimurium infection and is susceptible to several other 
pathogens, including S. aureus [35, 36] and mice deficient in MPO exhibit higher 
sensitivity to Candida albicans infection [32, 37]. On the other hand, the deletion 
of bacterial systems involved in the detoxification of reactive oxygen species 
(discussed forward) increases the susceptibility of pathogens to the killing by 
phagocytes [38, 39]. 
An imbalance between ROS production and antioxidant defences results in 
cellular oxidative stress, which causes damage to all type of biomolecules, 
including DNA, lipids and proteins. Much of the damage is caused by hydroxyl 
radicals [40]. 
 
DNA 
Superoxide or hydrogen peroxide, at physiological levels do not react with 
DNA. However, the negatively charged of DNA molecules are prone to the binding 
of metal ions, namely iron and copper. The binding of metals to DNA favours the 
site-specific generation of hydroxyl radicals that are able to attack sugars, purines 
and pyrimidines on DNA, generating a multitude of products. For example, 
hydroxyl radical attacks the carbon-8 of guanine, generating a 8-hydroxyguanine 
radical, which is oxidised to 8-hydroxyguanine or reduced to give a ring-opened 
product (2,6-diamino-4-hydroxy-5-formamidopyrimidine) [40]; the abstraction of a 
hydrogen atom from the ring of thymine results in a radical that is converted into 
thymine peroxides or attacks the sugar moiety forming carbon-centred radicals, 
which in the presence of dioxygen are converted in sugar peroxyl radicals. The 
exposition of DNA to ROS results in single and double breaks in the backbone, 
adducts of base and sugar groups, and also cross-links to other molecules, 
interfering with the DNA repair, replication and transcription mechanisms [30].  
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Lipids 
Polyunsaturated fatty acids in membranes are susceptible to the attack by 
hydroxyl radical which leads to the initiation of lipid peroxidation [40]. Lipid 
peroxidation is a process that is initiated by the abstraction of a hydrogen atom 
from an unsaturated lipid (LH) by a radical species (R•) yielding a lipidic radical (L•) 
(Equation 1.7). Once formed the lipidic radical, it reacts with dioxygen to form the 
lipidic peroxyl radical (LOO•) (Equation 1.8), which is the central specie in the 
propagation of lipid peroxidation (Equation 1.8-9) [41]. Therefore, a single 
initiation event can lead to the formation of multiple molecules of peroxyl radicals. 
The primary effect of lipid peroxidation is a decrease in membrane fluidity, which 
alters membrane proprieties and disrupts the membrane-bound proteins leading to 
the loss of membrane integrity [30]. As polyunsaturated fatty acids are degraded a 
variety of products are formed, namely aldehydes, which are very reactive 
molecules that damage other biomolecules such as proteins. For example, the 4-
hydroxy-2-nonenal, a highly toxic product of lipid peroxidation, is a potent inhibitor 
of mitochondrial respiration by inhibiting -ketoglutarate dehydrogenase, an 
enzyme of the citric acid cycle that catalyses the conversion of -ketoglutarate to 
succinyl-CoA [40, 42]. 
 
EQUATION 1.7  LH + R•  L• + RH  
 
EQUATION 1.8  L• + O2  LOO
• 
 
EQUATION 1.9  LOO• + LH  LOOH + L•  
 
Proteins 
Proteins are susceptible to be oxidised by ROS, which leads to modifications of 
amino acid side chains and consequently to the protein structure alteration.  
Thiol groups are highly susceptible to be attack by ROS, and therefore, 
methionine and cysteine amino acids residues of proteins are particularly proned to 
be damaged by ROS. The oxidation of sulphydryl groups forms thyl radicals, 
especially in the presence of transition metals (Equation 1.10), which generates 
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disulphides (Equation 1.11). For example, methionine is oxidised by the hydroxyl 
radical to methionine sulphoxide (Table 1.5) [40]. 
 
EQUATION 1.10  RSH + Cu2+  RS• + 2 H+ + Cu+ 
 
EQUATION 1.11  2 RSH  RS-SR + 2 H+ + 2 e- 
 
Irreversible oxidation of amino acid residues occurs when a radical (e.g. 
hydroxyl) reacts with an -hydrogen atom of an amino acid to form a carbon 
center radical, which in the presence of dioxygen forms an alkoxyl radical that 
causes cleavage of the peptide bond. In the absence of dioxygen, the carbon 
centered radical selft reacts generating protein-protein cross-linked derivates [40]. 
For example, tyrosine residues are hydroxylated to dihydroxyphenylalanine or the 
reaction of two tyrosine radicals results in bityrosine. Several other products of 
protein oxidation are shown in Table 1.5 [30].  
 
TABLE 1.5 Amino acids oxidation products. 
Amino acid Oxidation product 
Arginine Glutamic semialdehyde 
Cysteine Disulphides, cysteic acid 
Histidine 2-oxohistidine, asparagines, aspartic acid 
Lysine 2-aminoadipic semialdehyde 
Methionine Methionine sulfoxide, methionine sulfone 
Phenylalanine 2-3-dihydroxyphenylalanine, 2-, 3- and 4-hydroxyphenylalanine 
Proline 2-pyrrolidone, 4- and 5-hydroxyproline pyroglutamic acid, glutamic semialdehyde 
Threonine 2-amino-3-ketobutyric acid 
Tryptophan 2-, 4-, 5-, 6-, and 7-hydroxytryptophan 
Tyrosine 3,4-dihidroxyphenylalanine, tyrosine-tyrosine cross-linkages 
Adapted from [40] 
 
Iron-sulphur (Fe-S) clusters are present in several proteins that participate in 
many cellular processes and are very susceptible to ROS [43]. The [4Fe-4S] 
clusters of dehydratases are the primary intracellular target of ROS, since their 
clusters are substantially exposed to the solvent [44]. Superoxide and hydrogen 
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peroxide are small enough to invade the active site, to which they coordinate 
oxidising the Fe-S cluster. The loss of one or more iron ions causes the 
degradation of the cluster and, consequently, the inhibition of enzyme activity. 
Furthermore,  the release of iron contributes to the increase of oxidative stress via 
the Fenton reaction (Equation 1.6) [30, 45-47]. 
In Escherichia coli it has been shown that superoxide is able to damage Fe-S-
containing proteins that are involved in citric acid cycle (e.g. aconitase and 
fumarase), in amino acids biosynthesis (e.g. dihydroxyacid dehydratase) and in 
DNA synthesis (e.g. ribonucleotide reductase) [47, 48]. 
 
Microbial defences against oxidative stress 
Microbes are able to counteract the toxic effects of ROS through the action of 
scavenging substrates (e.g. glutathione, ascorbic acid, -tocopherol), DNA and 
proteins repairing systems, and detoxification systems [49]. 
Superoxide dismutase, catalase, alkyl hydroperoxidase reductase and 
glutathione peroxidase are important detoxification systems that afford protection 
against oxidative stress [50].  
Superoxide dismutase efficiently dismutates superoxide into dioxygen and 
hydrogen peroxide (Equation 1.2). Four types of prokaryotes superoxide 
dismutases have been identified: the copper-zinc type (Cu/Zn-SOD), the 
manganese type (Mn-SOD), the iron type (Fe-SOD) and the nickel type (Ni-SOD) 
[17, 32]. Most bacteria possess two types of SODs: the Fe-SOD and Mn-SOD. The 
two enzymes are cytoplasmic and while the first is constitutive expressed the 
second is frequently induced by dioxygen and other stress agents (e.g. metals) 
[51]. The bacterial Cu/Zn-SOD are periplasmic and, as their eukaryotic 
counterparts, are constitutively expressed. The Ni-SOD has been identified in 
Streptomyces coelicolor, and its expression is induced by nickel [52, 53].  
Catalases participate in the removal of hydrogen peroxide by converting it into 
dioxygen and water (Equation 1.12) [54, 55]. Deletion of this enzymatic system 
has been shown to increase the sensitivity of bacterial cells to hydrogen peroxide 
and the extension of DNA damage [56]. 
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EQUATION 1.12   2 H2O2  O2 + 2 H2O  
 
Alkyl hydroperoxidase reductase and glutathione peroxidase reduce toxic 
organic hyperoxides (e.g. linoleic acid and cumene peroxide) to the corresponding 
alcohols. In addition, both enzymes are able to reduce hydrogen peroxide and 
peroxynitrite [57-60]. However, while alkyl hydroperoxidase reductase uses 
NADH(P)H as electron donor, glutathione peroxidase reaction is coupled to the 
oxidation of reduced glutathione [30]. The importance of these systems is 
evidenced in several microbial models. For example, the disruption of alkyl 
hydroperoxide reductase increases the susceptibility of S. typhimurium to cumene 
hydroperoxide, an oxidising agent that promotes lipid peroxidation [57], whereas 
the deletion of glutathione peroxidase increases the sensitivity of Neisseria 
meningitidis to paraquat (a potent superoxide generator) and decreases the 
pathogenecity of Streptococcus pyogenes in murine models of infection [58, 61].  
 
1.2.2 Nitrosative stress 
 
Production of nitric oxide in biological systems 
Nitric oxide (NO) is produced non-enzymatically by mild acidification of nitrite 
(Equation 1.13-15). This source of NO is proposed to contribute to the killing of 
pathogens especially in the stomach and in urine [62].  
 
EQUATION 1.13   NO2
- + H+  HNO2 
 
EQUATION 1.14  2HNO2  N2O3 + H2O 
 
EQUATION 1.15  N2O3  NO + NO2  
 
The major source of endogenous production of NO occurs enzymatically 
through the oxidation of L-arginine to citruline catalysed by NO synthase (NOS) 
(Figure 1.3) [63, 64]. NOSs are constituted by two domains: an oxygenase and a 
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reductase domain, which are linked by a regulatory calmoduline binding domain. 
The oxygenase domain contains a haem as the active center that binds the L- 
arginine substrate. The reductase domain binds co-factors and provides electrons 
from NADPH, via FAD and FMN, for L-arginine [64]. The synthesis of NO occurs in 
the presence of tetrahydrobiopterin (BH4) via two sequential monooxygenase 
reactions (Figure 1.3) [63]. Mammalians contain three types of NOS: the 
endothelial, the neural and the inducible (eNOS, nNOS and iNOS, respectively) 
[65]. The two first isoforms are constitutively expressed and their activity depend 
 
FIGURE 1.3 Synthesis of NO by NOS. L-
arginine is first oxidised to Nω-OH-L-arginine, 
which is further oxidised to L-citruline releasing 
NO. Both reactions require dioxygen and the 
NADPH is used as electron-donor. Adapted from 
[63]. 
 
on calcium concentrations, while the 
activity of the last one is calcium-
independent and inducible by stimulus 
such as cytokines (e.g. IFN-γ) and 
microbial products (e.g. LPS) [63, 65]. 
Another important difference between 
these enzymes is the amount and the 
duration of NO produced by each one 
[49]. eNOS and nNOS release 
picomoles of NO during some minutes, 
whereas iNOS can produce NO up to 
five days when care is taken to 
replenish both the inductive stimuli and 
the L-arginine substrate reaching the 
concentration of NO the micromolar 
levels [63]. NO has a high diffusion 
coefficient (3300 µm2s-1), and due to its
lipophilic character and small size it diffuses across the biological membranes by 
passive transport. Consequently, the diffusion distance of NO from NO-releasing 
cells is 100-200 µm [66, 67]. At concentrations as low as those present in vascular 
or neural cells, NO has been shown to be involved in numerous biological 
processes such as signalling messenger, vasodilatation, inhibition of platelet 
aggregation, blood pressure regulation and neurotransmission [68-72]. At high 
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concentrations, like the ones produced by iNOS, NO plays an important role in 
pathogen eradication (see below) [73-75]. 
 
In bacteria, NO can be also produced by NOS activity. Bacterial NOS proteins 
are smaller than their mammalian counterparts and do not contain the reductase 
domain which is essential to supply electrons during NO biosynthesis [76]. There 
are few reports on bacterial NOS and although most of the enzymes, so far 
identified, lack the reductase domain they successfully produce NO in vitro when 
provided with an electron donor, such as hydrogen peroxide, or with a mammalian 
reductase domain [77]. Nevertheless, bacterial genomes encode many reductases 
that might support the NOS activity. One example is the YkuNP reductase from 
Bacillus subtilis that bears NOS activity in vitro [78]. Recently, Gusarov and co-
workers have shown that NO is indeed produced in vivo in B. subtilis [76]. 
Furthermore, the S. aureus NOS was purified in an intact functional form that 
contains a reductase subunit and the enzyme was shown to produce NO [79]. 
Although the physiological function of endogenous mammalian NO production is 
well established, the role of NOS enzymes in bacterial system remains to be 
elucidated [68].  
 
NO is also generated in bacterial cells during the bacterial denitrification 
process. Denitrification is an anaerobic respiration in which N-oxide, instead of 
dioxygen, serves as the electron acceptor for the generation of an electrochemical 
gradient across the cytoplasmic membrane [80, 81]. During denitrification, nitrate 
is enzymatically and successively reduced via nitrite, NO and nitrous oxide to 
dinitrogen gas (Figure 1.4) [80]. 
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FIGURE 1.4 Enzymatic reactions involved in denitrification. Nitrate (NO3
-) is reduced to 
nitrite (NO2
-) by NO3
- reductase. Nitrite is reduced, via the NO2
- reductase, to nitric oxide (NO), which is 
reduced to nitrous oxide (N2O) by NO reductase. Nitrous oxide yields dinitrogen gas (N2) by the reaction 
of the N2O reductase. Adapted from [80]. 
 
Although all the genes encoding the enzymes mentioned in Figure 1.4 are 
found in denitrifying bacteria, nitrate and nitrite reductase are also found in 
pathogenic bacteria and its function is associated with the persistence of 
pathogens in anaerobic environments [81, 82]. For example, N. gonorrhoeae 
contains a nitrite reductase, which has been associated with the ability of the 
bacteria to growth under anaerobic conditions, using nitrite as a terminal electron 
acceptor. Nitrate reductase of Mycobacterium bovis, an obligate aerobe that 
encodes both a nitrate and a nitrite reductase has been shown to be essential for 
the persistence of M. bovis in the lungs, liver, and kidneys of mice [83, 84]. 
 
Reactivity of nitric oxide 
The chemical proprieties of NO (Table 1.6) were firstly described in 1772 by 
Joseph Priestley  and until the mid-1980s it was considered only as an atmospheric 
pollutant [85]. The discovery of NO as the endothelium-derived relaxing factor 
changed the perception of NO as a toxic to a molecule of mount importance 
involved in a wide range of biological processes [68-70, 86]. These findings 
initiated a new era for NO biology and, in 1992, NO was elected the molecule of 
the year by Science and in 1998, R. F. Furchgott, L. J. Ignarro and F. Murad won 
the Nobel Prize in Physiology or Medicine for their discoveries on NO as a signalling 
molecule (http://nobelprize.org/nobel_prizes/medicine) [87]. 
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NO is a diatomic paramagnetic molecule that, at room temperature and 
atmospheric pressure, is a colourless gas, slightly soluble in water (Table 1.6) and 
approximately nine times more soluble in organic solvents [67, 88]. 
NO is a free radical, that has one unpaired electron in an anti-bonding  
orbital and, in spite of its radical character, is considered a relatively stable radical 
when compared  with  other species (Table 1.7). The product of one-electron 
reduction of NO is the 
nitroxyl ion (NO-), which is 
isoelectronic to dioxygen, 
whereas the removal of the 
unpaired electron of NO 
yields the nitrosonium cation 
(NO+) that is isoelectronic 
with carbon monoxide. 
Although NO is quite difficult 
to oxidise and its reduction 
 
 
TABLE 1.6 Chemical and physical 
proprieties of NO. 
Property Value 
Interatomic distance (pm) 115 
Melting point (ºC) -163.6 
Boiling point (ºC) -151.8 
Density (g/L) 1.34 
Solubility in water (mM) 2* 
* at room temperature 
Adapted from [89] 
 
is rather unfavourable, the interconversion of NO into NO- and NO+ can occur 
under physiological conditions, and therefore the three species must be considered 
in order to fully account for its biological activity. The nitroxyl ion is an unstable 
molecule, with a short lifetime in solution (order of milliseconds), that rapidly 
decomposes to give nitrous oxide. The nitrosonium cation has a even smaller 
lifetime (~ 3 x 10-10 seconds) been rapidly hydrolysed, in aqueous solutions, to 
give nitrous acid [90]. 
 
TABLE 1.7 Halflife and reactivity of oxygen and nitrogen species. 
Reactive species 
Half-life 
(s) 
Reaction rate 
(M-1s-1) 
Hydroxyl radical (•OH) 10-9 109-1010 
Peroxynitrite anion (ONOO-) 0.05-1.0 102 
Peroxyl radical (ROO•) 7 103 
Nitric oxide (•NO) 1-10 <101 
Superoxide anion (O2
•-) hours (by SOD 10-6) 101 
Adapted from Mascio. P. (personal communication) 
 Resistance of S. aureus to oxidative and nitrosative stress 
____________________________________________________________________________________ 
 21 
NO reacts with others radicals and gives rise to species of greater reactivity 
and toxicity, the so-called reactive nitrogen species, which have a relevant role in 
biological processes. Among them, is the oxidant peroxynitrite that results from the 
reaction of NO with superoxide (Equation 1.16). This reaction is extremely fast (~7 
x 109 M-1s-1) and occurs at a rate higher than the superoxide decomposition 
catalysed by superoxide dismutase (Equation 1.2) [91]. Peroxynitrite can form 
peroxynitrous acid, an unstable molecular and reactive oxidising species that yields 
hydroxyl and nitrogen dioxide radicals [90].  
The chemistry of NO in the presence of molecular oxygen is complex due to 
the large number of parallel occurring reactions. NO reacts rapidly with dioxygen to 
form nitrogen dioxide (Equation 1.17). Nitrogen dioxide has an unpaired electron, 
been unlike NO, a potent oxidant. In aqueous solution, nitrogen dioxide may react 
with another NO molecule yielding dinitrogen trioxide (Equation 1.18), which is the 
anhydride of nitrous acid and therefore the product of the reaction of NO with 
dioxygen in aqueous solution is indeed nitrite. With air, nitrogen dioxide dimerises 
to give dinitrogen tetroxide (Equation 1.19), which when dissolved in water forms 
nitrite and nitrate [92]. 
 
EQUATION 1.16   NO + O2
•-  ONOO− 
 
EQUATION 1.17   2NO + O2  2NO2 
 
EQUATION 1.18   NO + NO2  N2O3  
 
EQUATION 1.19   NO2 + NO2  N2O4  
 
Cellular targets of reactive nitrogen species 
The ability of the host to control microbial proliferation and elimination is 
linked with its ability to induce the production of NO by iNOS since it has been 
demonstrated that: i) the in vitro treatment with NO gas or organochemical NO 
donors decreases the viability of several microorganisms [63, 68]; ii) in sites of 
infection of animal models the expression of iNOS is augmented [93]; iii) NOS 
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inhibitors contribute to worsen the course of several diseases caused by bacteria 
[63]; and iv) mice deficient in iNOS are more susceptible to infection caused by a 
wide number of intracellular pathogens such as Salmonella enterica [49]. 
The antimicrobial action of NO generated by iNOS have been attributed to the 
NO radical as well as to the several NO-derivatives products (Figure 1.2), which 
are highly toxic to biological components. RNS react with cellular components, like 
DNA, lipids, proteins-containing metals, thiols, and aromatic residues, leading to 
several cell damage (Figure 1.5). 
 
 
 
 
 
 
 
FIGURE 1.5 Microbial cellular targets 
of reactive nitrogen species. Adapted from 
[93] 
 
DNA 
NO by itself cannot damage DNA since in vitro experiments indicated that NO 
requires the presence of dioxygen to deaminate DNA [94]. However, RNS like 
nitrogen trioxide and peroxynitrite cause DNA injuries. Nitrogen trioxide nitrosates 
amines on DNA bases to form N-nitrosamines leading to deamination, mispairing 
and cross-links. For example, guanine can be deaminated by nitrogen trioxide to 
form xanthine and the mispairing of xanthine causes a G:C to A:T transition. 
Alternatively, xanthine can be depurinated to form an abasic site which is cleaved 
by endonucleases given rise to single strand breaks [95]. Peroxynitrite oxidises 
DNA causing single-strand breaks by attacking the sugar-phosphate backbone 
[96]. Unlike nitrogen trioxide, which can react with adenine, guanine and cytosine, 
the peroxynitrite preferentially reacts with guanine, and the two main products 
from the reaction of deoxyguanosine with peroxynitrite are 8-oxo-deoxyguanosine 
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and 8-nitro-deoxyguanosine. The first product is known to also causes G:C to A:T 
mutations and the second rapidly depurinates leading to the formation of abasic 
bases sites [95].  
 
Lipids  
NO is not a strong oxidant and cannot begin the lipid peroxidation. However, 
in presence of superoxide or dioxygen NO forms peroxynitrite and the nitrogen 
dioxide radical, respectively (Equation 1.16-17), and both are powerful oxidising 
species capable of initiating and propagating lipid peroxidation [41, 97, 98]. NO 
also reacts with organic peroxyl radicals generating alkyl peroxynitrite (LOONO) 
(Equation 1.20), which recombines to give unreactive alkyl nitrates (LONO2) 
(Equation 1.21) or produces through homolytic cleavage, alkoxyl (LO•) and 
nitrogen dioxide radicals (Equation 1.22). 
 
EQUATION 1.20  •NO + LOO•  LOONO 
 
EQUATION 1.21  LOONO  LONO2 
 
EQUATION 1.22  LOONO  LO• + •NO2 
 
Although the radicals formed by homolytic cleavage of LOONO are expected 
to contribute to the propagation of lipid peroxidation, the major product, LONO2, 
does not [99, 100]. Therefore, through radical-radical reactions, NO can also act as 
an inhibitor of lipid peroxidation and, in fact, it has been shown that NO is 104-105 
times a more potent peroxyl radical scavenger than -tocopherol [101]. 
Nevertheless, NO will react more rapidly with superoxide than with organic peroxyl 
radicals and hence the oxidant proprieties of NO should prevail [91, 99]. 
 
Proteins 
The thiol groups of cysteine and methionine residues are among the most 
important protein targets of NO, and under anaerobic conditions this reaction 
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generates disulphide and nitrous oxide (Equation 1.23) [102]. NO also reacts with 
thiyl radical species to form S-nitrosothiols (Equation 1.24) [92]. 
 
EQUATION 1.23  2 RSH + 2 NO  RSSR + N2O + H2O 
 
EQUATION 1.24  •NO + RS•  RSNO 
 
In the presence of dioxygen, NO is oxidised to species containing NO+ which 
display high electrophilicity and reactivity towards nucleophilic centers. The 
predominant nitrosating agent arising from NO at physiological pH is nitrogen 
trioxide which is a strong 
electrophile able to 
nitrosylate thiols and 
amines. However, under 
physiological conditions, 
nitrosylation of sulphur 
(S-nitrosylation) (Figure 
1.6A) is preferred over 
nitrogen (N-nitrosylation) 
[90, 103]. The S-
nitrosylation of sulphydryl 
groups leads to the 
formation of S- 
nitrosothiols (Figure 
1.6A), which also contain 
 
 
FIGURE 1.6 Schematic representation of 
nitrosothiols adducts formation. NO is oxidised by dioxygen 
to species containing NO+ such as N2O3, that S-nitrosylate 
sulfhydryl groups forming S-nitrosothiols (upper panel). S-
nitrosothiols are also able to transfere its NO+ group to thiol-
containing proteins/peptides in a process named 
transnitrosylation (lower panel).  
the NO+ group and therefore are able to nitrosylate thiol groups generating others 
S-nitrosothiols in a process named transnitrosylation (Figure 1.6B). The NO- 
species also display reactivity toward thiol groups, particularly when in the 
presence of ferrous iron or other transition metals [90, 103]. 
S-nitrosoglutathione (GSNO) is the most abundant S-nitrosothiol in eukaryotic 
cells (in a concentration range of µM) and is formed by the nitrosylation of 
glutathione, a tripeptide with potent antioxidant proprieties that is composed by 
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glutamic acid, cysteine and glycine [103, 104]. In bacteria, glutathione is found 
predominantly in Gram-negative species and among the Gram-positive, so far, only 
the steptococcus and enterococcus species are able of producing glutathione 
[105]. Nevertheless, most bacteria encounter GSNO intracellularly at the sites of 
infections, since glutathione and NO are present in host cells at high 
concentrations. In particular, glutathione reaches concentrations as high as 10 mM 
in eukaryotic cells [106].  
GSNO participates in protein transnitrosylation through NO+ chemistry, and its 
homolytic cleavage, which occurs in the presence of cellular reductants and 
transition metals, generates NO. However, the transnitrosylation reaction of S-
nitrosothiols generally occurs more rapidly than its decomposition [107, 108].  
 
The aromatic residues tyrosine, tryptophan, phenylalanine and histidine are 
susceptible to oxidation (Table 1.5). Peroxynitrite, by reacting with carbon dioxide 
(Figure 1.2), mediates the nitration of tyrosine groups yielding 3-nitrotyrosine in a 
two-step reaction in which the carbonate abstracts a hydrogen atom from a 
tyrosine residue, generating a tyrosyl radical that reacts with nitrogen dioxide 
[100]. Nitration has an important role in biological systems since it is an 
irreversible process. In particular, the nitration of one tyrosine residue per subunit 
of the adenylated glutamine synthetase leads to the complete loss of the enzyme 
activity [109, 110]. 
 
NO binds to most transition metal-containing proteins [89, 111]. Of notable 
importance in biological processes is the reaction of NO with iron, particularly the 
reaction with the iron of haem groups and with iron-sulphur centers. Like other 
gaseous molecules, such as dioxygen and carbon monoxide, NO binds reversibly to 
ferrous haem (Equation 1.25) [112]. For example, the binding of NO to the ferrous 
haem of cytochrome c oxydase results in the impairment of the respiration [113]. 
In contrast to molecular oxygen and carbon monoxide, NO also binds to ferric 
haem forming ferrous-nitrosonium complex (Equation 1.26) [114]. The binding of 
NO to the ferric haem is less tightly than that to ferrous iron; however, once 
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bound, the latter reaction is less reversible [112]. An example of the deleterious 
effects of NO is observed upon binding to catalase that contains a ferric haem 
center, which leads to inhibition of the enzyme and consequently decreased of the 
cellular resistance to oxidative stress (see 1.2.1) [115]. NO also reacts with oxy-
haem complexes generating nitrate and ferric haem (Equation 1.27), a reaction 
that occurs typically with haemoglobins [112]. 
 
EQUATION 1.25  NO + Fe2+   Fe2+―NO 
 
EQUATION 1.26  NO + Fe3+  Fe3+―NO (Fe2+―NO+) 
 
EQUATION 1.27  Fe3+―O2
•- + NO  Fe3+―ONOO-  Fe3+ + NO3
- 
 
The reaction of NO with iron-sulphur centers results in the formation of 
dinitrosyl-iron-dithiol complexes (DNIC) (Figure 1.7), which have been detected in 
biological systems that have a high content of NO (e.g. macrophages and 
tumors) [112]. As stated before, 
dehydratases contain a [4Fe-4S] 
center, in which the iron is very 
exposed to solvent and therefore 
they are a class of enzymes prone to 
be also damaged by NO [116]. The 
most studied example is aconitase, a 
  
 
FIGURE 1.7 Dinitrosyl-iron-dithiol 
complex.  
key enzyme in the citric acid cycle that catalyses the conversion of citrate and 
isocitrate into aconitate [117]. The formation of DNIC leads to the disruption of the 
Fe-S center causing the inhibition of aconitase activity [118-120]. 
 
Bacterial defence against nitrosative stress 
The three major known NO-metabolising enzymes are the NO reductases, the 
flavodiiron proteins and the globin-like proteins, that include the 
flavohaemoglobins (discussed in 1.4) [121-123].  
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Bacterial NO reductases (NORs) reduce NO to nitrous oxide and can be set 
into two distinct groups: one is the cytochrome bc-type complex which is typically 
found in denitrifiers [124]; the other group only contains a cytochrome b-type 
component and is present in several non denitrifiers pathogens [121]. The role of 
NORs in the protection against nitrosative stress is well established. For example, 
the nor mutant of N. meningitidis displays higher susceptibility to exogenously 
added NO and NO-related compounds and exhibits impaired survival within 
nasopharyngeal mucosa [125, 126]. Similar results were report for a nor deficient 
mutant of Pseudomonas aeruginosa which besides exhibiting high sensitivity to 
exogenous NO-treatment it has reduced intracellular survival within macrophages 
when compared to that of the parental strain [127].  
Flavodiiron proteins (FDPs) are constituted by a metallo -lactamase like-
domain harboring a diiron catalytic site in the N-terminal and a flavodoxin-like 
domain with a FMN moiety. Additionally, several members of this family have extra 
domains fused at the C-terminal [122]. For example, E. coli FDP (also refered as 
flavorubredoxin) has an extra rubredoxin domain and is able to reduce NO, being 
the first FDP implicated in the detoxification of NO [128]. Subsequent studies have 
confirmed the role of other FDPs as NO detoxifiers, revealing the correspondent 
mutant strains increased sensitivity to nitrosative stress conditions [129-131]. 
 
1.3 S. aureus defence mechanisms 
Although S. aureus represents the prototype of an extracellular pathogen, 
several investigations Revealed its ability to infect various types of host cells, 
including neutrophils [132-136].  
In the first hours after bacterial infection, pathogens are cleared from the 
blood stream, in part by the phagocytic activity [137]. In particular, it was 
demonstrated that the deletion of the Toll-like receptor 2, a receptor that is 
implicated in the recognition of Gram-positive bacterial components such as 
lipoproteins, increases the mice susceptibility to S. aureus infections [138]. On the 
other hand, S. aureus variants lacking lipoproteins can effectively escape the 
immune recognition and cause lethal infection [139].  
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As all successful pathogens, S. aureus possesses several structures and 
biochemical features that allow to avoid phagocytosis and to resist inside the 
phagocytic cells. For example, S. aureus produces coagulase that causes 
deposition of fibrin in the pathogen’s membrane and protects it from the attack of 
host cells. In addition, S. aureus synthesises leukocidins, proteins that are able to 
destroy the phagocytes. Hence, the pathogen is not killed upon ingestion; instead 
it lyses the phagocyte causing the release of the lysosomal content to the 
cytoplasm [4]. S. aureus is also able to neutralise the toxic products released by 
phagocytic cells [4]. For example, staphylokinase, a serine protease-like 
exoprotein, can inhibit the antibacterial effect of -defensis on S. aureus cell wall 
[140]. Moreover, several S. aureus strains are proposed to produce other 
extracellular products such as exotoxins (e.g. haemolysin), enterotoxins (e.g. 
staphylococcal enterotoxin B) and proteolitic enzymes (e.g. fibrinolysin) [4].  
Of particular importance are the mechanisms that S. aureus uses to acquire 
iron, an element present at low concentration inside host cells and vital to the 
survival of all organisms. The majority of iron in the human body (60-75 %)  is 
present intracellularly and bound to haemoglobin (Hb), an abundant protein of the 
erythrocytes [141]. S. aureus can activate the lysis of erythrocytes by producing 
haemolysin, which leads to the releasing of haemoglobin/haem to the extracellular 
fluids [142]. The cell-wall sorted proteins of the S. aureus iron-regulated surface 
determinant system bind haemoglobin and other haemoproteins to remove the 
haem molecule and transport it through the cell wall and plasma membrane. Once 
inside the bacterium, haem is either degraded by staphylococcal haem 
monoxygenases (described in Chapter 2) or segregated to the bacterial membrane, 
where it is likely incorporated intact into the bacterial haem-binding proteins [143, 
144].  
Other strategy employed by S. aureus to acquire iron involves siderophores. 
Siderophores are low-molecular-weight iron-binding complexes that are secreted 
from the bacterial cell and are responsible for removing host iron from sources 
such as transferrin, lactoferrin and ferritin. S. aureus has been shown to contain at 
least four type of siderophores: staphyloferrin A, staphyloferrin B, aureochelin  and 
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hydroxamate siderophores [145-148]. The contribution of siderophores to S. 
aureus pathogenesis is highlighted by the demonstration that a siderophore 
synthesis mutant exhibits a defect in virulence in a mouse model of abscess 
formation [149].  
 
1.3.1 S. aureus defences against oxidative stress 
S. aureus has efficient tools to defend against oxidative stress. It has been 
shown that inside neutrophils, S. aureus has higher mRNA expression levels of 
catalase, superoxide dismutase, thioredoxin, alkyl hydroperoxide reductase and 
glutathione peroxidase [136].  
Catalase activity is associated with pathogenicity since virulent S. aureus 
strains have higher levels of catalase in opposition to non-virulent strains [150]. 
Exogenous addition of catalase decreases the ability of neutrophils to kill low-
catalase expressing S. aureus strains and a catalase-deficient strain showed to be 
hypersensitive to hydrogen peroxide [55, 151]. However, the catalase mutant does 
not have attenuated pathogenicity in a murine skin abscess model of infection 
[151]. In S. aureus, catalase and alkyl hydroperoxide reductase seem to have 
compensatory roles since a catalase mutant contains higher levels of alkyl 
hydroperoxide reductase which is in agreement with the resistance studies 
performed in the murine skin abscess model of infection [151, 152]. In addition, 
alkyl hydroperoxide reductase and catalase are reported to be required for survival 
and persistence of nasal colonisation of S. aureus [152].  
S. aureus has two superoxide dismutases, SodA and SodM, both with 
manganese as co-factor. Although only the sodA-mutant exhibits high susceptibility 
to oxidative stress, the over-expression of SodM in a double mutant was shown to 
decrease the susceptibility of S. aureus  to oxidative stress [153, 154].  
S. aureus produces carotenoid pigments that are proposed to be involved in 
protection against phagocyte generating oxidative burst as judged by the results 
showing that in a model mouse of subcutaneous abcess the S. aureus crtM 
mutant, that encodes an essential gene involved in carotenoid biosynthesis, 
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exhibits lower degree of oxidative stress resistance, neutrophil survival and 
pathogenicity [2].  
 
1.3.2 S. aureus defences against nitrosative stress 
S. aureus proteins involved in anaerobic metabolism are proposed to afford 
protection to S. aureus cells when challenged with NO. In fact, a recent study 
showed that when exposed to NO S. aureus shifts its metabolism by inducing 
lactate dehydrogenase (ldh1), which converts piruvate into L-lactate. The ldh1-
mutant has high sensitivity to NO, decreased viability within macrophages and 
lower virulence in a murine sepsis model, demonstrating that lactate 
dehydrogenase activity is essential to S. aureus resistance to NO [155]. Another 
study conducted by the same authors showed that S. aureus deleted in srrAB, 
genes encoding a two component regulatory system that controls the transition to 
anaerobic metabolism, are also very sensitive to nitrosative stress [156]. 
S. aureus is highly resistant to nitrosative stress [156]. However, the 
mechanisms by which bacteria detoxify the reactive nitrogen species are almost 
unknown. Recently, our laboratory has identified a novel S. aureus nitroreductase 
that, apart from being involved in the activation of nitrofurans, also confers 
protection against GSNO. In fact, the nitroreductase-mutant strain exhibits higher 
growth impairment upon exposure to GSNO and enzymatic studies Revealed that 
the protein is able to reduced GSNO [157]. In this thesis we showed that S. aureus 
genome encodes a flavohaemoglobin that efficiently metabolise NO and afford 
protection to S. aureus cells against nitrosative stress (Chapter 3) [156, 158]. 
 
1.4 Flavohaemoglobins 
Microbial haemoglobins are a diverse group of proteins which are divided into 
three classes (Figure 1.8) [123].  
The first class is typified by the Vitreosilla globin (Vgb). Vgb was the first 
bacterial globin to be isolated and is a dimeric protein containing two haems b per 
molecule [159]. All proteins of this class are predicted to possess a typical globin 
fold and share amino acid sequence identities with Vgb ranging from 22 % 
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(Thermobifida fusca) to 66 % (Clostridium perfringens) with key amino acids 
around the haem pocket strictly conserved (His-F8, Phe-CD1 and Tyr-B10) [123]. 
The physiological function of these globins is associated with transport of dioxygen 
[123]. Interestingly, a chimeric protein comprising Vitreosilla–globin domain fused 
with a flavoreductase domain of Alcaligenes eutropha flavohaemoglobin was found 
to consume NO and provide E. coli protection from nitrosative stress [160]. This 
suggests that when present in the monomeric form Vgb may became associated 
with a reductase domain, therefore acquiring the ability to relieve the nitrosative 
stress [160]. The homologous globin of Vgb in Campylobacter jejune (Cgb) is also 
involved in the defence against nitrosative stress as demonstrated by the 
hypersensitivity of a cgb-mutant strain upon exposure to NO and other nitrosating 
agents, and by the markedly inhibition of the aerobic respiration of the cgb-mutant 
strain [161]. 
 
FIGURE 1.8 Classification of microbial haemoglobins by their domain architecture. The 
class I comprises the proteins that have a typical globin fold like the Vitreoscilla globin (Vgb) while class 
II contains the truncated haemoglobins. Class III includes the two domains proteins like 
flavohaemoglobins which are proteins constituted by a haem-globin domain plus a reductase domain. 
Adapted from [123] 
 
The second class comprises the truncated haemoglobins (trHb), which display 
a smaller globin domain with a different fold but retained the key residues required 
for haem binding and interaction with small ligands [123, 162]. The function of 
these proteins is not completely understood; however, it has been demonstrated 
that they may be involved in dioxygen and NO metabolism. TrHb binds dioxygen 
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with high affinity making unlikely that it acts as an oxygen carrier. However, trHb 
of M. tuberculosis (trHbO) has been shown to enhance oxygen uptake of E. coli 
membrane fractions [163]. A second trHb was identified in M. tuberculosis (trHbN) 
and reported to detoxify NO and to protect aerobic respiration from NO inhibition 
[164].  
Flavohaemoglobins (Hmps) are the third class of microbial haemoglobins and 
have a unique two-domain structure, composed by a globin fused with a reductase 
domain. Hmps are widely distributed in Gram-positive and Gram-negative bacteria, 
in yeasts and fungi [123, 162]. The first bacterial hmp gene discovered was that of 
E. coli [165]; although many years before a haemoglobin-like containing protein 
was purified from yeast, a physiological function could not be assigned at that time 
[166, 167].  
Hmps display a globin-like domain in the N-terminal with a binding site for a 
haem b and a C-terminal domain, that resembles a ferredoxin NADP+ reductase, 
with binding sites for flavin (FAD) and NAD(P)H (Figure 1.9) [168, 169].  
 
 
FIGURE 1.9 Structure of E. 
coli flavohaemoglobin. Heart-
shaped structure in which three 
different domains are distinguished: 
the globin domain at the N-terminal 
(red), a flavin-binding domain 
(cyan), and the NAD-binding 
domain on the C-terminal (green). 
Adapted from [169]. 
The X-ray structures of E. coli (Figure 1.9) and A. eutrophus Hmp show that 
the architecture of the globin domain correspond to a classic globin fold composed 
by six helices (from A to H) and the amino acids sequence alignment of all known 
Hmps Revealed that these proteins share conserved residues in both the haem and 
flavin binding sites [169-171]. The conserved amino acids within the haem domain 
include the residues linked to the haem pocket on proximal and distal sites. 
Residues His85 and Phe88, located on proximal site, allow the 
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covalently linkage of haem to the polypeptide chain and the correct orientation of 
haem within the pocket, respectively [170], while the distal-side residues, Tyr29 
and Gln53, control the interaction with the iron-bound ligand. Mutagenic studies 
Revealed that the replacement of the Tyr residue by Phe decreases the reaction 
rate of Hmp with NO by a factor of ~ 30 [172].  
The amino acid residues responsible for the flavin binding are also strictly 
conserved, namely Phe290, Gly270, Glu388, Thr272, Pro273, Gly186, Gln187, 
Tryr188 and Ser232. These residues appear to control and shape the flavin-binding 
cavity, thus reducing the solvent access and providing the structural basis for the 
interaction with NAD(P)H as substrate [171]. 
 
1.4.1 Physiological function 
The first indication that Hmp could be involved in NO metabolism arised from 
the observation that hmp expression is markedly induced by NO gas, as well as by 
GSNO and sodium nitroprusside (SNP) [173, 174]. Studies performed with E. coli 
mutants selected on a screening of NO-resistance genes Revealed that they 
exhibited an oxygen-dependent NO-consuming activity which was attributed to 
flavohaemoglobin [175]. Further work reported that hmp-mutants of E. coli are 
sensitive to nitrosative stress and presently, the role of Hmp-mediating NO 
protection is well established for a large array of microorganisms [175-177]. In 
particular, Hmps have been shown to protect S. typhimurium, P. aeruginosa, 
Erwinia chrysanthemi, B. subtilis, Saccharomyces cerevisiae  and Cryptococcus 
neoformans  from nitrosative stress generate by different agents [178-184]. The 
deletion of hmp gene results in strains hyper-sensitive to the killing by 
macrophages [178, 184-186] and Hmp is required to confer virulence in mice and 
to allow E. chrysanthemi infection of Saintpaulia ionantha plants [156, 178, 181]. 
Therefore, Hmp is considered a NO-detoxifying enzyme that provides protection 
against nitrosative stress under aerobic and anaerobic conditions [187].  
Interestingly, the E. coli Hmp was also shown to interact with bacterial lipid 
membranes and is able to specifically bind unsaturated or cyclopropanated fatty 
acids [188, 189]. Hmps are also able to mediate the electron transfer to an array 
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of molecules/enzymes when haem is blocked (e.g. with CO). Under such 
conditions, FAD is able to transfer electrons from NAD(P)H to a number of external 
acceptors like cytochrome c  and paraquat, among others [190-192]. 
 
1.4.2 Enzymatic activity 
Flavohaemoglobins are able to detoxify NO either aerobically by oxidising NO 
to nitrate and anaerobically by reducing NO to nitrous oxide [175, 193, 194]. 
However, the reaction rate occurring in the presence of dioxygen is higher than 
that under anoxic conditions and the mechanism beyond Hmp catalytic activity is a 
matter of debate since two hypotheses are considered: the NO dioxygenase and 
the NO denitroxylase (Figure 1.10) [175, 193-196]. 
Gardner and co-workers proposed a mechanism analogous to that described 
for haemoglobin, in which the dioxygen that binds to the Hmp ferrous haem is 
reduced to superoxide while the haem is oxidised. Then, NO reacts with the 
bounded superoxide producing nitrate and regenerating the ferric haem. This 
reaction is denominated as NO dioxygenase activity (Figure 1.10 low part, right 
reaction) [112, 175, 194]. Since dioxygen and NO have similar association 
constants (17-50 µM-1s-1 for O2 and 10-26 µM
-1s-1 for NO), the binding to ferrous 
haem will be dependent on the relative concentrations of dioxygen and NO; if [O2] 
> [NO], dioxygen will bind first, whereas when [O2] < [NO] NO will preferentially 
bind to the haem. Furthermore, the KM for dioxygen is higher than for NO (KM[O2] 
= 30-100 µM and KM[NO] = 0.1-0.25 µM) and, therefore, when present at similar 
concentrations the binding of NO is preferred over that of dioxygen [175, 197]. 
Considering the kinetic parameters mentioned above and the higher dissociation 
constant (Kd) for dioxygen when compared to that of NO, (Kd[O2] = 12 nM and 
Kd[NO] = 0.008 nM), the NO dioxygenase activity (Figure 1.10 low part, right 
reaction) will be only functional when [O2] >> [NO] [172, 175, 193, 197, 198].  
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FIGURE 1.10 Catalytic activity of Hmp. Ferric Hmp (Hmp-
Fe(III)) reacts with either NAD(P)H or NO, forming  ferrous Hmp (Hmp-
Fe(II)) or ferric-nitrosyl Hmp (Hmp-Fe(III)NO), respectively. The latter 
is subsequently reduced by NAD(P)H to form ferrous-nitrosyl Hmp 
 
 
(Hmp-Fe(II)NO). Hmp-
Fe(II) reacts either with NO 
or O2, forming Hmp-
Fe(II)NO or HmpFe(II)O2, 
respectively; the first reacts 
with O2 to give nitrate 
(NO3
-) or dimerises in the 
absence of O2 forming N2O 
(NO denitroxylase activity, 
upper reactions); the 
second reacts with NO 
generating also nitrate. The 
oxidase activity reaction, in 
which dioxygen is reduced 
to superoxide is also shown 
in left site of the lower part 
of the figure. Adapted from 
[195]. 
 
However, pathogens are exposed to high concentrations of NO generated by 
macrophages in low dioxygen environments and since Hmp displays higher affinity 
for NO than for dioxygen, and NO binds both ferric and ferrous haem whereas 
dioxygen only binds the ferrous form, the reaction of Hmp is likely to proceed 
through a denitrosylase pathway, as proposed by Hausladen et al., in which NO 
will bind to ferrous haem, being then reduced to nitroxyl anion that subsequently 
reacts with dioxygen generating nitrate (Figure 1.10, upper part). In the absence 
of dioxygen, the reaction proceeds more slowly, yielding nitrous oxide by 
dimerisation and dehydration of HNO [195] (Figure 1.9 upper part, right reaction). 
This mechanism seems to be the most probable one based on physiological 
conditions and, in fact, it has been shown that Hmp is able to protect microbes 
against high NO concentrations anaerobically, a condition under which the NO 
dioxygenase activity cannot be operative [172, 175, 193, 195, 197, 198]. 
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Hmps have the potential of exhibiting different enzymatic activities by 
mediating the electron transfer from NAD(P)H to the haem bound-ligand. Hence, in 
an environment lacking NO, Hmp is also able to reduce dioxygen to superoxide 
(Figure 1.10 lower part, left reaction) 
[199-201]. Furthermore, under 
anaerobic conditions, Hmp reduces 
hydroperoxides (e.g. tert-butyl 
hydroperoxide, cumyl hydroperoxide 
and linoleic acid hydroperoxide) to the 
corresponding alcohols (Table 1.8), 
acting as an alkyl hydroperoxide 
reductase [202]. Since hmp 
expression is induced by paraquat and 
the lipids hydroperoxides can be 
 
TABLE 1.8 Michaelis constant (KM) for 
E. coli Hmp. 
Substrate 
KM  
(µM at 25 ºC, 
pH 7) 
NO 0.11 
O2 27 
Linoleic acid hydroperoxide 26 
Cumyl hydroperoxide 55 
Tert-butyl hydroperoxide 76 
H2O2 260 
Adapted from [171] 
generated during oxidative and nitrosative stress, it is also proposed that Hmp may 
be involved in the repair of membrane lipids [202, 203]. 
 
1.4.3 Regulation of flavohaemoglobin transcription 
The expression of hmp gene is increased by several factors: by NO and NO 
related compounds [173, 180, 204-206]; in the stationary cell growth phase [203, 
207]; by the decrease of iron generated by the iron chelator 2,2’-dipyridyl [173]; 
by paraquat [203]; and limitation of dioxygen [208, 209]. 
Microarrays studies performed in cells of a wide array of microorganisms have 
shown that hmp is one of the few genes whose expression is always induced by 
NO, independently of the agent used to generate nitrosative stress [130, 156, 204, 
210-213]. However, the available data Reveals that the mechanism beyond the 
regulation of hmp by NO is very complex involving several regulators [173]. 
Most of the studies on hmp regulation have been performed in E. coli but, at 
least, two regulators have been shown to also regulate the hmp transcription in 
several other microorganisms, namely the transcription factor fumarate-nitrate 
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reduction, known as FNR, and the NO-sensitive repressor NsrR [178, 182, 214-
218]. 
FNR is a dioxygen and a NO sensing transcription factor via its labile [4Fe-4S] 
cluster and it represses the hmp expression under anaerobic conditions [214]. 
Several evidences link the regulation of hmp to FNR: i) the fnr mutation enhances 
hmp expression [173, 217]; ii) the hmp promoter displays two putative FNR 
binding motifs [207, 214]; and iii) the anaerobic reaction of NO with the Fe-S 
cluster of FNR leads to the formation of a dinitrosyl-iron cysteine complex, 
decreasing the affinity of FNR to the hmp promoter and leading to a derepression 
of the hmp transcription [214]. 
NsrR, a member of the Rrf2 family of transcriptional repressors, regulates the 
expression of genes involved in nitrosative stress response, including hmp [215]. 
NsrR is a NO sensor that contains a [2Fe-2S] cluster whose nitrosylation results in 
the lost of its DNA binding activity [216]. The activity of hmp promoter is 
constitutively expressed in a nsrR mutant, under both aerobic and anaerobic 
conditions, which indicates that hmp promoter is a target for repression mediated 
by NsrR [178, 215]. 
In E. coli it has been demonstrated that, under aerobic conditions, MetR also 
participates in the hmp regulation. MetR regulates the expression of glyA (a gene 
that is divergently transcribed from hmp in E. coli, as well as in other bacterial 
genomes), and uses homocysteine as a cofactor [123, 210]. High levels of 
homocysteine decreases the expression of hmp, and the low levels present in metC 
mutant are associated with high levels of hmp expression [174]. Since GSNO can 
nitrosylate homocysteine, it is considered that the induction of hmp by nitrosating 
agents such as GSNO may be explained by the decrease of homocysteine levels, 
enhancing the binding of MetR at a proximal site of hmp promotor and therefore 
inducing the hmp transcription [174].  
In B. subtilis, hmp transcription, which is repressed by NsrR, is also 
dependent of ResDE, a transduction system that is induced by oxygen limitation 
and by NO [182, 218]. However, while in a nsrR null mutant the hmp transcription 
is derepressed in the presence of NO, the NO-inducible expression of hmp in a 
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resED deleted strain is diminished but not completely abolished [219]. 
Interestingly, S. aureus genome encodes an analogue transduction system of B. 
subtilis ResDE, the SrrAB system and, like it occurs in B. subtilis, S. aureus NO-
dependent hmp transcription is decreased in a srrAB-deleted strain, but not 
completely eliminated [156]. 
 
1.4.4 Azole antibiotics and flavohaemoglobin 
Azole antibiotics are N-1 substituted compounds containing two or three 
nitrogens atoms in the azole ring that are thereby classified as imidazoles (e.g. 
miconazole and clotrimazole) or triazoles (e.g. fluconazole and itraconazole). 
The azoles were initially used to treat fungal infections [220]. Clotrimazole 
was one of the first imidazole to be developed. It was synthesised, in 1969, by 
chemists at Bayer AG and it is nowadays used for the topical treatment of both 
cutaneous and vaginal candidiasis and other superficial fungal infections [221, 
222]. However, oral administration of clotrimazole has been shown to cause side 
effects that include gastrointestinal disturbances and alterations in hepatic and 
adrenal functions [223, 224]. In the same year, Jassen Pharmaceutica synthesised 
miconazole [225]. In contrast to clotrimazole, miconazole exhibits low toxicity and 
was the first azole derivative to be applied intravenously for the therapy of 
systemic fungal infections. Furthermore, miconazole was the first azole reported to 
be active against Gram-positive bacteria [226]. The two azoles continue to be 
administrated today and are used as control drugs in many clinical trials of newer 
azole derivatives [222]. Ketoconazole was also developed by Jassen Pharmacetica 
in 1977 and is a broad-spectrum antifungal agent, which can be also administrated 
orally [227]. Ketoconazole is widely used to treated topical and systemic fungal 
infections, being considered the most successful azole derivative. Latter, Pfizer U.K. 
developed fluconazole, one of the first triazole agents to be synthesised. Triazoles 
have a broad range of applications in the treatment of both superficial and 
systemic fungal infections and display greater affinity for fungal rather than 
mammalian cytochrome P450 enzymes, which contributes to an improved safety 
profile [228]. 
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The principal mode of action of azoles antibiotics lays on the inhibition of 
P450 lanosterol 14 -demethylase, which is a key enzyme in ergosterol 
biosynthesis, a major component of the fungal plasma membrane. The inhibition of 
P450 lanosterol 14 -demethylase activity occurs by the binding, as a sixth ligand, 
of the nitrogen atom of the imidazole ring to the haem of the enzyme causing the 
depletion of ergosterol and accumulation of the toxic 14 -methylated sterols, 
which alters the normal permeability and fluidity of the membranes [220].  
The ability of azoles to coordinate the haem of several others enzymes 
suggests the existence of other potential cellular targets. For example, in C. 
albicans and S. cerevisiae catalase and peroxidase are inhibited by miconazole, 
with consequent increase of the endogenous ROS production [220, 229, 230]. 
Clotrimazole inhibits the haemoperoxidase of Plasmodium falciparum, which leads 
to the increase of oxidative stress and results in the impairment of the growth of 
the different strains of P. falciparum and contributes to the antimalary action of 
clotrimazole [231-233]. Recently, the action of azoles was also correlated with the 
inhibition of the NO scavenger activity of flavohaemoglobin in E. coli, S. cerevisiae 
and C. albicans [234].  
Although azoles are also active against bacteria, in particular for Gram-
positive bacteria, the cellular targets remains elusive [235, 236]. Earlier reports 
demonstrated that miconazole has antimicrobial activity against S. aureus and 
causes K+ release suggesting membrane damage [237]. In the present thesis’s 
work, the mode of action of azole antibiotics was explored in S. aureus, as shown 
in Chapter 4. 
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2.1 Historical overview 
The harmful action of carbon monoxide (CO) gas in humans was recognized 
for a long time. However, only in 1857 Claude Bernard showed that the toxic 
effects of CO were related to the reversible binding of CO to haemoglobin, forming 
carboxy-haemoglobin (COHb) and leading to asphyxia [1]. This gaseous molecule 
was considered for many years only as an environmental poison that results from 
the incomplete combustion of organic matter. Although in the second half of 1800s 
the first indication of endogenous production of CO was reported [2, 3], only fifty 
years later the synthesis of CO gas in the human body was indeed demonstrated 
[4-6]. Shortly after, the production of CO in bacteria was also reported [7].  
In the late 1960s the production of CO was attributed to haem oxygenase 
(HO) activity [8-10]. However, it was regarded as a metabolic waste for about 
twenty years and the study of CO as a signaling molecule was only explored after 
the discoveries made in 1980s regarding the physiological role of nitric oxide [11-
16]. Since then research on CO developed rapidly and, in 1993, Snyder and co-
workers reported that CO could act as a neural messenger and Rattan and Chakder 
demonstrated that endogenous CO was involved in relaxation of the internal anal 
sphincter [17, 18]. Two years later, it was reported that CO, like NO, binds to 
soluble guanylate cyclase and activates the enzyme albeit to a minor extension 
than NO [19-21]. 
The physiological function and the pharmacological application of CO have 
been extensively explored [22]. The search for new compounds that could safely 
carry and delivery CO into a biological environment led to the development of CO-
releasing molecules (CO-RMs) [23]. CO-RMs are proposed to mimic the 
physiological action of CO gas and are currently under preclinical evaluation since 
they are a promising tool for therapeutic CO-delivery [24-26].  
In the last decade, it has been a huge and growing interest in the biology of 
endogenous generated gases, such as NO, CO and more recently hydrogen sulfite 
(H2S) [27, 28]. All three gases seem to work together, exerting a similar biological 
role albeit via different mechanisms and its regulation seems to be intimately 
linked [27-29]. The multiplicity of targets and the diversity of physiological 
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functions of these gaseous molecules have attracted much attention and several 
investigations have revealed the biological significance of its endogenous 
production [30]. In this chapter a summary of the most important findings in CO 
bioactivity will be presented. 
 
2.2 Reactivity of carbon monoxide 
The direct oxidation of carbon in a limited supply of oxygen or air yields CO. 
Hence, the incomplete combustion of carbon-containing fuels, such as coal, petrol, 
natural gas and wood releases CO [31]. 
CO is a colourless, odourless, tasteless and flammable gas that, at standard 
temperature and pressure (IUPAC), has a density 1.25 g/L (about the same density 
as that of air). Above -205 °C, CO changes directly from a solid phase to a gaseous 
phase through sublimation with a boiling point of -192 ºC [31, 32] (Table 2.1). 
 
TABLE 2.1 Chemical and physical 
proprieties of CO. 
Property Value 
Interatomic distance (pm) 112.8 
Melting point (ºC) -205 
Boiling point (ºC) -192 
Density (g/L) 1.25 
Solubility in water (mM) 1* 
* at room temperature 
Adapted from [31] 
CO has ten valence electrons, 
four from the carbon and six from 
oxygen. Two electrons are used to 
form the σ-bond and four to form 
two π-bonds. Therefore, CO has a 
triple bond leaving four electrons to 
form a lone pair on each of the 
carbon and oxygen atoms [31]. The 
lone-pair on carbon is available, 
albeit weakly, for donation to an 
acceptor. Hence, most of CO chemistry occurs via the carbon atom, which is 
negatively charged, and not through the oxygen. The short interatomic distance of 
CO (Table 2.1) and the great strength of the bond confer stability to the molecule. 
Thus, the chemical reduction of CO requires temperatures well above 100 ºC. For 
example, the catalytic reduction to methanol occurs at 230-400 ºC and 50-100 
atmosphere (atm) (Equation 2.1). The oxidation of CO to carbon dioxide also takes 
place at high temperatures via the metal-catalysed water-gas-shift reaction 
(Equation 2.2) [31]. 
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EQUATION 2.1   CO + 2H2  CH3OH 
 
EQUATION 2.2   CO + H2O  CO2 + H2 
 
CO is weakly soluble in water (Table 2.1) and is soluble in organic solvents 
such as chloroform, benzene, ethanol and methanol [33]. In addition, CO does not 
readily react with reducing agents (including molecular hydrogen) and the reaction 
with molecular oxygen is slow with a high activation energy (~ 213 kJ mol-1) [22].  
CO is considered to be a relatively inert molecule and the reduction of CO can 
be greatly facilitated by transition metals in low oxidation states, especially those 
from 6-10 group (as molybdenum, manganese, iron, cobalt or nickel), with which 
it forms stable complexes [31]. The 
bond between the transition metal 
and the CO ligand occurs through a 
donation of a pair of electrons from 
the lone pair on the carbon atom to 
the hybrid orbital of the metal to 
form a σ-bond, and a back donation 
from the filled d-orbital on the metal 
to the empty anti-bonding π-orbital 
on the CO [31, 34]. Consequently, 
the bioactivity of CO proceeds almost 
exclusively through the binding to 
 
TABLE 2.2 Haemoproteins reported 
as potential targets for CO. 
Haemoproteins 
Myoglobin 
Soluble guanylate cyclase 
Inducible nitric oxide synthase 
Cytochrome P450 
Cytochrome c oxidase 
NADPH oxidase 
Dopamine β hydroxylase 
Tryptophan oxidase 
Haem oxygenase 
Adapted from [35] 
transition metals which are present in structural and functional proteins, especially 
via binding to ferrous haem (Table 2.2). On the other hand, CO is an important 
organometalic ligand and the knowledge of the CO related chemistry helped in the 
development of CO-RMs. 
 
2.3 Carbon monoxide toxicity 
Although CO has been present in our environment since the beginning of life 
and might had a fundamental role, along with oxygen and nitrogen, in the creation 
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of amino acids and proteins, it represents today the most abundant pollutant in the 
lower atmosphere [36, 37]. The industrial activity and the automobile exhaustion 
are the major sources of CO atmospheric accumulation. Other sources include 
fires, stoves, portable heaters and cigarette smoke [38].  
The atmospheric ambient contains approximately 10 parts per million (ppm) 
of CO (Table 2.3) and even though it can reach 50 ppm in metropolitan areas, 
acute clinical poisoning does not normally arise [39]. Nevertheless, CO is 
responsible for a great number of deaths every year in the United States of 
America through inhalation of CO that usually happens accidently in closed spaces 
due to inappropriate air ventilation [40, 41]. Actually, the Center for Disease 
Control in USA estimates that CO poisoning results in more than 20000 visits to 
hospital emergency departments annually. Of those more than 4000 were 
hospitalised and nearly 400 died (http://www.cdc.gov/co). 
CO is absorbed through the lungs and diffuses across the alveolar capillary 
membrane. Once absorbed, CO diffuses through the plasma, passes across the red 
blood cell membrane and finally enters the red cells where it binds to haemoglobin 
[22]. CO competes with dioxygen for binding to the four haem iron centers of 
haemoglobin and since the CO affinity to haemoglobin-haem is approximately 250 
times higher than that of dioxygen, CO reduces the number of oxygen molecules 
transported [42]. As a consequence, CO decreases the haemoglobin storage 
capacity and increases the blood pressure. The partial occupation of CO at the 
haemoglobin binding sites also inhibits the liberation of dioxygen from the 
remaining haem groups to the recipient tissues. The decrease of dioxygen supply 
to the tissues leads to hypoxia, and ultimately to cell death and organ failure [43, 
44]. The inhalation of CO gas has toxic effects within the body, specially on the 
organs with the highest oxygen requirement, like the brain and the heart [44]. 
The adverse health effects associated with CO vary with its concentration and 
duration of exposure since the ligation of CO to haemoglobin is reversible, and 
once exposure has ceased CO dissociates from it and is eliminated through the 
lungs [45]. In fact, the half-life of CO in the blood of adults is 30-180 min [46]. In 
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severe cases of CO exposure, oxygen therapy under hyperbaric conditions (100 % 
oxygen in 2.5 atm) may be applied as antidote [47]. 
The percentage of haemoglobin occupied by CO in normal tissues is less than 
1 % (0.4-0.96 % COHb) [33]. However, basal levels of carboxy-haemoglobin can 
reach 3 % in non-smokers and may be as high as 10-15 % in smokers [46]. 
No standards value for CO levels have been agreed for indoor air and owing 
to the lack of a consensus unit of measurement for CO, whether be in ppm, ml/h, 
µM or % COHb, it became a challenge to advocate and agree on a safe and 
tolerable dose of CO [35]. Currently, the USA Occupational Health and Safety 
Administration stated a 
limit of 50 ppm over 8 
h/day (Table 2.3) which 
generates carboxy- 
haemoglobin levels of ~ 
8-10 % [35]. In most 
animal models, CO is 
lethal in the upper range 
of 10000 ppm (Table 
2.3) [26, 35]. To obtain 
the benefits of CO, the 
 
TABLE 2.3 Carbon monoxide levels and its medical 
relevance. 
CO concentration 
(ppm) 
Medical Relevance 
10000 Lethal in min 
10-500 Preclinical efficacy (1 h) 
10 Ambient air 
35/50 Limit for 8 h work/day (EPA/OHSA) 
EPA: Environmental protection agency, USA 
OHSA: Occupational Health and Safety Administration, USA 
Adapted from [26] 
 
percentage of  carboxy-haemoglobin in the blood should be 12-20 % and, in fact, 
most of the positive effects of CO observed in a range of 50 to 500 ppm per hour 
lead to a tolerable level of carboxy-haemoglobin (15-18 %) with no physiological 
toxicity (Table 2.3) [26, 35]. Symptoms of CO poisoning begin to appear at 20 % 
carboxy-haemoglobin and include, headache, dizziness, weakness, nausea, 
vomiting, chest pain and confusion [46]. However, an ambient level of 100 ppm of 
CO can generate 16 % carboxy-haemoglobin at equilibrium, which may be enough 
to produce some clinical symptoms [38]. Prolonged exposure to CO leads to 50-80 
% of blood carboxy-haemoglobin that results in seizure, coma and can ultimately 
conducted to death [46]. 
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Although 80 % of CO loaded in our body is bound to haemoglobin, other 
cellular targets cannot be excluded. CO also binds to other haemoproteins (Table 
2.2), namely cytochrome c oxidase and cytochrome P450, inhibiting their activity. 
However, sufficient inhalation of CO to inhibit respiration and xenobiotic 
metabolism is most likely preceded by tissue hypoxia that originates death [46]. 
Hence, the contribution of such mechanisms to the overall toxicity remains 
controversial. 
 
2.4 Endogenous production of carbon monoxide 
Nearly every organism generates CO as a normal cellular function. Haem 
oxygenase activity accounts for about 86 % of the CO produced in humans [46], 
with the remaining 14 % of the CO generated from the oxidation of organic 
molecules that include auto-oxidation of phenols, flavenoids and halomethanes, 
photo-oxidation of organic compounds, peroxidation of membrane lipids and 
xenobiotic metabolism [48]. The rate of CO production in the human body is 
approximately 16.4 μmol/h [49]. The production of CO can be detected in exhaled 
air and an adult breathes out approximately 6 ml of CO per day. This level may 
increase substantially under disease states such as asthma, bronchiectasis, cystic 
fibrosis, diabetes and rhinitis [50] 
Haem oxygenase catalyses the first rate-limiting step in the degradation of 
the haem. The oxidation of the α-methene bridge of haem by haem oxygenase 
yields stoichoimetric quantities of biliverdin, ferrous iron and CO (Figure 2.1) [51]. 
In this reaction, haem acts as prosthetic group and as substrate and three 
molecules of dioxygen are consumed per haem. The catalytic activity of haem 
oxygenase plays a crucial role in maintaining cellular haem homeostasis and 
haemoprotein levels [52].  
All products of haem oxygenase activity are biologically active. CO is primarily 
a signaling molecule that has important physiological function which will be 
discussed below (2.5). Iron is traditionally considered as a pro-oxidant molecule 
since it participates in the Fenton reaction generating the highly reactive hydroxyl 
radical. However, iron also regulates the transcription of several genes by binding 
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to iron regulatory proteins (IRP) and influencing the mRNAs stability [52]. In 
particular, the binding of iron to IRP releases IRP from ferritin mRNA allowing its 
transcription and conferring cytoprotection against oxidative stress [53]. In 
contrast, the removal of IRP by iron binding, destabilizes the transferrin receptor 
mRNA, diminishing the cellular capacity for iron uptake [52]. Biliverdin is reduced 
to bilirubin by biliverdin reductase (Figure 2.1) and both metabolites are believed 
to be potent endogenous antioxidants, which efficiently scavenges peroxy radicals 
inhibiting lipid peroxidation [54-56]. 
 
 
To date, three isoenzymes of haem oxygenase were identified, HO-1, HO-2 
and HO-3 (Table 2.4). The HO-1 was first characterised in 1974, HO-2 was 
discovered about a decade after HO-1, and HO-3 was identified in 1997 [57-61].  
 
 
FIGURE 2.1 Haem oxidative degradation by haem 
oxygenase. Haem oxygenase (HO) catalyses the oxidation of 
haem yielding biliverdin, Fe2+ and CO. Biliverdin is converted to 
bilirubin by biliverdin reductase (BVR). 
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TABLE 2.4 Characteristics of haem oxygenase isoforms. 
 HO-1 HO-2 HO-3 
Physiological 
Function 
Haem degradation 
Anti-oxidant defence 
Modulation of vascular 
tone and liver perfusion 
Neural signaling 
Anti-inflammatory 
Regulation of 
haemoproteins activity 
Haem degradation 
Haem binding 
Maintenace of vascular 
tone 
Neural signaling 
Haem 
binding 
Constitutive 
tissue 
expression 
Spleen 
Liver 
Most tissues 
e.g. 
Brain 
Retina 
Liver 
Spleen 
Testis 
Lungs 
Kidney 
Vasculature 
Most 
tissues 
Inducers 
Endotoxin 
Heat – shock 
Heavy metals 
Haem 
Hydrogen peroxide 
Hyperoxia 
Hypoxia 
NO 
Phorbol esters 
Shear stress 
Sodium arsenite 
UV radiation 
Adrenal glucocorticoids 
opiates 
Not 
known 
Enzyme 
activity 
Km = 0.24 μM 
Vmax = 3.4 μmol/mg/h 
Km = 0.67 μM 
Vmax = 0.24 μmol/mg/h 
Negligible 
Adapted from [52] 
 
The HO-2 and HO-3 are constitutively expressed and display high amino acid 
sequence similarity among them, while HO-1 is inducible and presents low 
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percentage of sequence identity and similarity with the other two isoforms [61, 
62]. The three proteins also differ in their physiological functions, tissue 
distribution and regulation (Table 2.4). HO-1 occurs at undetectable levels in most 
tissues and cell types until a stress condition arises. Nevertheless, HO-1 is the 
predominant form that contributes to the haem oxygenase activity in spleen even 
under normal, unstressed conditions [63]. HO-2 may exist at detectable levels in 
most tissues in the absence of stress and in spite of being considered as 
constitutive, it is responsive to adrenal glucocorticoids [62]. HO-2 is the main form 
in neurons and endothelial cells and its function is associated with 
neurotransmission and regulation of vascular tone [62, 64]. Even though HO-3 is 
found in most organs (brain, heart, kidney, liver, testes and spleen), its role 
remains unknown since besides binding haem is not able to degrade it [52, 61]. It 
is proposed that HO-3 may derived from the retrotransposition of HO-2 as HO-3 
does not contain introns [65]. 
As mentioned, HO-1 is stimulated by conditions that cause a threat to cell 
homeostasis and survival (Table 2.4). Among the HO-1 inducers are haem and 
haem derivatives, UV radiation, heavy metals, NO and its derivatives, hypoxia and 
hyperoxia, heat shock and oxidative stress namely hydrogen peroxide (Table 2.4). 
HO-1 expression is also augmented by pro-inflammatory cytokines (IL-1, IL-6, IL-
10, TNF-α and INF-γ), bacterial endotoxins (e.g. LPS), growth factors (PDGF and 
TGF-β), tumor promoters and oxidised lipids (Table 2.4) [22, 44]. These agents 
share the ability to direct or indirectly generate intracellular reactive oxygen 
species and/or modulate intracellular redox equilibrium. Therefore, the enhancing 
of HO-1 expression is considered a general indicator of oxidative stress in cells and 
tissues [66]. After induction, the expression of HO-1 overpowers the protein level 
of the others isoenzymes, namely in testes, lung and brain [22]. The importance of 
HO-1 in host defence has been demonstrated in mice since the deletion of HO-1 
gene increases the susceptibility of mice to inflammatory conditions associated 
with atherosclerosis, endotoximia, chronic graft rejection and haem metabolism 
[67-69]. 
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2.5 Carbon monoxide: signaling pathways and physiological 
function 
Several studies have shown that HO-derived CO has an important role in the 
cardiac, immune, respiratory, reproductive, gastrointestinal, kidney and liver 
systems [22]. Such importance is due to the anti-inflammatory, anti-proliferative, 
anti-apoptotic and vasoregulatory effects of CO [70] (Figure 2.2). CO confers 
cytoprotection by modulating relatively defined signaling pathways. The CO 
modulation of the soluble guanylate cyclase (sGC) activity and subsequent 
stimulation of the cyclic guanosine monophosphate (cGMP) production is the best 
well known function. Other mechanisms include the modulation of various 
mitogen-activated protein kinase (MAPK) pathways and the stimulation of large 
conductance calcium-activated potassium (KCa) channels activity (Figure 2.2) [70]. 
 
FIGURE 2.2 Signaling pathways modulated by carbon monoxide. CO activates soluble 
guanylate cyclase (sGC) increasing the levels of cyclic guanosine monophosphate (cGMP). CO also 
activates large conductance calcium-activated potassium (KCa) channels and modulates mitogen-
activated protein kinase (MAPK) pathways. Adapted from [70]. 
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Soluble guanylate cyclase is a heterodimeric protein consisting of an  and a β 
subunit and catalyses the conversion of guanosine 5’-triphosphate (GTP) to cGMP 
and pyrophosphate (PPi) (Figure 2.3). The β subunit contains a haem co-factor 
where CO binds directly stimulating its enzymatic activity [44].  
The binding of CO to the haem of sGC occurs via a hexacoordinate complex 
and the dissociation of CO from sGC proceeds through a pentacoordinate 
intermediate and this transition is proposed to be responsible for sGC activation 
[71]. In contrast, the interaction mode of NO with the haem of sGC occurs through 
a pentacoordinate complex with concomitant displacement of the axial ligand His 
[50]. This may be the reason why the activation of sGC by CO is 30-100 times 
lower than that of NO and that the CO may only activate sGC when the NO 
concentration is relatively low [72].  
 
FIGURE 2.3 Schematic representation of soluble guanylate cyclase activity. Binding of 
CO as the sixth coordinated ligand of the ferrous iron of sGC haem and the displacement of the 
histidine (His) yields a five-coordinated haem-carbonyl that activates the protein activity [50]. 
 
Interestingly, the combination of CO with 1-benzyl-3-(5’-hydroxymethyl-2-
furyl)indazole (YC-1), a chemically synthetic benzylindazole compound, that 
possesses antiplatelet activity by activating sGC, makes CO an activator of sGC as 
effective as NO [73]. YC-1 interacts with the α-domain of the sGC and induces the 
displacement of His, producing a five-coordinated iron in the haem-carbonyl 
complex in a similar way as NO does [50, 74]. On the other hand, at high NO 
concentration CO blocks the effect of NO on sGC activation [75]. Therefore, the 
importance of CO on sCG activation is likely to increase not only when the NO level 
is too low or too high but also when molecules like YC-1 are present in cells or 
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tissues [50, 75]. By increasing cGMP levels, CO regulates vasorelaxation, 
neurotransmission and inhibition of platelet aggregation and has anti-proliferative 
and anti-apoptotic effect in vascular smooth muscle cells and in fibroblasts [17, 76-
80]. 
 
The mechanism of CO activation of KCa channels is not completely 
understood. Wang and co-workers showed that in vascular smooth muscle cells, 
CO enhances the calcium sensitivity of KCa channels but does not affect the levels 
of intracellular calcium, whereas Lin et al. reported that CO reduces the 
intracellular calcium concentrations [81, 82]. A more recent work showed that CO 
activates KCa channels by direct interaction with the α-subunit of KCa channels, 
lowering their apparent dissociation constant for calcium [83]. It was also reported 
that haem binds KCa channels inhibiting transmembranar potassium currents and 
decreasing the frequency of the channel opening [84]. The inhibition of sGC 
pathways and KCa channels completely abolishes the CO-induced vasorelaxation in 
rat tail artery, while blockers of one of those pathways only partially abolishes the 
vasodilatation induced by CO. These results showed that CO mediates 
vasodilatation by activating, in an independent mode, the two pathways [85]. 
 
The molecular mechanism by which CO activates/inhibits MAPK pathways 
remains elusive, especially because these pathways do not involved haemproteins. 
A potential candidate to which CO may bind is the protein phosphatase 2C, a 
serine/threonine phosphatase that contains Mn2+ at its active site [86]. 
Nevertheless, several studies have been shown that CO down-regulates 
extracellular signal-regulated kinase (ERK), which leads to inhibition of proliferation 
of human airway smooth muscle cells and activates p38 pathways resulting in the 
reduction of vascular smooth muscle cells and T lymphocytes proliferation and in 
inhibition of endothelial cells apoptosis [87-91]. The anti-inflammatory effect of CO 
involves the activation of p38 pathway as well as the inhibition of c-Jun amino-
terminal kinases (JNK) as demonstrated in macrophages, in which CO exposure 
inhibited the expression of pro-inflammatory cytokines (TNF-α, IL-1 , MIP-1β and 
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IL-6) and increased the expression of anti-inflammatory cytokine interleukin-10 
[92-94].  
 
2.6 Carbon monoxide and bacteria 
 
2.6.1 Carbon monoxide as carbon and energy source 
Some type of bacteria can use CO as carbon and energy sources. In aerobic 
and anaerobic bacteria, CO is oxidised to carbon dioxide by CO dehydrogenase 
(CODH), which also catalyses the reverse reaction (Equation 2.3) [95].  
 
EQUATION 2.3   CO + H2O  CO2 + 2H
+ + 2e- 
 
CODH contains as active site a non-haem iron and either molybdenum (in 
aerobes) or nickel (in anaerobes), and the CO oxidation is coupled to several 
metabolic pathways that occur in the presence and absence of oxygen [95, 96]. 
Therefore, the reducing equivalents generated by CO oxidation are received by 
electron acceptors into a respiratory chain leading to the reduction of the terminal 
electron acceptor. For example, in aerobic microorganisms, like P. 
thermocarboxydovorans, which possesses a CO-insensitive respiratory chain, the 
reducing equivalents are used for oxygen reduction or, in some cases, for nitrate 
reduction [97, 98]. Under anaerobic conditions the respiratory processes that are 
coupled to CO oxidation distinguish three groups of CO-metabolising bacteria: i) 
the sulfate reducers that include the desulfuricants (e.g. Desulfovibrio vulgaris), in 
which the oxidation of CO yields carbon dioxide and molecular hydrogen that is 
subsequently utilised for sulfate reduction (Equation 2.4) [95]; ii) the 
hydrogenogens such as Rhodospirillum rubrum that are able to, in absence of an 
electron acceptor, oxidise CO and reduce the protons derived from water to form 
hydrogen (in a reaction analogous to the water-gas-shift reaction) (Equation 2.5) 
[95]; and iii) the acetogens, which are a diverse group of bacteria that possess a 
bifunctional CODH/acetyl-coenzyme A (-CoA) synthase that confers the ability to 
utilise acetyl-CoA as a terminal electron-acceptor. Several bacteria of clostridia 
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(e.g. Clostridium aceticum) contain the bifunctional enzyme and are able to 
produce acetyl-CoA from a methyl-group, CoA and CO (Equation 2.6) [50, 95, 99].  
 
EQUATION 2.4   4 CO + SO4
2- + H+  4 CO2 + HS
+ 
 
EQUATION 2.5   CO + H2O  CO2 + H2 
 
EQUATION 2.6   4 CO + 2 H2O  CH3COO
- + 2 CO2 + H
+ 
 
2.6.2 Bacterial haem oxygenase 
Iron is essential for bacterial growth and is particular important for pathogens 
during the infection process. Since the most abundant source of host iron is usually 
the haem-containing proteins, bacteria have developed efficient haem/iron 
acquisition mechanisms [100]. Bacterial haem oxygenase are enzymes that 
cleavage the haem macrocycle, leading to the release of iron, CO and biliverdin in 
a reaction analogous to that of the human haem oxygenase previously described 
(2.4; Figure 2.1). In contrast to the eukaryotic counterparts, bacterial haem 
oxygenases are smaller and soluble enzymes that lack the C-terminal membrane 
anchor [101]. 
The first bacterial haem oxygenase was identified in Corynebacterium 
diphtheriae due to the high amino acid sequence similarity with the human HO-1 
(70 %) [102]. In S. aureus two bacterial haem oxygenases have been identified: 
IsdG and IsdI, which in spite of showing no significant sequence similarity with 
human haem oxygenases nor with haem oxygenase of C. diphtheria (Table 2.5), 
possess haem-degrading activity [103]. The two S. aureus haem oxygenase 
enzymes share a high percentage of identity/similarity (63/78 %) and homologues 
are found in staphylococci species such as S. epidermidis, B. species (e.g. B. 
anthracis) and Listeria monocytogenes (Table 2.5) [104]. 
In addition to their role in iron acquisition, bacterial haem oxygenases seem 
also to protect bacterial cells against haem toxicity. In particular, it has been 
shown that strains of B. anthracis and N. meningitides deleted in the haem 
oxygenase genes show growth impairment in the presence of hemin [105, 106].  
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TABLE 2.5 Amino acid sequence 
identity/similarity of haem oxygenase with 
S. aureus IsdG and Isd. 
Haem oxygenase 
IsdG 
(% I/S) 
IsdI 
(% I/S) 
S. epidermidis 30/58 29/58 
B. anthracis  33/45 31/45 
L. monocytogenes 22/45 23/47 
HO-1 (Homo sapiens) 5/10 6/12 
HO-2 (Homo sapiens) 4/12 5/13 
C. diphtheria  5/12 4/13 
%I/S: Percentage of identity/similarity 
 
Although it is well accepted that the function of HO activity in bacteria is 
related to iron acquisition, the fate of the other HO-products remains elusive. In 
eukaryotes, biliverdin is rapidly converted into bilirubin (as described in 2.4), [54-
56]. However, due to the lack of genes encoding homologues of mammalian 
biliverdin reductase it seems unlike that, in bacteria, biliverdin is metabolised to 
bilirubin. The significance of CO production in bacteria also remains unclear, 
although the presence of CO receptors in prokaryotes suggest that CO may 
participate in signaling pathways as it occurs in eukaryotes [101]. 
 
2.6.3 Sensors of carbon monoxide 
The ability of bacteria to sense small gaseous molecules is an important tool 
that allows bacteria to adapt to different environments. In general, bacteria 
possess proteins/sensors that bind CO and regulate the transcription of genes, 
namely those involved in CO metabolism. The first CO sensor described was CooA 
from R. rubrum [107]. This protein contains haem as prosthetic group that ligates 
CO as a sixth coordinate ligand, stabilising the dimeric conformation of CooA and 
allowing the binding of the protein to the DNA target, leading to the activation of 
the CODH expression [108]. NO also binds to CooA but is unable of inducing DNA 
binding [109].  
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Other example of a CO sensor is DosST, a two-component system from M. 
tuberculosis [110]; DosS and DosT bind haem as prosthetic group and are both 
able to ligate CO forming haem-carbonyl complexes [111]. The binding of CO to 
DosS or DosT induces the dormancy regulon shifting M. tuberculosis to a latent 
state in which the bacterium remains unresponsive to drug therapy. The deletion 
of dosS severely attenuates the M. tuberculosis ability to induce the Dos regulon, 
while the disruption of dosT gene only moderately affect the Dos regulon, 
suggesting that CO is primarily sensed by DosS. As usually observed for bacterial 
sensors, DosS and DosT are not specific CO sensors since they are also responsive 
to dioxygen and NO [110, 111]. The same has been described for the E. coli  
oxygen sensor EcDos that, in addition to oxygen, also binds CO and NO being its 
activity inhibited by the two gases [112]. It is then expected that other bacterial 
regulators, particularly those containing haems, might act as CO sensors. 
 
2.7 Carbon monoxide-releasing molecules 
The discovery that endogenous production of CO has an essential role in the 
biological systems triggered the search for compounds that could mimic the action 
of HO-derived CO. Because the prolonged inhalation of CO gas may compromise 
the oxygen transport and the delivery to the human body, the use of this gas in a 
therapeutic context seems unlike. This problem prompted the search and design of 
a novel class of molecules capable of safely store and release CO into physiological 
media, the so-called CO-RMs [23]. Such molecules contain a transition metal, like 
manganese, cobalt or iron, coordinated to carbonyl groups and have the ability of 
liberating a CO group to myoglobin as indicated by the formation of carboxy-
myoglobin [23]. CO-RMs exhibit pharmacological activity and their biological 
activity is attributed to the release of CO since the addition of reduced myoglobin 
and/or the substitution of the CO-RM molecule by an inactive form (iCO-RM), in 
which the CO groups were depleted, impairs the bioactivity [24].  
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2.7.1 Chemical proprieties and bioactivity of CO-RMS 
One of the first metal carbonyl complexes identified and tested for its ability 
of carrying and releasing CO to myoglobin was the dimanganese decacarbonyl 
[Mn2(CO)10] molecule, named CORM-1 [34] (Figure 2.4). This compound, insoluble 
in water, is soluble in dimethyl sulfoxide (DMSO) or ethanol and it only releases CO 
upon stimulation with light (Table 2.6) [23]. CORM-1 is able to rapidly liberate CO 
(Table 2.6) in a 1:1 ratio, as quantified by the formation of carboxy-myoglobin [23, 
34]. CORM-1 induces vasodilatation of cerebral arterioles and attenuates the 
vasoconstriction of isolated rat hearts perfused, even when the eNOS enzyme is 
inhibited, indicating that CORM-1 causes vasorelaxation in a NO-independently way 
[24, 83, 113]. Studies in mice also show that CORM-1 has anti-inflammatory 
proprieties [114].  
 
 
FIGURE 2.4 Chemical structure 
of several transition metal 
carbonyls. CORM-1 is a manganese-
complex that liberates CO by 
photodissociation. CORM-2 and CORM-3 
are ruthenium-complexes that release CO 
by ligand substitution. CORM-A1 is the 
first prototypic of a CO-RM that instead 
of a transition metal contains a carboxylic 
group convertible into CO by hydrolysis.  
 
 
 
FIGURE 2.5 Chemical structures of 
the two CORM-2 monomers. The ration 
between the tri-carbonyl (A) and a di-
carbonyl (B) formed upon dissolution in 
DMSO (OSMe2) is 40:60 [23]. 
 
Tricarbonyldichloro ruthenium(II) dimmer ([Ru(CO)3Cl2]2), also denominated 
of CORM-2, is a ruthenium-based carbonyl (Figure 2.4) able to rapidly promote 
carboxy-myoglobin formation after dissolution in DMSO (Table 2.6), liberating 0.7 
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moles of CO per molecule [23, 34]. In fact, it has been shown that, after being 
dissolved in DMSO, CORM-2 does not exist as a dimer but as two distinct 
monomers, namely a tri-and a di-carbonyl monomer (Figure 2.5) [23].  
 
TABLE 2.6 Proprieties and bioactivity of CO-releasing molecules 
CO-RM Solubility CO release mode Physiological role 
CORM-1 
Ethanol 
DMSO 
Light–dependent 
*t1/2 < 1min 
Vasodilator 
Reno-protective 
Anti-inflammatory 
CORM-2 
Ethanol 
DMSO 
Ligand substitution 
t1/2 ~ 1min 
Vasodilator 
Anti-inflammatory 
Anti-proliferative 
Anti-apoptotic 
Reno-protective 
Anti-carcinogenic 
CORM-3 Water 
Ligand substitution 
t1/2 ~ 1min 
Vasodilator 
Anti-inflammatory 
Anti-proliferative  
Anti-apoptotic 
Cardioprotective  
Reno-protective 
CORM-A1 Water 
pH dependent 
t1/2 ~ 21min 
Vasodilator 
Anti-apoptotic 
Reno-protective 
*t1/2: half-life 
Table adapted from [24] 
 
CORM-2 has been used in vitro and in vivo models and showed to mimic the 
known physiological functions of CO (Table 2.6). CORM-2 induces vasorelaxation of 
smooth muscle cells and, even at concentrations as high as 420 µM it does not 
seem to promote any detectable cytotoxicity. Furthermore, CORM-2 induces the 
vasodilatation of aortic rings pre-contracted with phenylephrine and the total 
removal of phenylephrine does not restore the vessel contraction, suggesting that 
CORM-2 has a prolonged effect. Moreover, the intravenous administration of 
CORM-2 reduces acute hypertension of rats whereas the iCO-RM ([RuCl2(DMSO)4]) 
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does not. Importantly, the administration of CORM-2 to rats (5-20 µmol/Kg) do not 
changed the levels of oxy-haemoglobin [23].  
The anti-inflammatory effect of CORM-2 has been demonstrated in several 
models. In macrophages, CORM-2 reduces the production of reactive oxygen 
species and NO, and inhibits the up-regulation of iNOS [115]. In neutrophils, 
CORM-2 decreases the generation of superoxide suggesting that CO may inhibit 
the NADPH oxidase [115, 116]. Furthermore, it was shown that CORM-2 impairs 
the neutrophil adhesion to the human umbilical vein endothelial cells [117, 118]. 
Treatment with CORM-2 of thermally injured mice also attenuates neutrophils 
accumulation in kidney, liver and small intestine of burned mice [119-121]. The 
role of CORM-2 in cell proliferation and apoptosis was also reported, with CORM-2 
inhibiting the proliferation of human airway smooth muscle cells, pulmonary artery 
smooth muscle cells and Jurkat T cells [122-124]. The anti-apoptotic effect of 
CORM-2 was demonstrated in rat adrenal pheochromocytoma cells (PC12) and in 
murine fibroblast cells [125, 126]. The biological proprieties of CORM-2 are 
attributed to CO release since the effects are abolished in the presence of 
haemoglobin or when using an inactive form [122-124, 126]. 
 
To improve the compatibility of CO-RMs with biological systems the first water 
soluble CO-RM was produced. The tricarbonylchloro(glycinato) ruthenium(II) 
([Ru(CO)3Cl(glycinate)], known as CORM-3 (Figure 2.4), is like CORM-2 a 
ruthenium-based carbonyl and a fast CO releaser (Table 2.6), and the presence of 
a glycine coordinated to the metal center confers water solubility to the molecule 
[23]. The vasorelaxant activity of CORM-3 was first demonstrated in aortic rings 
[24, 34]. The administration of CORM-3 to rat aortic smooth muscle cells induces 
vasodilatation in a concentration dependent manner and concentrations up to 500 
µM CORM-3 do not cause decrease of cell viability [24]. CORM-3 also has a 
significant anti-inflammatory role. In particular, in microglia and macrophages cell 
lines, CORM-3 decreases the level of NO production and reduces the TNF-α release 
[116, 127, 128]. In both cases, the inhibitory effects are cancelled when using 
iCORM-3 [116, 127, 128]. Moreover, the intravenous injection of CORM-3 in mice, 
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lowers the number of neutrophil extravasation, attenuating the acute inflammation 
[129]. Finally, CORM-3 was shown to have anti-proliferative and anti-apoptotic 
effects in porcine aortic endothelial cells and in primate peripheral blood 
mononuclear cells [24]. 
 
Sodium boranocarbonate (CORM-A1) is another water-soluble CO releaser 
(Figure 2.4). This compound was the first CO-RM that does not contain a transition 
metal but a carboxylic group, which is converted into CO through hydrolysis. Unlike 
the other molecules described above, CORM-A1 liberates CO at a much slower rate 
(Table 2.6) and the CO release is pH and temperature dependent; the rate of CO 
liberation is accelerated by decrease of pH and increase of temperature [130]. The 
physiological activity of this compound has not been yet intensively explored. 
Nevertheless, it was reported that CORM-A1 displays vasorelaxation activity, 
inducing a gradual but profound dilation of isolated aortic rings [130]. More 
importantly, the administration of CORM-A1 in vivo lowers the mean arterial 
pressure of rats while the inactive form (sodium borate) does not promote 
vasodilatation in vitro or hypotension in vivo [24, 130]. 
 
2.7.2 Therapeutic applications 
The protective role of HO/CO is well established in an array of disease models 
(Figure 2.6) [22, 52]. Since CO-RMs mitigate the beneficial effects of CO gas (as 
mention in 2.7), these compounds represent a valid alternative as therapeutic 
agents to overcome the systemic problem raised by CO inhalation. Unlike CO gas, 
the CO liberated from CO-RMs is tightly controlled and delivered at a given 
concentration, and bypass, in a more effective way, the biological trapping by 
haemoglobin. In particular, the intravenous application of CO-RMs on mice does 
not increase carboxy-haemoglobin to dangerous levels (COHb levels < 10 %) 
[131].  
The major constraint of the first developed CO-RMs lay on their poor solubility 
in water, which made their in vivo utilisation very limited, but water-soluble CO-
RMs compatible with the biological systems are presently available. Hence, CO-RMs 
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possess all the features required to become CO-based pharmaceuticals to be used 
to delivery CO to tissues and organs. 
 
 
FIGURE 2.6 Physiological function of CO and their possible medical applications. The 
figure summarises the known physiological functions of HO/CO (left) as well as the potential medical 
applications (right).  
 
The beneficial effects of the therapeutic application of CO-RMs includes: i) 
cardioprotection, as ischemic rat hearts reperfused in the presence of CORM-3 are 
able to recover the perfusion and contractility, and its intravenous administration 
prolongs the survival of mice after heart transplantation and reduces the infarct 
size of mice subjected to coronary artery occlusion [34, 132, 133]; ii) renal 
protection, as the administration of Ru-based CO-RMs decrease the plasma 
creatinine level and limit renal damage in a mouse model of ischaemia-induced 
acute renal failure, and the intrarenal administration of CORM-1 and CORM-A1 to 
rats increase of renal blood flow, glomerular filtration, and urinary cGMP excretion 
[134-137]; iii) anti-carcinogenic effects since the topical application of CORM-2 in 
mice skin leads to the reduction of tumor multiplicity, regression of established 
tumor and impairs the formation of locally invasive tumors [138]; and iv) 
attenuation of the systemic inflammation causing the administration of CORM-1 to 
mice the decrease of neutrophils migration and their rolling and adhesion to the 
endothelium in the inflammation site, while the use of CORM-2 decreases 
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myeloperoxidase activity in liver of mice with induced polymicrobial sepsis [114, 
117].  
 
2.8 Parallelism between carbon monoxide and nitric oxide 
There is a parallelism between CO and NO regarding not only the structure 
and molecular size but also the endogenous production and biological function. 
Additionally, their regulation seems to be intimately linked. CO and NO are two 
diatomic molecules that have similar structure, molecular weight and solubility. 
Furthermore, they share similarity in biochemical reactivity since both bind to the 
haem iron center of most known haemoproteins [62]. However, while CO only 
binds ferrous iron, NO may ligate to either ferrous and ferric haem. An important 
difference between the two gases arises from the radical nature of NO that, in 
contrast to CO, reacts with other free radicals and assumes several oxidation 
states, being a more reactive molecule (see Chapter 1). 
CO and NO are endogenously produced by HO and NOS, respectively, and 
both enzymes have constitutive and inducible forms triggered by several common 
stimulus. Concerning their regulation, NO has been shown to both inhibit and 
activate the HO activity. As a radical, NO is perhaps the strongest inducer of the 
HO-1 expression [139]. On the other hand, the binding of NO to the haem of HO 
prevents the ligation of oxygen and impairs its activity. CO ligates to NOS and 
inactivates the enzyme [140]. In contrast, it is not clear the effect of CO on NOS 
expression since it was reported that CO up-regulates iNOS in hepatocytes 
whereas in other models HO-derived CO inhibits the iNOS expression [22, 141]. 
Regarding their biological function, both gases are important signaling 
molecules and their action is mediated by activation of sGC. As stated previously 
(2.5), the ability to activate the sGC differs between the two gases and the 
relevance of their action depend on several factors. For example, the enzymatic 
production of NO is more dependent on oxygen concentration than on CO. Since 
NOS requires normal oxygen concentrations, as the system becomes anaerobic 
NOS ceases to work whereas HO continues to produce CO. It is therefore possible 
that, under anaerobic conditions, CO becomes a more important signaling molecule 
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than NO [50]. Interestingly, a study conducted in mice hepatocytes has shown that 
the removal of iNOS/NO from the system results in a loss of protection which can 
be reversed upon HO-1 induction. However, if HO-1 is removed, in spite of the 
presence of iNOS/NO, the protection afforded is lost [141]. 
Since the 19th century, NO-releasing drugs, like amyl nitrite and nitroglycerine 
have been used to treat angine pectoris [142-144]. Even though the methods for 
delivering CO to treat human diseases are well behind the knowledge of NO-based 
compounds, CO-RMs are already envisaged to become relevant pharmaceutical 
tools. 
Although NO has also a established function in pathogen elimination (as 
discussed in Chapter 1), the role of CO in pathogen eradication has never been 
explored. In this thesis we have analysed the effect of CO on bacteria survival 
through the use of CO-RMs and we showed that CO has the ability of killing 
bacteria, namely E. coli and S. aureus (Chapter 5).  
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Summary 
Flavohaemoglobins and flavodiiron proteins are two families of enzymes 
involved in nitrosative detoxification. However, the physiological oxygen-related 
conditions under which they work, and their relative role are still a matter of 
debate. To address this question we analysed the function of the putative 
flavohaemoprotein of Staphylococcus aureus, an organism that lacks a flavodiiron-
like gene. In this report we show that the recombinant protein contains all features 
typical of canonical flavohaemoglobins and that the transcription of 
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flavohaemoglobin gene was up-regulated by nitrosative stress in an oxygen-
dependent manner. However, and in contrast to other bacterial flavohaemoglobins, 
the S. aureus protein has no apparent role in aerobic nitrosative protection, being 
only beneficial when cells of S. aureus are submitted to nitrosative stress in a 
microaerophilic environment. The in vivo data corroborates the proposal that 
flavohaemoglobin acts physiologically as a denitrosylase. 
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3.1 Introduction 
The prokaryotic defence systems against nitrosative stress involve at least 
two families of enzymes that directly detoxify nitric oxide or S-nitrosothiols: the 
flavodiiron NO reductases and the flavohaemoglobins [1, 2]. Flavohaemoglobins, 
which have a two-domain structure formed by a haemoglobin-like domain 
(containing a single b-type haem) and a NADP+:ferredoxin oxidoreductase-like 
domain (harbouring a FAD moiety and a NAD(P)H binding motif) are able to 
function as NO scavengers. In the presence of oxygen, Hmp oxidises NO to nitrate, 
with a range of activities that varies from 7.4 to 128 s−1, at 20 °C [3-5]. 
Anaerobically, Hmp is also able to reduce NO to nitrous oxide, but with a much 
lower activity of 0.14–0.5 s−1 [2, 6]. Both the oxidation of NO to nitrate as well as 
the reduction of NO to nitrous oxide are proposed to occur through a common NO-
(nitroxyl anion-bound haem) intermediate. Since the former reaction can operate 
very efficiently under microaerobic conditions [3, 4], Hmp may be adapted mainly 
to protect under microaerobic conditions, which are typical in vivo.  
The beneficial role of Hmp in protection from nitrosative stress under aerobic 
and anaerobic conditions has been demonstrated for several microorganisms [2-9]. 
In E. coli, both under microaerobic and anaerobic growth conditions, 
flavohaemoglobin was found to confer a degree of NO protection similar to that of 
the flavodiiron NO reductase [7, 8, 10]. It was also observed that, when compared 
with flavorubredoxin, the higher levels of Hmp expression are reached at longer 
times after the addition of the nitrosative stress, and that the lack of 
flavohaemoglobin production was not compensated by an increase in the 
expression of flavorubredoxin and vice-versa [10]. These results strongly suggest 
that in E. coli the two enzymes play different roles in nitrosative cell protection. 
Flavodiiron NO reductases and flavohaemoglobin-like proteins are widely 
distributed among bacteria, fungi and protozoa and, as in E. coli, in a large number 
of genomes the two genes are present in the same organism. On the contrary, in 
the S. aureus genome sequence only the gene encoding for a putative 
flavohaemoprotein is present, making S. aureus a good system to study the role of 
Hmp per se. In addition, S. aureus is a major human pathogen capable of causing 
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from mild to life-threatening systemic diseases, which results from the ability to 
colonise different environmental niches, i.e., to survive a diverse range of stresses. 
Furthermore, the spread of antibiotic-resistance of S. aureus strains constitutes a 
major worldwide concern [11, 12]. In spite of its clinical importance the S. aureus 
cellular components involved in the response to reactive nitrogen species, that 
constitutes a major mammalian defence mechanism against pathogens, remains 
almost unknown. 
In the present work, we have cloned and produced the recombinant S. 
aureus Hmp and performed its biochemical characterisation. To elucidate its 
physiological function the S. aureus hmp gene was disrupted and the resistance to 
the nitrosative stress of the mutant was analysed. 
 
3.2 Materials and methods 
 
Bacterial strains, plasmids, media and growth conditions 
Strains E. coli XL2-Blue, E. coli BL21Gold(DE3), S. aureus NCTC 8325 and its 
derivative S. aureus RN4220, and plasmids pET-28a (Novagen) and pSP64E [13, 
14] were used in this work. S. aureus strains and pSP64E were a kind gift of Prof. 
H. de Lencastre. S. aureus cells were grown, in tryptic soy broth (TSB) or Luria-
Bertani (LB) media, at pH 7, aerobically in flasks filled with 1/5 of its volume, 
microaerophilically in closed flasks completely filled or anaerobically in rubber seal 
capped flasks that, once filled with media and closed, were extensively bubbled 
with nitrogen. Cells were cultivated at 37 °C and only the aerobically grown 
cultures were shaken at 180 rpm. 
 
Cloning, expression and purification of S. aureus recombinant Hmp 
To clone the hmp gene, primers based on flaking sequences that generated 
NcoI and EcoRI restriction sites were used to amplify a 1.2-kb fragment from the 
S. aureus NCTC 8325 genomic DNA [15], isolated as described in [16]. The gene 
was ligated into pET28a (Novagen), yielding pETHmp, and introduced into E. coli 
XL2-Blue. Positive recombinant plasmids were selected from kanamycin-resistant 
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colonies and DNA sequenced. Over-expression of the recombinant protein was 
achieved in pETHmp containing E. coli Bl21Gold(DE3) cells, grown aerobically in LB 
supplemented with 3 μM FeCl3, 100 μM riboflavin and 30 μg/mL kanamycin. When 
cells reached OD600 of 0.4, 500 μM isopropyl-1-thio-β-d-galactopyranoside and 50 
μM aminolevulinic acid were added and growth continued for another 6 h. Cells 
were disrupted and the soluble extract loaded into a Q-Sepharose High 
Performance column, previously equilibrated with buffer A (Tris–HCl 10 mM, pH 
7.6, and glycerol 20 %). Hmp eluted at ~ 240 mM NaCl, was applied to a 
Superdex S-75 gel filtration column equilibrated with buffer A + 150 mM NaCl. The 
protein was then reloaded on the Q-Sepharose column and the protein eluted at   
~ 170 mM NaCl was found to be pure, as judged by SDS–PAGE. Protein 
concentration was assayed by the bicinchoninic acid method with BSA as the 
standard [17], flavin content was quantified after acid extraction with 
trichloroacetic acid [18], and haem content assayed using the 
haemochromopyridine method [19]. 
 
EPR, UV–Vis spectroscopy and redox titration 
EPR spectra were obtained on a Bruker ESP 380 spectrometer, equipped with 
an Oxford Instruments continuous flow helium cryostat. UV–Vis absorption spectra 
of S. aureus Hmp were acquired using a Shimadzu UV-1603 spectrophotometer, at 
room temperature. S. aureus Hmp (~ 11 μM) was titrated anaerobically as 
described in [20]. 
 
Construction of S. aureus hmp deletion strain and complementation 
analysis 
To disrupt the hmp gene, an internal fragment (800 bp) of the S. aureus 
NCTC 8325 hmp was PCR amplified, using oligonucleotides (SAHECO:5′-
GAAAGGGACAGAATTCACGTCAATC-3′ and SAHBAM: 5′-
GTTGTCATGATGGATCCCGATACT-3′), and ligated into pSP64E. The resulting 
pSPHmp, was electroporated into S. aureus RN4220 [21, 22], and transformants 
were selected on TSB-agar (TSA) plates containing erythromycin (10 μg/ml). 
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Chromosomal DNA isolated from single colonies and PCR analysis was used to 
confirm the correct integration of pSPHmp into the chromosome of RN4220. One 
of such colonies was designated LMS800 and used in subsequent studies. 
For the complementation analysis, the plasmids pETHmp and pET28a were 
individually transformed into LMS2710 strain (E. coli norV mutant) [10]. Single 
colonies were grown overnight and used to inoculate minimal salt medium [10] 
containing chloramphenicol and kanamycin. The growth was performed under 
anaerobic conditions and monitored at 600 nm. 
 
RNA extraction and RT-PCR analysis 
Total RNA was isolated from cells grown under the indicated conditions using 
the hot-phenol method, and treated with DNaseI. The forward and reverse primers 
used to create the disruption of the hmp gene were also utilised in the RT-PCR 
assays, performed with USB Reverse Transcriptase Kit. After confirming the 
absence of any residual DNA, RT-PCR reactions were performed with 150 ng of 
RNA. The 16S rRNA gene was used to guarantee that equal amounts of RNA were 
compared. 
 
NADH oxidase, NO denitrosylase and NO reductase activities of S. 
aureus Hmp 
The kinetic experiments were recorded in a Shimadzu UV-1603 
spectrophotometer and performed at 25 °C. The NADH oxidase activity of S. 
aureus Hmp (30 nM) was measured by monitoring the anaerobic NADH 
consumption (200 μM), using potassium ferricyanide (K3Fe(CN)6) (500 μM) as 
artificial electron acceptor, and following the absorbance decrease at 420 nm 
(εFe(CN)6 = 1020 M
−1 cm−1). The NO denitrosylase activity of Hmp (36 nM) was 
measured aerobically by following the NADH oxidation (200 μM) (ε340 nm = 6200 
M−1 cm−1) upon addition of aliquots of a saturated NO solution [10]. The NADH:NO 
oxidoreductase activity was determined by anaerobically incubating NADH (200 
μM) with Hmp (365 nM), and monitoring the NADH oxidation by NO. Activities are 
reported in terms of NO consumption, using the proposed stoichiometry of 2 NO 
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molecules per NADH molecule, for both the denitrosylase and reductase reactions 
[23]. All activities were calculated taking into account the stoichiometric haem and 
flavin content of the as purified protein. 
 
3.3 Results and discussion 
 
S. aureus flavohaemoprotein is a canonical flavohaemoglobin  
In all known genome sequences of S. aureus strains it is present a gene 
predicted to encode a flavohaemoprotein that shares ~ 30 % sequence similarity 
with the E. coli Hmp. To assess the function of the S. aureus Hmp, the 
recombinant protein was produced and characterised. Upon purification, S. aureus 
Hmp exhibited a molecular mass of 44 kDa that corresponds to a monomeric 
protein, and contained 0.7 mol flavin and 1 mol haem. The UV–Vis spectrum of S. 
aureus Hmp displayed the features typical of the canonical Hmps in the oxidised, 
reduced and CO bound states (Figure 3.1A). Also, the EPR spectrum is 
characteristic of high-spin ferric iron (data not shown). A reduction potential of 
−170 mV was measured for the haem center and two identical reduction potentials 
of −190 mV were measured for the FAD center (Figure 3.1B). The NADH oxidase 
activity of S. aureus Hmp was determined to be 34 s−1, using potassium 
ferricyanide as the electron acceptor. Hmp exhibited an NO denitrosylase activity 
of 66 s−1, measured upon addition of 20 μM NO, and a NADH:NO oxidoreductase 
activity of 0.7 s−1. These values are within the range usually reported for 
homologous enzymes [23]. 
 
S. aureus hmp transcription is mainly regulated by oxygen limitation 
The mRNA level of hmp under nitrosative stress conditions in aerobic and 
oxygen-limiting conditions was evaluated in RT-PCR experiments (Figure 3.2). The 
transcription of hmp was found to be low under aerobic conditions and to 
increase considerably on switching to oxygen-limited growth conditions. S-
nitrosoglutathione (GSNO) caused an increase in the hmp transcription level under 
aerobic conditions, and no major variations were observed in microaerophilic or 
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anaerobic grown conditions. Hence, the results indicate that the major trigger for 
hmp induction is oxygen limitation, thus suggesting a physiological function under 
oxygen limited conditions. In general, hmp exhibit oxygen-dependent gene 
expression via the oxygen sensor-regulator Fnr [2], but analysis of the upstream 
sequence of the S. aureus hmp coding region did not allow identification of any 
obvious Fnr binding motif. 
 
FIGURE 3.1 Characterization of the as-purified S. aureus Hmp. (A) UV–Vis spectra of Hmp 
oxidized (—), reduced with sodium dithionite (– – –), and reduced and CO ligated (–·–·–). (B) Redox 
titration of the haem centre (♦) and of the FAD centre (□) of S. aureus Hmp. Full lines were calculated 
with the Nernst equation for a monoelectronic (reduction potential of −170 mV) and two 
monoelectronic consecutive processes (identical reduction potentials of −190 mV), for the haem and 
FAD centres, respectively. 
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FIGURE 3.2 S. aureus hmp expression 
increases upon oxygen limitation. RNAs 
isolated from S. aureus grown aerobically (A), 
microaerophilic (B) or anaerobically (C) in LB for 4 
h in the absence (−) or in the presence (+) of 
200 μM (A,B) or 50 μM (C) GSNO. The equal 
loading of total RNA was confirmed by the same 
intensity of the 16S rRNA band (lower panel). Data 
are representative of reactions performed with two 
independent RNA samples. 
 
Protection of S. aureus by flavohaemoglobin in response to GSNO 
depends on the oxygen-related conditions 
To infer the role for Hmp in nitrosative protection, the physiological effects of 
various concentrations of GSNO and oxygen on S. aureus hmp mutant and wild 
type strains were analysed (Figure 3.3). Under aerobic conditions, GSNO 
concentrations up to 100 μM did not cause growth inhibition of wild type S. aureus, 
while 200 μM GSNO induced a severe growth arrestment (Figure 3.3A). Under 
microaerophilic conditions, all tested concentrations of GSNO ranging from 50 to 
200 μM only caused a negligible effect on growth of wild type S. aureus (Figure 
3.3C). However, when wild type S. aureus was grown under anoxic conditions the 
effect of similar concentrations of GSNO was more pronounced, as judged by the 
significant degree of growth impairment observed with 50 μM GSNO (Figure 3.3E). 
Therefore, no additional work was done with GSNO and the hmp mutant under 
anaerobic conditions. 
In the absence of GSNO, the S. aureus hmp mutant displayed an oxygen-
dependent growth behaviour similar to that of wild type RN4220 strain (Figure 
3.3B,D). Under aerobic conditions, and for all the concentrations of GSNO tested, 
there was no discernible difference in the rates and extents of growth, as 
measured by the OD600 between the parent and mutant strain (Figure 3.3B). 
However, under microaerophilic conditions exposure of the wild-type S. aureus to 
200 μM GSNO caused a decrease of the growth rate of ~ 7 %, whereas the Δhmp 
strain exhibited a lag in growth of ~ 50 % (Figure 3.3D). A similar behaviour was 
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also observed for the S. aureus hmp mutant in the presence of 50 μM of NO gas 
(data not shown). Hence, Hmp seems to be able to protect S. aureus submitted to 
a strong nitrosative stress only under microaerophilic conditions. 
 
FIGURE 3.3 Microaerophilic GSNO-protection conferred by flavohaemoglobin to S. 
aureus. S. aureus wild type strain RN4220 (wt) and mutant strain LMS800 (Δhmp), were grown 
aerobically (A,B), microaerophilically (C,D) or anaerobically (E) in LB medium and left untreated (■) or 
treated with 50 μM GSNO (▲), 100 μM GSNO (♦) and 200 μM GSNO (•). Each growth curve represents 
the average of at least three independent cultures. Panel (F) Analysis of complementation of E. coli 
LMS2710 (ΔnorV) with S. aureus Hmp. Growth curves acquired under anaerobic conditions in minimal 
medium for the E. coli flavorubredoxin mutant strain LMS2710 harbouring either vector alone (pET) (∆) 
and with pETHmp expressing S. aureus Hmp (◊)  without addition of GSNO or in the presence of 50 μM 
GSNO: LMS2710 (pET) (▲) and LMS2710 (pETHmp) (♦). 
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S. aureus Hmp attenuates the anaerobic NO damage in E. coli 
flavorubredoxin mutant 
Our previous work showed that deletion of flavorubredoxin gene (norV) in E. 
coli, strain LMS2710, resulted in a mutant with increased sensitivity to 
anaerobically added NO [10]. Complementation studies were conducted to test 
whether S. aureus Hmp could perform the role of flavorubredoxin in E. coli. The 
results showed that expression of S. aureus hmp in the E. coli norV mutant, 
LMS2710, lead to a significant increase in the anaerobic GSNO resistance of the 
mutant strain (Figure 3.3F), indicating that S. aureus Hmp has the ability to 
perform anaerobic nitrosative detoxification. In fact, this ability could not be 
analysed in S. aureus since the wild type strain is itself highly sensitive to GSNO 
under anaerobic conditions. Nevertheless, the possibility that the low NO reductase 
activity of S. aureus Hmp was compensated by the presence of a large amount of 
protein generated by overexpression cannot be excluded. Since only over-
expression of S. aureus hmp could improve nitrosative protection, the level of 
anoxic expression S. aureus hmp and/or lower NO reductase activity seems to be 
insufficient to protect S. aureus anaerobically. Furthermore, it is already well 
documented in other organisms that, besides flavorubredoxin and Hmp, there are 
many other factors involved in the response to nitrosative stress, e.g. [10], which 
are so far unknown in S. aureus and may be also responsible for the high 
sensitivity of S. aureus to anaerobic nitrosative stress. 
 
3.4 Conclusion 
S. aureus infection is related to the versatility of the pathogen to grow in 
different and often hostile environmental niches. In this study we observed that 
wild type S. aureus grows, although differently, under aerobic and anaerobic 
conditions and also in the presence of GSNO. However, GSNO resistance is fully 
dependent on the degree of oxygenation. While, in anaerobic conditions S. aureus 
is very sensitive to GSNO since slow growth is observed in any of the tested 
concentrations, in microaerophilic S. aureus sustains growth up to 200 μM GSNO. 
Interestingly, Hmp confers S. aureus protection against nitrosative challenge only 
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under microaerophilic conditions. This suggests that in vivo Hmp acts as a 
denitrosylase, i.e., under low oxygen concentration and high NO concentration the 
denitrosylase mechanism is operative, as previously proposed by Hausladen and 
co-workers [4]. Last but not least, it is quite interesting that recent studies on S. 
aureus indicated that the pathogenesis of this microbe, and in particular the 
production of virulence factors, is also dependent on the oxygen concentration [24, 
25]. 
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Summary 
In this work we report that flavohaemoglobin contributes to the azole 
susceptibility of Staphylococcus aureus. We first observed that deletion of the 
flavohaemoglobin gene leads to a viability increase of imidazole-treated S. aureus 
cells and that reversion to the wild-type phenotype occurs upon expression of 
flavohaemoglobin from a multicopy plasmid. Further spectroscopic analyses 
showed that miconazole, the most efficient azole antibiotic against S. aureus, 
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ligates to haem of both oxidised and reduced flavohaemoglobin. The binding of 
miconazole to oxidised flavohaemoglobin, with an association constant of 1.7 x 106 
M-1, typical of a tight, specific binding equilibrium, results in augmentation of the 
superoxide production by the enzyme. These results are corroborated by in vivo 
studies showing that imidazole-treated S. aureus cells expressing flavohaemoglobin 
contain a higher amount of reactive oxygen species. Moreover, it was observed 
that the survival of miconazole-treated S. aureus internalized by murine 
macrophages is higher for cells lacking flavohaemoglobin. Altogether, the present 
data revealed that in S. aureus flavohaemoglobin enhances the antimicrobial 
activity of imidazoles via an increase of intracellular oxidative stress.  
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4.1 Introduction 
S. aureus is an opportunistic pathogen responsible for a large number of 
human infections that cause systemic diseases of mild to life-threatening character. 
The increasing incidence of methicillin-resistant S. aureus strains observed in the 
past few years make S. aureus infections a leading threat to the public health, 
causing in the United States and Europe more deaths than the human 
immunodeficiency virus [1]. Like other Gram-positive bacteria, staphylococci are 
sensitive to imidazoles [2]. Imidazoles (such as clotrimazole, miconazole, 
ketoconazole, sulconazole, Figure 4.1) represent one of the major classes of azole 
antifungal that are useful in the treatment of infections, including cutaneous and 
vaginal candidiasis [3]. The activity of these antifungal drugs derives primarily from 
inhibition of the biosynthesis of ergosterol, an essential component of the fungal 
plasma membrane, at the level of lanosterol 14-  demethylase. Furthermore, in 
fungi and yeast, azole treatment leads to an increase in the endogenous 
production of reactive oxygen species [4, 5]. For example, in C. albicans and S. 
cerevisiae  the miconazole inhibition of cytochrome c oxidase, peroxidase and 
catalase has been reported to be responsible for a high level of ROS production [6, 
7]. It has also been reported that clotrimazole inhibition of P. falciparum 
haemoperoxidase leads to ROS accumulation in this protozoan pathogen [8]. For 
S. cerevisiae, C. albicans and E. coli the action of imidazoles was also correlated 
with the inhibition of the nitric oxide scavenger activity of flavohaemoglobin [9].  
Flavohaemoglobins are widespread among bacteria and yeast, and contain 
three domains: C-terminal NAD- and FAD-binding domains that together constitute 
a ferredoxin-NADP+ oxidoreductase-like domain, and an N-terminal globin domain, 
that harbours a single b-type haem. The high-spin haem contains one axial 
histidine and binds small molecules like NO, CO and O2. The haem can also bind 
bulky aromatic bases, since it is inserted in a large hydrophobic pocket [9]. We 
observed that the binding of imidazoles to S. aureus flavohaemoglobin results in an 
increase of the amount of deleterious reactive oxygen species produced by 
flavohaemoglobin that contributes to the bactericidal effect of azoles antibiotics 
towards S. aureus.  
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4.2 Materials and methods 
 
Reagents 
Miconazole, sulconazole, clotrimazole, ketoconazole and 2’,7’-
dichlorofluorescein diacetate (DCFH-DA) were purchased from Sigma, and 5-tert-
butoxycarbonyl 5-methyl-1-pyrroline N-oxide (BMPO) from Northwest. All the 
reagents were dissolved in DMSO, except for ketoconazole and BMPO, which were 
prepared in methanol and water, respectively. For the UV-Visible and Resonance 
Raman spectroscopic studies, a water-saturated solution of miconazole was used, 
to avoid the effect of DMSO on the reduced form of flavohaemoglobin.  
 
Bacterial strains, culture conditions and viability assays 
Overnight cultures of S. aureus wild-type (RN4220) and S. aureus Δhmp 
(LMS800) [10] grown in TSB medium were used to inoculate, to an optical density 
at 600 nm (OD600nm) of 0.1, LB medium supplemented with the appropriate 
antibiotics (2 µM miconazole, 5 µM sulconazole, 12 µM clotrimazole and 120 µM 
ketoconazole) and contained in closed flasks. For control purposes, untreated 
cultures, in which an equal volume of correspondent antibiotic’s solvent was 
added, were also analysed. S. aureus viability was then evaluated after 5 h 
treatment of the liquid cultures with antibiotic, and the number of viable cells was 
determined by measuring the colony forming units (CFU) per milliliter upon plating 
5 µl of each dilution on agar and counting the isolated colonies formed after 
overnight incubation. The percentage of survival was calculated as the number of 
cells originated by the treated cultures divided by the number of colonies formed 
after plating the control cultures. 
Minimal inhibitory concentration (MIC) of the azole antibiotics were 
determined on 24-well microtitre plates as previously described [11]. Assays were 
conducted in LB, at 37 ºC, performed in triplicate, and repeated at least twice.  
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Complementation studies 
For the complementation analysis, a vector expressing S. aureus hmp was 
constructed. To this end, a fragment containing the complete S. aureus hmp gene 
was amplified, using oligonucleotides SAHmpFw (5’-
TCACATTTTTATTATCATGTTTACTTTTTTCTAGGA-3’) and SAHmpEcoRI (5’-
CGTTGATTAAGTTTCATATGAGCACTAATTCTCTTT-3’) and ligated to pMK4 [12]. The 
resulting vector (pHmp) and the empty vector (pMK4) were electroporated into S. 
aureus Δhmp and wild-type (RN4220) strains. For the mutant strain the positive 
transformants were selected on TSA medium containing 10 µg/ml erythromycin 
plus 5 µg/ml chloramphenicol, while selection of the wild-type was achieved using 
only chloramphenicol. Cell growth was performed in liquid medium treated with 
miconazole for 5 h, as above described, and analysed by serial dilutions plated on 
agar. 
 
Spectroscopic studies: UV-Visible, Resonance Raman and EPR 
S. aureus flavohaemoglobin was cloned, expressed and purified as described 
previously [13]. UV-Visible spectra were recorded on a Shimadzu UV-1700 
spectrophotometer, using 10 µM flavohaemoglobin in 10 mM Tris-HCl, pH 7.6 
buffer containing 9 % glycerol.  
EPR spectra were obtained on a Bruker EMX spectrometer equipped with an 
Oxford Instruments continuous flow helium cryostat. BMPO was used as a spin-
trap for the detection of reactive oxygen species, which allows to distinguish 
between superoxide anion and the hydroxyl radical [14]. These experiments were 
performed using 10 µM S. aureus flavohaemoglobin, 200 µM NADH, 25 mM BMPO, 
and 50 µM miconazole, in a quartz flat cell, at room temperature.  
Resonance Raman (RR) spectra were measured using a confocal microscope 
coupled to a Raman spectrometer (Jobin Yvon U1000) equipped with 1200 l/mm 
grating and a liquid-nitrogen-cooled back-illuminated CCD detector. Samples of 
flavohaemoglobin (20 μM) were placed in a quartz rotating cell and excited with 
the 413 nm line of a krypton ion laser (Coherent Innova 302), with a laser power 
of 2-4 mW and accumulation times of 60 s. After polynomial background 
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subtraction, the positions and line-widths of the Raman bands were determined by 
component analysis using in-house software.  
 
Enzymatic studies  
The equilibrium constant for miconazole binding was determined by titrating a 
fixed amount of flavohaemoglobin with increasing quantities of the antibiotic, and 
monitoring the changes in absorbance in the visible region. The amount of 
miconazole-protein complex was calculated using a differential absortivity at 418-
500 nm, determined from the difference of a spectrum of a solution having excess 
antibiotic (thus assuring full complex formation) and the spectrum of the oxidised, 
isolated protein. A value of Δε (418-500) = 69565 M-1cm-1 was obtained; from this 
value, the amount of complex at each solution could be determined, and by using 
the appropriate mass balance equations, the concentrations of free antibiotic and 
free protein were also calculated. The number of binding sites and the equilibrium 
constant were then determined by a Scatchard equation [15]. The same procedure 
could not be applied with precision to the reduced protein, due to the interference 
of DMSO; nevertheless, a lower limit for the binding constant could be determined 
using a differential absortivity at 426-390 nm. The assays were performed with 5 
µM S. aureus flavohaemoglobin and the miconazole concentrations varied between 
2 µM and 60 µM. The percentage of DMSO used in all the assays was 0.4 % v/v. 
 
Measurement of endogenous ROS production 
Endogenous ROS production was determined by a fluorometric assay 
according to the method described previously [4]. Cells of wild-type S. aureus 
(RN4220) and Δhmp (LMS800) mutant were grown for 5 h, in the absence or 
presence of azoles. Cells were then collected by centrifugation, washed, and 
resuspended in phosphate buffer (PBS), followed by the addition of 10 µM DCFH-
DA. The fluorescence intensities (FI) were measured on a Varian Eclipse 96-well 
spectrofluorimeter (excitation at 485 nm and emission at 538 nm). The FI’s were 
normalized in relation to the final OD600nm of each culture. To assess the variation 
of ROS, the FI of control cultures and the FI of azole-treated cultures were 
subtracted. 
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Quantitative real-time RT-PCR  
For real-time RT-PCR experiments, 2.0 μg of S. aureus total RNA derived from 
samples grown in LB and treated with 2 µM miconazole for 5 h was used to 
synthesise cDNA, according to the Transcriptor High Fidelity cDNA Synthesis kit 
protocol (Roche Applied Science). Real-time PCRs were performed in a LightCycler 
Instrument using LightCycler FastStart DNA Master SYBER Green I Kit according to 
the manufacturer’s instructions (Roche Applied Science). The amplification 
reactions were carried out with equal amounts of cDNA (100 ng) as initial 
template, and each reaction contained 0.5 μM of specific primers, 2 mM of MgCl2, 
and the hot-start PCR reaction mix from Roche Applied Science. The expression 
ratio of the target gene was determined relatively to a reference gene, the S. 
aureus 16S rRNA whose transcription abundance remains invariant under the 
tested conditions. The samples were assayed in triplicate. 
 
Assay of intracellular S. aureus viability in J774A.1 macrophages 
Murine macrophages J774A.1 (LGC Promochem) were inoculated with 5 x 105 
cells/ml and cultured for 2 days, at 37 ºC in a 5 % CO2/air atmosphere, in 24-well 
plates containing Dulbecco’s Modified Eagle medium (DMEM) supplemented with 
4.5 g/l glucose, 110 mg/ml sodium pyruvate (DMEM Glutamax), 10 % fetal bovine 
serum, 100 µM non-essential amino acids, 50 U/ml penicillin and 50 µg/ml 
streptomycin, all from GIBCO. Prior to infection, macrophages were activated for 5 
h with 1 µg/ml interferon-γ (Sigma) and 5 µg/ml lipopolysaccharides (Sigma). 
When required, 800 µM NG-Monomethyl-L-arginine acetate salt (L-NMMA; Sigma) 
was also added to achieve inhibition of the murine macrophage inducible NO 
synthase. S. aureus wild-type and Δhmp were grown for 5 h in the presence or 
absence of miconazole (2 µM), washed three times with PBS and resuspended in 
DMEM, to obtain for all cultures an initial bacterial concentration of 107 cfu/ml. 
Macrophages were then infected with these bacterial suspensions, at a multiplicity 
of infection (MOI) of at least 16, for 30 min at 37º C. The supernatants were then 
collected to determine the number of bacteria not internalized. Extracellular 
bacteria were killed by incubation in DMEM supplemented with 50 U/ml penicillin 
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and 50 µg/ml streptomycin, for 5 min, and the wells were washed three times with 
PBS. After that, macrophages were lysed with 2 % saponin, and the number of 
intracellular bacteria determined by CFU counting of viable bacteria.  
 
4.3 Results 
 
S. aureus is susceptible to azole antibiotics 
The susceptibility of S. aureus to several azole antibiotics was analysed. For 
S. aureus RN4220, the minimal inhibitory concentrations were of the same order of 
magnitude for miconazole (15 ± 2 µM), sulconazole (20 ± 0 µM), and clotrimazole 
(30 ± 3 µM), while a much higher value was determined for ketoconazole (500 ± 
70 µM). In previous work, S. aureus viability was also reported to decrease 
significantly with miconazole, while essentially no effect (> 200 µM) was observed 
with ketoconazole [16]. Additionally, we observed that S. aureus is resistant to 
concentrations of the triazole antibiotics fluconazole and itraconazole (Figure 4.1) 
up to 2 mM.  
 
FIGURE 4.1 Structures of the azole (imidazole; 1,2,4-triazole) antibiotics investigated. 
 
S. aureus susceptibility to azoles involves flavohaemoglobin 
We next investigated the possible role of flavohaemoglobin in the sensitivity of 
S. aureus to imidazoles. To this end, we compared the viability of S. aureus wild-
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type and Δhmp mutant cells upon treatment with several azole antibiotics. The 
results showed that inactivation of flavohaemoglobin caused an increase in the 
resistance of S. aureus to imidazoles, i.e., the mutant strain produced higher 
number of viable cells, a result which was observed for all imidazoles tested 
(Figure 4.2A-B).  
 
FIGURE 4.2 Flavohaemoglobin contributes to imidazole-sensitivity of S. aureus. (A) Cell 
viability of S. aureus wild-type and Δhmp in the absence (-) and in the presence (+) of 2 µM 
miconazole, 5 µM sulconazole, 12 µM clotrimazole and 120 µM ketoconazole. (B) The number of S. 
aureus  wild type  (gray bars) and ∆hmp (white bars) cells was evaluated by measurement of CFU per 
milliliter, and the percentage of survival was calculated dividing the number of colonies of treated 
cultures by that of control cultures (*P<0.05). (C) Viability of S. aureus Δhmp and wild-type cells 
transformed with pHmp and pMK4, untreated (-) and treated with miconazole (2 µM) (+). 
 
To confirm that imidazole resistance was a specific consequence of 
flavohaemoglobin gene deletion, the viability of the Δhmp strain expressing 
flavohaemoglobin (from a multicopy plasmid) treated with miconazole was 
evaluated. As expected, upon complementation, reversion to the wild-type 
phenotype was observed (Figure 4.2C). Furthermore, the over-expression of S. 
aureus flavohaemoglobin in the wild-type strain led to an increase in the sensitivity 
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to imidazoles (Figure 4.2C). These results show that flavohaemoglobin contributes 
to the activity of imidazoles against S. aureus, independently of any other stress 
agent. 
To understand the mechanism by which flavohaemoglobin affects the 
susceptibility of S. aureus to imidazoles, we analysed the binding of miconazole, 
the most active commercially available azole antibiotic against S. aureus, to 
flavohaemoglobin by UV–Visible, EPR and Resonance Raman (RR) spectroscopies.  
The UV–Visible absorption spectra of S. aureus flavohaemoglobin in the 
oxidised and reduced states displayed the characteristic features of high-spin ferric 
and ferrous b-haems, respectively (Figure 4.3A). Upon addition of miconazole, the 
spectra of both redox forms changed considerably, indicating binding of the 
antibiotic to the haem and formation of six-coordinated, low-spin forms. 
Miconazole shifts the Soret band of the oxidised form to 414 nm, and a broad band 
at 538 nm appears; also, the charge-transfer band at 645 nm, characteristic of 
high-spin haems, bleaches completely. In the reduced form, the Soret band shifts 
to 427 nm and bands at 531 and 560 nm are clearly distinguished (Figure 4.3A). 
The binding of the imidazole antibiotic to S. aureus flavohaemoglobin was also 
studied by EPR spectroscopy. In the absence of the antibiotic, the EPR spectrum of 
oxidised flavohaemoglobin exhibits resonances characteristic of a high-spin ferric 
haem, with g= 6.34, 5.31 and 2.0. Upon addition of miconazole, the high-spin 
signature almost disappears, being substituted by a set of resonances indicative of 
the formation of a low-spin ferric haem in a rhombic ligand field, with g-values at 
2.85, 2.27 and 1.59, compatible with a ligation by two imidazoles from the axial 
histidine and from miconazole (Figure 4.3B). A lower intensity signal is also 
observed at gmax=3.25, which suggests the presence of a second low-spin ferric 
haem configuration, with a more axial ligand field. The rhombic species (the one 
with gmax=2.85) corresponds to a geometry where the two imidazole planes are 
essentially parallel, while the more axial one (gmax=3.25) reflects a situation where 
the dihedral angle between those two planes is higher (e.g., [17]). The UV-Visible 
and EPR data show that miconazole binds to the oxidised flavohaemoglobin haem, 
yielding a low-spin ferric species, as expected for ligation through imidazole 
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FIGURE 4.3 Spectroscopic analysis of miconazole binding to S. aureus 
flavohaemoglobin. (A) UV-Visible spectra of 10 µM oxidised Hmp (Hmp(III)), after the binding of 
miconazole (M) to the ferric protein binding of miconazole (M) to the ferric protein (Hmp(III)-M), of 
dithionite reduced Hmp (Hmp(II)) and upon addition of miconazole to ferrous Hmp (Hmp(II)-M). (B) 
EPR spectra of S. aureus Hmp (Hmp(III)) and of flavohaemoglobin treated with miconazole (Hmp(III)-
M). At 16 K, spectra were obtained at 9.4 GHz, 2.0 mW microwave power, 1 mT modulation amplitude 
and 100 kHz modulation frequency. The spectrum of Hmp(III) showed was divided by 5. (C) RR spectra 
of flavohaemoglobin. (I) reduced flavohaemoglobin; (II) reduced flavohaemoglobin upon addition of 
miconazole. All RR spectra were measured with 413 nm excitation, 20 μM flavohaemoglobin (in 10 mM 
Tris HCl, pH 7.6) in the presence or absence of miconazole, at ambient temperature with a laser power 
of 2 mW and accumulation times of 60 s. 
 
nitrogens. These results were confirmed by RR spectroscopy since the spectra of 
haems include marker bands that are sensitive to the oxidation, coordination and 
spin state of the haem iron [18-20], for both paramagnetic and diamagnetic 
species. We first investigated the ferric protein, in the presence/absence of 
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miconazole. RR spectra of oxidised flavohaemoglobin are characteristic of a five-
coordinated high-spin (5cHS) configuration, with the 4 and 3 vibrational modes at 
1370 cm-1 and 1494 cm-1, respectively. This form undergoes a change of spin state 
upon miconazole binding, as revealed by the shift of the 3 band to 1505 cm
-1, 
characteristic of a six-coordinated low-spin (6cLS) ferric haem (Table 4.1). The 
reduced S. aureus flavohaemoglobin is in a 5cHS configuration, with 4 at 1357 cm
-
1 and 3 at 1474 cm
-1 (Figure 4.3C, spectrum I). 
 
TABLE 4.1 Positions of the marker bands 4 and 3 (cm
-1) in the 
Resonance Raman spectra of oxidised (Hmp (III)) and reduced (Hmp(II)) 
flavohaemoglobin, unbound and bound to miconazole (M).  
Species 
5cHS (ox) 5cHS (red) 6cLS (ox) 6cLS (red) 
4 3 4 3 4 3 4 3 
Hmp(III) 1370 1494       
Hmp(III)-M     1372 1505   
Hmp(II)   1357 1474     
Hmp(II)-M       1364 1494 
 
Component analysis of the spectrum obtained upon addition of miconazole, 
revealed the presence of two species: five-coordinated ferrous haem, as in the 
pure protein, and a major component with 4 up shifted to 1364 cm
-1 (Figure 4.3C, 
spectrum II, Table 4.1), indicating the formation of a six-coordinated low-spin 
ferrous form. Moreover, since the 4 band up-shifts by 7 cm
-1 (in comparison with 
the 4 of the unbound ferrous flavohaemoglobin), it is apparent that delocalization 
of the electron cloud from the haem to the miconazole takes place upon binding of 
the antibiotic [19]. We have also observed, both by RR and UV-Visible 
spectroscopies that DMSO binds to the ferrous haem, resulting in a distinct low-
spin form of flavohaemoglobin. In summary, the spectroscopic results show that 
miconazole coordinates to the haem moiety of S. aureus flavohaemoglobin in the 
oxidised as well as in the reduced state.  
The binding of miconazole to S. aureus flavohaemoglobin was also studied by 
titrating the protein with different antibiotic concentrations and following the 
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absorption change of the Soret band of the flavohaemoglobin after ligation of the 
antibiotic. Following the procedure described in the methods section, we 
determined an equilibrium association constant of 1.7 x 106 M-1, indicating that one 
molecule of miconazole binds tightly to oxidised flavohaemoglobin. A lower limit for 
the association constant for the reduced form was determined to be 1.2 x 105 M-1 
(data not shown). 
 
Imidazoles increase the ROS production by flavohaemoglobin 
Since, as mentioned before, we detected an increase in imidazole resistance 
upon inactivation of S. aureus hmp (Figure 4.2), we next addressed the origin of 
this behavior. We first observed that the level of endogenously produced reactive 
oxygen species augmented in cells of wild-type S. aureus treated with miconazole 
or ketoconazole (Figure 4.4A). More importantly, when the ROS production was 
evaluated in the Δhmp mutant treated with imidazoles the ROS levels were lower, 
indicating that the presence of flavohaemoglobin contributes to the imidazole-
associated ROS generation (Figure 4.4A).  
It has been reported that, under certain conditions, E. coli flavohaemoglobin 
produces superoxide ions [21, 22]. To investigate the effect of antibiotic binding to 
flavohaemoglobin on radical formation, we used the spin trap BMPO, in EPR 
experiments. In the absence of the antibiotic, when using NADH and under aerobic 
conditions, the BMPO-OOH adduct was observed [14] being indicative of the 
formation of superoxide by flavohaemoglobin (Figure 4.4B, upper line). In the 
presence of miconazole, the same EPR species was detected but at a significantly 
higher concentration (Figure 4.4B, lower line). By comparing the intensities of the 
spectra of the BMPO-OOH adduct after 15 min (the time determined to yield the 
maximum concentration of this adduct), we determined the concentration of 
BMPO-OOH to be ca. 3-fold higher, in samples with miconazole. We thus conclude 
that not only is superoxide formed by S. aureus flavohaemoglobin, since its EPR 
spectrum is identical to that of the superoxide–BMPO adduct [14], but also that 
this production increases upon the binding of miconazole to flavohaemoglobin. 
Furthermore, we detected, by mass spectrometry, that the integrity of the 
Results 
Chapter 4 
_________________________________________________________________________ 
 118 
imidazole was maintained since no changes occurred in the mass and intensity of 
the peak of the antibiotic before and after incubation of miconazole with 
flavohaemoglobin in the presence of NADH (data not shown).  
 
 
 
 
 
 
 
FIGURE 4.4 Imidazoles increase the ROS 
production by flavohaemoglobin. (A) 
Evaluation of endogenous ROS production of S. 
aureus wild-type (black bar) and Δhmp (white bar) 
after treatment with 2 µM miconazole and 120 µM 
ketoconazole. Each data point represents the 
average of three independent measurements with 
the correspondent standard errors. (B) EPR spectra 
of BMPO-OOH obtained for a sample containing 10 
µM Hmp, 200 µM NADH, 25 mM BMPO and 50 µM 
miconazole (lower line) and for a sample in which 
the antibiotic was replaced by an equivalent 
amount of the antibiotic’s solvent (upper line). The 
spectra were recorded at ambient temperature, at 
9.8 GHz, microwave power of 10 mW and 
modulation amplitude of 0.1 mT, after 15 min of 
incubation. 
 
Real time RT-PCR experiments revealed that exposure of S. aureus to 
miconazole leads to an increase in the expression of the katA gene encoding 
catalase, a marker of oxidative stress, showing katA a 11.7±1.4-fold increase in 
wild-type strain but only a 7.8±0.4-fold increase in the hmp mutant, i.e, in the 
absence of flavohaemoglobin the expression of katA decreased ~ 30 %. These 
results are in agreement with a lower production of ROS in the hmp mutant.  
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Flavohaemoglobin decreases survival of miconazole-treated S. 
aureus in macrophages 
The increased resistance of S. aureus Δhmp to imidazoles when compared to 
the parent strain (Figure 4.2A-B) led us to examine the effect of flavohaemoglobin 
on the survival of miconazole-treated S. aureus cells phagocytised by 
macrophages. In the absence of the antibiotic, the Δhmp strain was killed more 
efficiently by activated macrophages (Figure 4.5A) due to the lack of the NO 
detoxifying activity of flavohaemoglobin. For miconazole-treated cells we observed 
that while incubation in macrophages of antibiotic-treated wild-type cells resulted 
in a decrease of survival of approximately 50 %, the Δhmp cell counts showed no 
statistical difference between cells unexposed and exposed to miconazole (Figure 
4.5A). Similar data were obtained in assays performed in the presence of L-NMMA, 
the mammalian inhibitor of iNOS, which shows that in the presence or absence of 
NO, flavohaemoglobin contributes for the lower survival of azole-treated cells 
(Figure 4.5B). The decreased viability of antibiotic-treated S. aureus in macrophage 
cell lines can be rationalised taking into consideration that the simultaneous 
presence of flavohaemoglobin and miconazole leads to an increase in the level of 
deleterious reactive oxygen species, as previously demonstrated by fluorometric 
and EPR experiments. 
 
FIGURE 4.5 Intracellular survival in murine macrophages of miconazole-treated wild-
type and Δhmp S. aureus cells. Murine macrophages activated with IFN-γ/LPS (A) and treated with 
the mammalian iNOS inhibitor L-NMMA (B) were infected with S. aureus wild-type in the absence (black 
bar) and in the presence of miconazole (diagonal striped bar), or incubated with Δhmp cells grown 
without antibiotic (white bar) and with miconazole (horizontal striped bar). After a period of infection of 
30 min macrophages were lysed and bacterial counts determined. Two independent assays were 
performed in triplicate, exhibiting the indicated standard errors (**P<0.01; *P<0.05).  
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4.4 Discussion 
In this study, we show that S. aureus is susceptible to several azole 
antibiotics with miconazole being, among those tested, the most effective one. The 
mechanism by which imidazole-treated bacteria undergo growth inhibition was 
assessed and the results provide the first evidence that imidazoles induce 
intracellular ROS production in S. aureus after miconazole and ketoconazole 
treatment. Remarkably, a strain of S. aureus lacking flavohaemoglobin resulted in 
increased cell viability, while over-expression of flavohaemoglobin restored the 
azole-susceptibility phenotype. These results indicate that flavohaemoglobin and 
imidazoles act together in the killing mechanism.  
The binding of miconazole to S. aureus flavohaemoglobin was analysed by 
UV-Visible, EPR and Resonance Raman and revealed that miconazole acts as a 
strong field haem ligand, since upon miconazole binding the five coordinated high-
spin configuration in both oxidation states is converted to a six-coordinated low-
spin species. Interestingly, the binding of similar-size imidazoles led to similar MIC 
values, while the larger imidazole ketoconazole exhibits a much higher MIC value. 
Intriguingly, the two triazoles tested, itraconazole and fluconazole, had no activity 
against S. aureus. As seen in Figure 4.1, this lack of activity cannot solely be 
related to the size of these molecules since fluconazole is, in fact, the smallest 
system investigated. Both fluconazole and itraconazole are potent azole anti-
fungals, but rather than having an imidazole side-chain, they possess 1,2,4-
triazoles. These triazoles do bind well to their P450 targets; since in the P450 
enzymes there is an axial cysteine, rather than an axial histidine (as in 
flavohaemoglobin), it seems likely there may simply be large differences between 
imidazoles and triazoles, binding to P450 or flavohaemoglobin, due to electronic 
effects. 
Flavohaemoglobins have been reported to have several enzymatic activities, 
namely NO denitrosylase and alkyl hydroperoxide reductase, as well as to produce 
superoxide [21, 23]. We noticed that ligation of imidazoles to S. aureus 
flavohaemoglobin leads to impairment of denitrosylase activity (data not shown), 
which is in accordance with results described for fungal, yeast and E. coli 
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flavohaemoglobins [9]. However, both the susceptibility of wild-type S. aureus to 
imidazoles and the increase in the resistance of S. aureus to imidazoles upon 
deletion of the flavohaemoglobin gene occurs in the absence of any source of nitric 
oxide. Hence, we tested if binding of imidazoles could interfere with superoxide 
generation by flavohaemoglobin. In fact, EPR spin trap experiments showed that 
the binding of miconazole magnifies the superoxide production by S. aureus 
flavohaemoglobin. Since the haem is blocked with miconazole, we concluded that 
the superoxide was generated at the level of the FAD centre. In this mechanism, 
FAD receives electrons from NAD(P)H and reduces oxygen to superoxide. This 
hypothesis is supported by the ability of several flavin-containing proteins to 
generate superoxide upon one-electron oxidation by dioxygen (e.g., [24]). Also, it 
was previously shown that NAD(P)H is oxidised by flavohaemoglobin with the 
electrons transferred via FAD to external acceptors when the ferrous haem is 
blocked [22].  
Therefore, upon ligation of azoles to flavohaemoglobin the S. aureus cells 
become exposed to higher amounts of deleterious ROS, which explains the lower 
survival of antibiotic-treated S. aureus wild-type cells and the higher resistance of 
the Δhmp mutant strain. 
Note that in the simultaneous presence of azoles and NO, the higher level of 
ROS and the inhibition of the NO scavenging activity of flavohaemoglobin both will 
contribute to the more efficient killing of wild-type S. aureus that was indeed 
detected in activated macrophages (Figure 4.5A). Interestingly, the present results 
may explain the previously observed synergistic antimicrobial action of imidazole 
antibiotics and NO releasers exerted on Candida species [25], which can be now 
rationalized considering that in the presence of the two compounds Candida 
flavohaemoglobin no longer can act as a fungal protective factor.  
Finally, we consider future prospects and possible applications. The 
observation that some azole antifungals also have antibacterial activity is not new 
with Janssen et al. [26] reporting as early as 1969 that miconazole had potent (10 
nM) activity against S. hemolyticus (S. pyogenes). It is also of interest to note that 
earlier works reported that miconazole killed S. aureus [16] and that cells grown in 
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the presence of miconazole had decreased levels of vitamin K2 and increased levels 
on octaprenyl diphosphate [27]. This would be consistent with targeting MenA 
biosynthesis, which could also potentially contribute to an increase in ROS levels, 
and indeed we did observe that in the hmp mutant strain there is still ROS 
production (Figure 4.4A), i.e., even in the absence of flavohaemoglobin. So, it is 
possible that the imidazole antibiotics have more than one target in S. aureus, and 
potentially, in other bacteria as well.  
In S. aureus, the buildup of ROS is of particular interest since S. aureus has a 
protective golden carotenoid “shield” called staphyloxanthin [28] that protects the 
bacterium from attack by neutrophil-generated ROS [29]. Inhibiting carotenoid 
biosynthesis [30] results in bacteria that are white (since they lack the carotenoid 
pigment) and are thus cleared by host defences. Combining azoles with 
staphyloxanthin biosynthesis inhibitors may enhance intracellular levels of ROS and 
NO killing by stripping bacteria of their defences.  
In conclusion, this work revealed for the first time that the binding of azoles 
to S. aureus flavohaemoglobin leads to an increase of the intracellular level of 
reactive oxygen species, therefore enhancing the antimicrobial activity of these 
antibiotics.  
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Summary 
Carbon monoxide is endogenously produced in the human body, mainly from 
the oxidation of haem catalysed by haem oxygenase enzymes. The induction of HO 
and the consequent increase in CO production play important physiological roles in 
vasorelaxation and neurotransmission and in the immune system. The exogenous 
administration of CO gas and CO-releasing molecules has been shown to induce 
vascular effects and to alleviate hypoxia-reoxygenation injury of mammalian cells. 
In particular, due to its anti-inflammatory, anti-apoptotic, and anti-proliferative 
properties, CO inhibits ischemic-reperfusion injury and provides potent 
cytoprotective effects during organ and cell transplantation. In spite of these 
findings regarding the physiology and biology of mammals, nothing is known about 
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the action of CO on bacteria. In the present work, we examined the effect of CO 
on bacterial cell proliferation. Cell growth experiments showed that CO caused the 
rapid death of the two pathogenic bacteria tested, Escherichia coli and 
Staphylococcus aureus, particularly when delivered through organometallic CO-
RMs. Of importance is the observation that the effectiveness of the CO-RMs was 
greater in near-anaerobic environments, as many pathogens are anaerobic 
organisms and pathogen colonisation occurs in environments with low oxygen 
concentrations. Our results constitute the first evidence that CO can be utilised as 
an antimicrobial agent. We anticipate our results to be the starting point for the 
development of novel types of therapeutic drugs designed to combat antibiotic-
resistant pathogens, which are widespread and presently a major public health 
concern. 
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5.1 Introduction 
Carbon monoxide is a colourless and odourless diatomic gas, chemically inert, 
that occurs in nature as a product of oxidation or combustion of organic matter. 
Owing to its lethal effect when present in high concentrations, CO was considered 
for many years to be only an environmental toxicant that results from air pollution 
by automobile exhaust. The knowledge that the human body is able to produce 
small quantities of CO and the evidence that CO derived from haem oxygenase 
activity contributes to important intracellular functions have modified our 
perception of CO as a pernicious toxin to include its beneficial effects [1-3]. In 
consequence, the application of CO gas or CO-releasing molecules has emerged as 
a new therapeutic strategy in medicine [4-6]. The evolution of CO from a toxicant 
to a molecule of mounting importance in mammals finds a parallel in another 
diatomic molecule, nitric oxide [7]. NO is produced in the body by the nitric oxide 
synthase and shares with CO many down-stream signalling pathways and 
regulatory functions, in particular, those associated with the activation of soluble 
guanylate cyclase [8-10]. In addition, there is an interplay between the two 
molecules, since it is proposed that CO is a modulator of nitric oxide synthase [3, 
4] and NO up-regulates haem oxygenase [11, 12], which in turn catalyses the 
oxidative degradation of free haem into biliverdin, with the concomitant release of 
iron and CO. NO also constitutes one of the weapons that the mammalian immune 
system uses to fight pathogens [13, 14]. The bactericidal function of NO relies on 
the deleterious effects caused in the pathogen, e.g., the nitrosylation of iron 
centres. Although CO is a stable neutral molecule with a long half-life, it shares 
with NO the high affinity for iron of haem proteins, which is the basis of its toxicity. 
We therefore set out to explore the possible action of CO on bacterial growth 
rates. For this purpose, we tested the bioactivity of CO, applied either in the 
gaseous form or via treatment with CO-RMs, on E. coli and S. aureus. These 
bacteria are major human pathogens that are widespread in the community and 
are responsible for hospital-acquired infections, exhibiting a concerning degree of 
antibiotic resistance.  
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5.2 Material and Methods 
 
Reagents 
The different sources or references for CO were as follows: tricar-
bonyldichlororuthenium(II) dimer (CORM-2), Sigma; tricarbonylchloro(gly-
cinate)ruthenium(II) (CORM-3), [15]; bromo(pentacarbonyl)manganese (ALF 021), 
[16]; and tetraethylammonium molybdenum pentacarbonyl bromide (ALF 062), 
[17]. All compounds were freshly prepared as 10 mM stock solutions by dissolution 
in dimethyl sulfoxide, pure distilled water, or methanol.  
 
Bacterial strains and growth conditions 
E. coli K-12 ATCC 23716 and S. aureus NCTC 8325 were grown in minimal 
salts (MS) medium (1.3 % [wt/vol] Na2HPO4, 0.3 % [wt/vol] KH2PO4, 0.05 % 
[wt/vol] NaCl, and 0.1 % [wt/vol] NH4Cl supplemented with 20 mM glucose, 2 mM 
MgSO4, 100 µM CaCl2, and 0.25 % [wt/vol] Casamino Acids) and in LB medium (1 
% [wt/vol] tryptone, 0.5 % [wt/vol] yeast extract, and 1 % [wt/vol] NaCl), 
respectively, under different oxygen supply conditions. Aerobic experiments were 
undertaken with flasks filled to one-fifth of their volume, microaerobic tests were 
conducted with closed flasks filled to one-half of their volume, and anaerobic 
conditions were produced in rubber-sealed flasks that, once filled with medium and 
closed, were extensively fluxed with nitrogen gas.  
 
CO gas and CO-RM treatment 
Overnight cultures of E. coli or S. aureus grown in LB or TSB, respectively, 
were used to inoculate fresh MS medium (E. coli) or LB medium (S. aureus), and 
the cultures on fresh medium were incubated at 37 °C under the required aeration 
conditions to an optical density at 600 nm of 0.3. At this point, cells were exposed 
to a flux of CO gas for 15 min or to CO-RMs. Untreated cells were bubbled with 
nitrogen gas or treated with dimethyl sulfoxide, water, or methanol, depending on 
the solvent used to dissolve the CO-RM. The inactive form of ALF 062 was 
prepared by mixing vigorously with 20 % methanol in a closed flask over 2 to 3 h. 
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The counter ion of ALF 062, tetraethyl ammonium bromide, and one of the 
products of ALF 062 decomposition, sodium molybdate, were used at the same 
concentration as ALF 062 (50 µM).  
 
Viability assays 
The number of viable cells was evaluated by measuring the CFU per milliliter 
upon plating serial dilutions of the various cultures onto agar plates. The percent 
survival was calculated as the number of colonies originated by treated cultures 
divided by the number of colonies formed upon the plating of untreated cultures. 
Sensitivity tests were conducted by plating 5 µl serial dilutions of cultures grown 
for 4 h and treated with CO-RMs, with or without the CO scavenger haemoglobin 
[bovine form used at 20 µM; Sigma]), onto agar. The experiments were performed 
with a minimum of three independent cultures, and the results are presented in 
the figures as averaged values with error bars representing one standard 
deviation.  
The investigation of MICs and minimal bactericidal concentrations (MBCs) was 
carried out by the tube dilution test. Briefly, 2.5 ml of minimal medium was 
inoculated with an overnight culture of E. coli or S. aureus to give an optical 
density at 600 nm of 0.005 to 0.01. Different concentrations of CORM-2, between 
150 µM and 2 mM, were added to the diluted suspensions in the wells of 24-well 
plates, and the plates were incubated for at least 18 h at 37°C and 90 rpm. The 
concentration of CORM-2 in the first well in the series with no sign of visible 
growth was reported as the MIC. All the cultures that exhibited a lack of cell 
growth were then subsequently plated onto agar devoid of any drug. After 
incubation at 37 °C for 24 h, the lowest concentration of CORM-2 in a culture with 
no growth was assumed to be the MBC.  
 
CO release kinetics 
CO-RMs were mixed with MS or LB medium in sealed vessels, and the vessels 
were incubated at room temperature under constant stirring and protected from 
light. Gas samples were collected after 30 min and 4 h and analysed using a gas 
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chromatograph (Thermo Finnigan Trace) equipped with a CTRI column (Alltech) 
and a thermal conductivity detector. The CO released was quantified using a 
calibration curve recorded prior to the reaction course.  
 
Inductively coupled plasma mass spectrometry analysis 
E. coli cells cultured in MS medium with or without 50 µM ALF 062 were 
collected after 1 h of growth, and the cellular metal content was analysed at 
Instituto de Investigacão das Pescas e do Mar, Lisbon, Portugal. The intracellular 
concentration of Mo in E. coli cultures was assayed on a quadropole inductively 
coupled plasma mass spectrometer (X series; Thermo Elemental) equipped with a 
Peltier impact bead spray chamber and a concentric Meinhard nebulizer. The 
experimental parameters were as follows: 790 W of forward power, peak jumping 
mode, and 150 sweeps per replicate (dwell time, 10 ms; dead time, 30 ns). A 
seven-point calibration within a range of 1 to 100 µg liter
-1 
was used to quantify 
metal concentrations. Coefficients of variation for determinations of metal content 
(n = 5) ranged between 0.5 and 2 %. The precision and accuracy of metal 
concentration measurements, as determined through the repeated analysis of 
reference materials (TORT-1, TORT-2, DORM-2, and DORM-3 from the National 
Research Council of Canada) by using indium as an internal standard, were within 
1 to 2 %. Procedural blanks always accounted for less than 1 % of the total 
molybdenum concentrations in the samples.  
 
5.3 Results and discussion 
The effect of CO on the viability of bacteria was investigated first by the direct 
delivery of CO gas. The administration of CO gas, fluxed into the growing cultures, 
led to a significant growth impairment of E. coli and S. aureus (Figure 5.1). To 
evaluate the potential of CO-RMs, the compounds indicated in Figure 5.2 were 
selected.  
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FIGURE 5.1 Effects of CO gas on E. coli and S. aureus viability. (A) E. coli and S. aureus 
cells were grown under microaerobic conditions in MS and LB media, respectively, and exposed to a flux 
of CO gas for 15 min. (B) Sensitivity tests were conducted by plating the indicated serial dilutions of the 
cultures collected after 4 h of exposure to CO gas (+) or to nitrogen gas (-). 
 
CORM-2 and CORM-3 are active in a variety of CO-mediated biological 
processes, both in vitro and in vivo [18]. In the first series of experiments, the 
effect of CO released from CORM-2 on the growth of E. coli and S. aureus was 
studied with bacteria cultured under different levels of oxygen supply. Shortly after 
 
 
 
FIGURE 5.2 Chemical structures of 
CO-RMs used in this study.
the exposure to CORM-2, the 
percentage of surviving cells 
significantly diminished (Figure 5.3). 
Experiments using water-soluble 
CORM-3 revealed that, albeit 
requiring higher concentrations than 
CORM-2 due to its chemical 
composition, the compound also 
strongly decreased the viability of E. 
coli and S. aureus cells (Figure 5.4). 
However, while the addition of 
CORM-3 resulted in a strong inhibition of E. coli cell growth, S. aureus was more 
resistant to CORM-3 (Figure 5.4A), particularly under aerobic conditions. In 
general, the action of the two compounds was rapid and extended over time, as 
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cells did not resume growth over the subsequent 4 h (Figures 5.3 and 5.4) or after 
8 h (data not shown). 
 
 
FIGURE 5.3 Effects of 
CORM-2 on E. coli and S. 
aureus cell viability. (A) E. 
coli cells were grown in MS 
under aerobic and anaerobic 
conditions and treated with 
250 µM CORM-2. S. aureus 
cells were grown aerobically 
and microaerobically in LB 
medium and exposed to 250 
µM CORM-2. (B) Results of 
tests of the sensitivity of 
cultures to CORM-2 (see 
Materials and Methods). The 
indicated dilutions of cultures 
were treated with CORM-2 
(+; 250 µM) or left untreated 
(-) and assayed in the 
absence or in the presence of 
haemoglobin (Hb). 
 
In order to examine whether the bactericidal effect of CO-RMs was due to CO, 
cell growth experiments with CO-RMs were also performed in the presence of Hb, 
a high-affinity CO scavenger. In all cases, the bactericidal effect on E. coli and S. 
aureus was completely lost (Figures 5.3B and 5.4B), thus demonstrating that the 
antimicrobial action of CO-RMs is dependent on their release of CO.  
Bactericidal activity has been defined as a ratio of the MBC to the MIC of < 4 
[19]. The determination of the CORM-2 MBC/MIC ratios for E. coli and S. aureus to 
be 1.5 and 1.0, respectively, revealed the bactericidal character of CORM-2. The 
two other CO-RMs used to investigate the bactericidal effect of CO, namely, 
manganese carbonyl ALF 021 and molybdenum carbonyl ALF 062, were also seen 
to be capable of strongly reducing the viability of E. coli and S. aureus (Figures 5.5 
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and 5.6). Again, the addition of Hb completely eliminated the harmful action of ALF 
compounds on the two bacteria (Figures 5.5 and 5.6). Furthermore, to ensure that 
the activity of ALF 062 was not related to its decomposition products, we tested 
the effects of tetraethyl ammonium bromide, sodium molybdate, and a solution of 
inactivated ALF 062, obtained after the cessation of CO release (see Materials and 
Methods), on bacterial growth. None of these compounds had bactericidal 
properties or altered growth kinetics (data not shown). Therefore, the bactericidal 
effects of ALF 062 are due to its capacity to release CO.  
 
 
FIGURE 5.4 Effects of 
CORM-3 on E. coli and S. 
aureus cell viability. (A) E. 
coli cells were grown in MS 
medium either aerobically or 
anaerobically and treated with 
400 µM CORM-3. S. aureus 
cells were grown aerobically or 
microaerobically in LB medium 
to which 500 or 400 µM CORM-
3 was added, respectively. (B) 
Sensitivity tests were 
conducted by plating dilutions 
of cultures grown as described 
in Materials and Methods after 
exposure to CORM-3 (+) or no 
treatment (-) in the absence or 
in the presence of haemoglobin 
(Hb). The concentrations of 
CORM-3 used were the same as 
those indicated in the legend to 
panel A. 
 
It should be mentioned that neither CORM-2 nor CORM-3 releases CO gas 
when dissolved in the media utilised, even at concentrations higher than those 
used in our experiments (Table 5.1). Furthermore, although ALF 021 and ALF 062 
release CO gas upon dissolution in the medium, they do so in rather small amounts 
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within the time scale of the experiment (Table 5.1). However, inductively coupled 
plasma mass spectrometry analysis of E. coli cells incubated with ALF 062 revealed 
a very large increase in the content of Mo (155 µg/g) compared to that in control 
cells (2.5 µg/g), confirming that the Mo from ALF 062 accumulates inside the E. 
coli cells, where it releases CO to the cellular targets. Since the bactericidal effect 
of the CO-RMs does not require the release of CO gas to the extracellular medium 
(Table 5.1), we must conclude that CO has to be delivered to the cellular targets 
directly from the CO-RMs. Because Mo from bactericidally active (CO-loaded) ALF 
062 is found to accumulate rapidly within cells, we infer that it transports CO and 
delivers it into the intracellular space, where it reaches the cellular targets and 
causes the decrease of bacterial cell viability. If Hb is present in the medium, the 
high affinity of Hb for CO results in a fast transfer (or abstraction) of the active CO 
from the CO-RMs (or from gas) to the protein haems and the effective scavenging 
of CO as COHb (see below). Under these conditions, no CO will be available for 
intracellular delivery and the cells remain alive.  
 
 
 
 
 
 
FIGURE 5.5 Sensitivity of E. coli to ALF 
021 and ALF 062 compounds. E. coli cells 
grown under aerobic or anaerobic conditions 
were treated with 500 or 200 µM ALF 021, 
respectively, and with 50 µM ALF 062 (see 
Materials and Methods) in the absence or in the 
presence of Hb. The indicated dilutions of 
cultures exposed to CO-RMs (+) or not exposed 
(-) were subjected to sensitivity tests.  
 
Albeit with some minor deviations, the general pattern of our results shows 
that CO-RM toxicity is enhanced when growth occurs under lower oxygen 
concentrations. For example, ALF 021 was more effective in reducing the viability 
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of E. coli cells grown anaerobically (200 µM ALF 021) than that of cells grown 
aerobically (500 µM ALF 021). The augmentation of the effect of CO at low oxygen 
concentrations may be explained by the preferential binding of CO to the ferrous 
form of haem proteins, which are predominant under reducing environments. More 
importantly, the bactericidal effect of CO-RMs under anaerobic conditions indicates 
that growth inhibition is not restricted to the impairment of the respiratory chain 
by the binding of CO to cytochrome oxidase, which is likely to contribute to the 
bactericidal activity of these compounds under aerobic conditions. This fact is quite 
important since pathogen colonisation occurs in near-anaerobic environments and 
since many pathogens are anaerobic organisms. On the other hand, the type of 
bacterial cell wall also seems not to interfere with the action of CO-RMs, as judged 
by the similar decreases in cell viability observed for the gram-positive (S. aureus) 
and gram-negative (E. coli) species upon treatment with the same CO-RM. Hence, 
CO-RMs have the potential for use as bactericides against a wide range of 
microorganisms independently of the type of bacterial cell wall and oxygen growth 
requirements. 
 
 
 
 
 
 
 
FIGURE 5.6 Sensitivity of S. aureus to 
ALF 021 and ALF 062 compounds. S. aureus 
cells grown under aerobic and microaerobic 
conditions were treated with 600 µM ALF 021 and 
50 µM ALF 062. The indicated dilutions of cultures 
exposed to CO-RMs (+) or not exposed (-) were 
subjected to sensitivity tests in the absence or in 
the presence of Hb, as described in Materials and 
Methods.  
 
The difference between the degrees of action of dissolved molecular CO gas 
and CO-RMs is striking. When administered as gas, CO had to be present in rather 
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high concentrations (ca. 1 mM) to become effective as a bactericide. The ability of 
CO-RMs to accumulate inside bacterial cells before they release CO makes these 
compounds highly effective CO donors to bacterial targets, thereby strongly 
enhancing the bactericidal efficacy of CO. In fact, the CO-RMs used in this study 
were able to transfer CO to Hb to form COHb, as judged by the shift of the Hb 
Soret band from 413 to 418 nm (data not shown) and by the results depicted in 
Figures 5.3B, 5.4B, 5.5, and 5.6. Hence, CO-RMs are capable of delivering CO to 
haem-containing molecules, as had been shown before for the rapid carbonylation 
of myoglobin by CORM-3 [20]. Likewise, the carbonylation of Hb by CORM-2 and 
CORM-3 occurs within the mixing time, while that by ALF 021 and ALF 062 takes 
place in less than 15 min. It is well known that the biological effect of CO on 
mammalian cells is due mainly to its interaction with iron-containing proteins, such 
as the above mentioned cytochrome oxidase. In addition to haem proteins and 
sensors, CO may bind to almost all transition metal-containing proteins, giving rise 
to structural modifications and alterations of their biological functions. Hence, in 
bacteria, there are a large number of likely intracellular targets that can account 
for the toxic effect of CO revealed in this study.  
 
TABLE 5.1. CO released into medium by CO-RMs.* 
 CO Equivalents * 
Medium MS LB 
Time (min) 30 240 30 240 
CORM-2 (5 mM) 0 0 0 0.1 
CORM-3 (12 mM) 0 0 0 0 
ALF 021 (6 mM) 0 0.5 0 0.5 
ALF 062 (6 mM) 1.4 3.8 0.2 1.6 
*
Amounts of CO are expressed as CO equivalents (number of CO groups released per CO-RM 
molecule 
 
In spite of the increasing expectations for the use of CO in medicine [4-6], 
until now, the role of CO as a bactericidal compound had remained unexplored. 
Nevertheless, in the early 1970s it was reported that the addition of CO to an 
aerobic culture of E. coli caused a decrease in DNA replication [21]. However, as 
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the authors of the study did not observe any effect of CO on cells growing 
anaerobically on glucose, they concluded that the inhibition of DNA synthesis in 
cells grown under aerobic conditions was not due to a direct effect on the 
replication apparatus but resulted from indirect effects, such as ATP or 
deoxynucleoside triphosphate depletion [21]. In more recent years, in spite of 
several public concerns, CO has been used by the food industry to generate the 
bright red color of the dark muscle tissue of meat and fish, which results from the 
great affinity of CO for the Fe (II) binding site of myoglobin. Interestingly, a very 
recent study of the influence of different packing systems on meat preservation 
indicated that packages to which CO gas had been added exhibited less bacterial 
growth than other packages. These results suggest that CO may be one of the 
packaging gases responsible for the inhibition of the growth of microorganisms 
[22]. We now show that CO and, in particular, CO-RMs have the ability to kill 
bacteria under aerobic and anaerobic conditions. We submit that CO-RMs 
constitute a novel class of antibacterial molecules that may become drug 
candidates upon the development of safe and controllable methods of CO delivery 
to bacterial targets that avoid the in vivo scavenging of CO by the red blood cells 
[4]. In particular, non systemic bactericides may be a relatively easy application for 
CO-RMs. Although this is a first visualisation of a still very distant goal, bactericides 
based upon completely new concepts are urgently required, as the emergence and 
spread of drug-resistant bacterial pathogens reveal a concerning decrease in the 
effectiveness of currently available antibiotics.  
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Summary 
We recently reported that carbon monoxide has bactericidal activity. To 
understand its mode of action we analysed the gene expression changes occurring 
when Escherichia coli, grown aerobically and anaerobically, is treated with the 
carbon monoxide releasing molecule, CORM-2. The E. coli microarray analysis 
shows that E. coli CORM-2 response is multifaceted with a high number of 
differentially regulated genes spread through several functional categories, namely 
genes involved in inorganic ion transport and metabolism, regulators, and genes 
implicated in posttranslational modification, such as chaperones. CORM-2 has 
higher impact in E. coli cells grown anaerobically, as judged by the existence of 
repressed genes belonging to eight functional classes which are absent in 
aerobically CORM-2 treated cells. 
The biological relevance of the variations caused by CORM-2 was 
substantiated by studying the CORM-2 sensitivity of selected E. coli mutants. The 
results show that the deletion of redox-sensing regulators SoxS and OxyR 
increased the sensitivity to CORM-2 and suggest that while SoxS plays an 
important role in protection against CORM-2 under both oxygen growth conditions, 
OxyR seems to participate only in the aerobic CORM-2 response. Under anaerobic 
conditions, we found that the heat shock proteins IbpA and IbpB contribute to 
CORM-2 defence since the deletion of these genes increases the sensitivity of the 
strain. The induction of several met genes and the hypersensitivity to CORM-2 of 
the ∆metR, ∆metI and ∆metN mutant strains suggest that CO has effects on the 
methionine metabolism of E. coli. CORM-2 also affects the transcription of several 
E. coli biofilm-related genes and increases the biofilm formation in E. coli. In 
particular, the absence of tqsA or bhsA increases the E. coli resistance to CORM-2, 
and deletion of tqsA leads to a strain that loses its capacity to induce the biofilm 
formation upon treatment with CORM-2.  
In spite of the relatively stable nature of the CO molecule, our results show 
that CO is able to trigger a significant alteration in the transcriptome of E. coli 
which necessarily has effects in several key metabolic pathways.  
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6.1 Introduction 
Carbon monoxide formed in nature results from the incomplete oxidation of 
organic matter and as the by-product of the activity of the haem oxygenase 
enzyme that oxidises haem to biliverdin [1]. In the latter process, which can occur 
in bacteria, plants and animals, the amount of CO endogenously produced by the 
various cell types is low. In humans, the CO formed has several physiological 
functions, namely in the neuronal and cardiovascular systems [2]. On the contrary, 
high concentrations of CO have a poisoning effect in mammals due to the binding 
of CO to haemoglobin, and the consequent impairment of oxygen storage and 
transport by haemoglobin causes hypoxia [2]. CO binds preferentially to transition 
metal-containing proteins, including haem-based proteins/sensors, giving rise to 
structural modifications and alteration of their biological function which may also 
account for the toxic effects of CO. However, it was shown that living cells can 
tolerate CO at the concentration of 0.01% (100 ppm) for several hours [3], and 
rodents could be exposed continuously for up to two years to 500 ppm CO without 
deleterious effects [3-5]. 
Following the discovery that carbon monoxide is physiologically important, 
molecules acting as CO-carriers, namely CO-releasing molecules, were developed. 
In order to mimic the role of CO derived from haem oxygenase [6], these 
molecules have to be able to liberate CO in a biological environment. This 
liberation is triggered by some physical, chemical, or enzymatic stimulus. For many 
CO-RMs that carry molecular CO as a ligand to a central transition metal, the lack 
of a pharmacological effect of a similar compound devoid or depleted of CO has 
been taken as a positive proof for the biological action of CO [7]. Following this 
principle, the beneficial therapeutic action of several CO-RMs in a wide range of 
vasoactive and anti-inflammatory situations and models has been attributed to CO 
[8]. 
Recently, we reported that four transition metal based CO-RMs at micromolar 
concentrations have antibiotic activity reducing the viability of bacteria, such as E. 
coli and S. aureus, both under aerobic and anoxic conditions [9]. In that work we 
also showed that the biological action of those CO-RMs as bactericides was only 
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effective when CO is taken up by the cells. In fact, we demonstrated that one of 
the CO-RMs led to extensive accumulation of the transition metal molybdenum 
inside bacterial cells. In all cases, the addition of haemoglobin to the medium, 
before addition of the CO-RM, prevented any bactericidal action. Separate 
experiments [10] (JD Seixas, personal communication) showed that these CO-RMs 
transfer CO to haemoglobin at a very fast rate. Taken together these results 
strongly suggest that the bactericidal action of a given CO-RM depends on its 
ability to sequentially enter bacterial cells and enable CO to reach specific targets.  
We have now extended these studies to the analysis of the global 
transcriptome of E. coli treated with tricarbonyldichlororuthenium (II) dimer, also 
named CORM-2, which reflects the organism’s immediate response to the 
environment. Additionally, we have examined the phenotype of twelve mutant 
strains to test the causative role of each deleted gene in E. coli CORM-2 response. 
Regulatory genes and genes involved in methionine metabolism and biofilm 
formation were found to play an important role when the microorganism is 
exposed to the bactericidal action of CORM-2. 
 
6.2 Material and methods 
 
Bacterial strains and growth conditions 
Escherichia coli MG1655 was grown, at 37 ºC and 150 rpm, in minimal 
medium salts (MS) [9] in the presence and in the absence of oxygen. Aerobic 
experiments were undertaken in flasks filled with 1/5 of its volume and anaerobic 
conditions were performed in rubber sealed flasks that, once filled with media and 
closed, were extensively fluxed with nitrogen gas. Cultures were grown until an 
optical density at 600 nm of 0.3, and at this point cells were left untreated or 
treated with tricarbonyldichlororuthenium (II) dimer, CORM-2 (Sigma). 
 
RNA isolation 
The hot-phenol method was used to extract total RNA from two independent 
cultures of cells grown either aerobically or anaerobically and treated with 250 μM 
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CORM-2 during 15 min. The concentration of the drug added to the cultures is 
equivalent to 0.5 times the MIC (500 µM) which was previously determined [9]. 
After the isolation procedure, RNA was incubated with DNase (Ambion), and once 
the absence of any residual DNA was confirmed, concentration and purity were 
determined in a Nanodrop ND-1000 UV-visible spectrophotometer. RNA integrity 
was checked in an Agilent 2100 Bioanalyser coupled to a RNA Nano-Assay (Agilent 
Technologies, Palo Alto, CA).  
 
Microarray analysis 
Total RNA (10 µg) was processed for use in the Affymetrix GeneChip E. coli 
Genome 2.0 Arrays, according to the manufacturer’s instructions. Arrays were 
scanned in an Affymetrix GeneChip scanner 2500 and analysed first with 
Affymetrix MAS 5.0 software to obtain Absent/Present calls and to assure that all 
quality parameters were within the recommended range. Hybridization, scanning 
and detection procedures were done at the Genomics Unit of Instituto Gulbenkian 
de Ciência (Portugal). The advantage of using the Affymetrix GeneChip is that it 
contains 20 probe pairs to detect each ORF, providing multiple independent 
measurements for each transcript. The subsequent analysis was performed with 
dChip software program [11]. The invariant set method [12] was used to 
normalise arrays at the probe cell level for comparison purposes, and the model-
base (Perfect Match-only model) was used to probe selection and computing 
expression values. The expression profile of 4306 genes encoding proteins of E. 
coli K-12 MG155 were analysed (intergenic regions were not included) and genes 
were considered to have significant differential expression when showing a 
transcriptional fold change >2 (with a 90 % confidence interval) and a P value < 
0.05 for a paired Student’s t-test. To minimise occurrence of false positives the 
comparison criterion was carefully chosen to ensure that the empirical false 
discovery rate (FDR) was low (random permuting of the samples by 200 times led 
to a median of FDR of 0 % and 1.1 % for the arrays acquired for cells grown 
anaerobically and aerobically, respectively). 
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Gene Ontology analysis 
To investigate the biological relevance of the differential gene expression 
profile, the microarray data was analysed with the FatiGO algorithm (Al-Shahrour 
et al., 2004; Al-Shahrour et al., 2006). Briefly, FatiGO considers two lists of genes 
(in this case the genes up or down regulated by CORM-2 anaerobically or 
aerobically were compared with the unchanged genes) and converts them into two 
lists of Gene Ontology (GO) terms. Subsequently, FatiGO determines separately 
the percentage of the relative frequency of genes in each group that is annotated 
with a particular GO term (biological process or molecular function) and finally, a 
Fisher’s exact test is used to determine if the GO term is significantly over- or 
under- represented in one of the groups with respect to the other one. Hence, it 
retrieves information about the predominant biological process or molecular 
function for the genes that are differently expressed in a certain experimental 
condition. In this study, the GO terms were considered differently represented 
when exhibited a FDR-adjusted P value lower than 0.2. The FatiGO is implemented 
in a web tool at: http://www.fatigo.org and within the Babelomics environment 
(http://www.babelomics.org). 
 
Quantitative real-time RT-PCR  
DNA microarray data was validated by quantitative real-time RT-PCR. To this 
end, 2.5 μg of E. coli total RNA, derived from two independent samples grown 
aerobically or anaerobically and treated with 250 µM of CORM-2 or with 500 µM of 
Ru(II)Cl2(DMSO)4 was used to synthesise cDNA, using the first strand synthesis 
protocol of the Universal RiboClone cDNA Synthesis System (Promega). Each cDNA 
synthesis reaction was performed using 40 μg/ml of random primers, 40 U of 
RNasin Ribonuclease Inhibitor, 4 mM of sodium pyrophosphate and 30 U of AMV 
Reverse Transcriptase. After amplification, cDNA was purified by phenol extraction 
and ethanol precipitation. Real-time PCRs were performed in a LightCycler 
Instrument using LightCycler FastStart DNA Master SYBER Green I Kit according to 
the manufacturer’s instructions (Roche Applied Science). For each target gene, 
specific oligonucleotides were designed to amplify nucleotide fragments of 200 to 
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580 base pairs (Table 6.A3). The amplification reactions were carried out with 
equal amounts of cDNA (120 ng), as initial template, and each reaction contained 
0.5 μM of primers, 2 mM of MgCl2, and hot-start PCR reaction mix (Roche Applied 
Science). The expression ratio of the target gene was determined relatively to a 
reference gene, the E. coli glyceraldehyde 3-phosphate dehydrogenase (gapA), 
which did not show variation in the transcription abundance under all the 
conditions tested by microarray analysis or real-time RT-PCR experiments. 
 
Viability assays and complementation studies 
In order to compare the sensitivity to CORM-2 of the E. coli parent strain 
versus the several mutant strains, cell viability was determined by evaluation of the 
number of CFU per millilitre, after 7 h of growth in the presence or in the absence 
of CORM-2. The percentage survival was calculated as the number of colonies 
obtained from CORM-2 treated cultures divided by the number of colonies formed 
upon platting untreated cultures. The experiments were performed in duplicate 
with a minimum of two independent cultures of the mutant strain and of its 
correspondent parental strain (Table 6.A4) and the results are presented as 
averaged values with error bars representing standard errors. For 
complementation purposes, ibpAB and metR genes were amplified from E. coli 
genomic DNA using the appropriated oligonucleotides (Table 6.A3), and cloned 
into pUC-19 to generate plasmids pibpAB and pmetR (Table 6.A5). These plasmids 
or the empty vector were transformed into the correspondent mutant strain and 
the phenotype was analysed by plating on agar successive dilution of the cultures 
treated with CORM-2 or left untreated. Concerning ΔsoxS, ΔoxyR, ΔtqsA and 
ΔbhsA the complementation experiments were performed using the plasmids 
described in Table 6.A5.  
 
Biofilm assays 
Biofilm formation was quantified by the crystal violet method [22, 23]. Briefly, 
overnight LB-grown cultures of wild type E. coli, ∆tqsA and ∆bhsA mutant strains 
were used to inoculate fresh medium to an OD600nm of 0.05 and then incubated for 
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6 h, at 37 ºC. At this stage, 250 µM of CORM-2 was added and the plates were 
incubated for another 18 h, at 37º C. The total biofilm formed was stained with a 
solution of 0.1 % crystal violet for 30 min and quantified by measuring the OD at 
540 nm. The relative biofilm formation was calculated as the total biofilm formed 
by the cultures treated with CORM-2 divided by the total biofilm obtained in 
untreated cultures; each data point represents the average of six replicated wells 
from four independent cultures. 
 
6.3 Results and discussion 
 
Analysis of the E. coli transcriptome of cells treated with CORM-2  
Microarray technology was utilised to analyse the genome-wide transcriptional 
pattern of E. coli cells, grown aerobically and anaerobically, in the presence of 
CORM-2. The complete list of genes that exhibited a twofold, or higher, increase or 
decrease (with P < 0.05) of the transcriptional expression is presented in Tables 
6.A1 (anaerobic growth) and 6.A2 (aerobic growth) in annexe section. In order to 
independently confirm the microarrays results, quantitative real-time PCR was 
carried out on ten selected genes that were found to be up-regulated or down-
regulated by the action of CORM-2. The values acquired in the real-time PCR 
experiments are in agreement with the fold variation obtained in the microarrays 
(Table 6.1-2).  
The microarray data acquired for cells grown under anaerobic conditions and 
treated with CORM-2 showed that 396 genes had their transcription altered (~ 9 
% of the total genome). Of these, the transcription of 228 genes was repressed (~ 
5 % of the transcriptome) with genes dispersed through nearly all functional 
categories, particularly the genes related to amino acid transport and metabolism 
(Figure 6.1A). The FatiGO analysis showed that the genes down-regulated are 
over-represented in the cellular metabolic processes (which correspond to 84 % of 
all repressed-genes), namely in the catabolic processes, nucleotide metabolisms, 
and energy production by oxidation of organic compounds (Figure 6.2A), indicating 
that CORM-2 induces metabolic adaptation.  
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TABLE 6.1 Quantitative real-time RT-PCR analysis 
performed in cells exposed to CORM-2 and to the CO 
free Ru(II)Cl2(DMSO)4 under anaerobic conditions. 
 Anaerobic 
  Real-Time PCR 
Gene Microarray CORM-2 Ru(II)Cl2(DMSO)4 
ibpB 40 427 ± 33 -2 ± 0 
soxS 10 14 ± 0 -3 ± 0 
marA 14 14 ± 0 2 ± 1 
frmA 10 57 ± 1 -1 ± 0 
lrhA 16 14 ± 5 -2 ± 0 
yncJ 42 85 ± 8 12 ± 2 
bhsA 26 33 ± 2 3 ± 2 
metR - - - 
gadX -10 -21 ± 0 2 ± 1 
sucA -9 -6 ± 0 1 ± 0 
 
TABLE 6.2 Quantitative real-time RT-PCR analysis 
performed in cells exposed to CORM-2 and to the CO 
free Ru(II)Cl2(DMSO)4 under aerobic conditions. 
 Aerobic 
  Real-Time PCR 
Gene Microarray CORM-2 Ru(II)Cl2(DMSO)4 
ibpB 79 2798 ± 27 12 ± 8 
soxS 15 268 ± 63 -3 ± 0 
marA 10 56 ± 3 -2 ± 0 
frmA 16 133 ± 0 -2 ± 0 
lrhA 5 23 ± 8 -2 ± 0 
yncJ 62 162 ± 49 7 ± 2 
bhsA - - - 
metR 21 432 ± 85 4 ± 0 
gadX -4 -4 ± 0 -2  ± 0 
sucA -5 -4 ± 0 -1 ± 0 
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The largest class of genes that were up-regulated belongs to the category of 
the hypothetical proteins (~ 39 %). Apart from these, the genes that showed 
increased transcription are divided essentially into three classes: inorganic ion 
transport, posttranslational modification and transcription (Figure 6.1A). Further 
analysis revealed that the genes up-regulated by CORM-2 were significantly over-
represented within the class of transcriptional regulation and protein folding 
(Figure 6.2B). Among the latter, two heat shock proteins that are directly 
connected with protein stability, ibpA and ibpB, were strongly induced (19 and 40-
fold, respectively). The data also showed that, under anaerobic conditions, the 
addition of CORM-2 had effects on iron metabolism since several genes related to 
this function were altered, e.g. ferritin (ftn), and bacterioferritin (bfr) (Table 6.A1). 
 
FIGURE 6.1 Effect of CORM-2 on E. coli transcriptome analysed according to the 
distribution of the genes with altered expression into functional categories. The differentially 
regulated genes in cells grown under anaerobic (A) and aerobic conditions (B) were divided into 21 
functional categories according to NBCI and EcoCyc databases. The black and white bars represent the 
number of genes whose transcription was up- and down-regulated by CORM-2, respectively. In bold are 
highlighted the functional categories that include genes up- and down-regulated by CORM-2 in both 
oxygen growth conditions and in italics are represented the eight functional classes containing genes 
that were repressed by CORM-2 under anaerobic conditions and are absent in aerobically grown cells. 
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E. coli cells grown aerobically and exposed to CORM-2 displayed alteration in 
the transcription of 175 genes, ~ 4 % of the global gene expression profile, with 
46 genes repressed and 129 genes induced. Apart from genes encoding 
hypothetical proteins, three functional categories exhibited a similar number of 
transcriptionally repressed genes, namely the classes of energy production, amino 
acid and carbohydrate transport and metabolism (Figure 6.1B). The FatiGO 
algorithm revealed over-representation of repressed genes in the coenzyme 
catabolic processes, tricarboxylic acid cycle (TCA) and aerobic respiration classes 
(Figure 6.2C). This trend would ultimately lead to the inhibition of the aerobic 
respiratory metabolism. 
 
FIGURE 6.2 Biological processes modified by CORM-2. The genes down- and up-regulated 
by CORM-2 anaerobically (A and B) or aerobically (C and D) were compared with those unaltered by 
CORM-2 (reference genes), using the FatiGO algorithm (see Methods). The y-axis displays the biological 
processes that were considered differentially represented between the two groups compared in each 
case. The specificity of the biological process increases from the top to the bottom of the y-axis, as 
indicated in parenthesis. The x-axis represents the differences in percentages of the relative frequency 
of genes annotated for each biological process. The right and left part of the x-axis correspond to the 
biological processes over- and under-represented, in the down-regulated genes (A and C) and in up-
regulated genes (B and D), respectively. 
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The genes whose expression was induced by CORM-2 were spread through 
several functional classes, containing the inorganic ion transport category the 
second highest number of genes transcriptionally modified (Figure 6.1B). 
Interestingly, the FatiGO analysis indicates that under aerobic conditions the 
addition of CORM-2 to E. coli cells led to a significant up-regulation of genes 
involved in sulphur metabolism, such as tauABC, ssuAD, cysWA and sbp, and in 
methionine metabolism, like the gene clusters metNI and metBLF (Figure 6.2D).  
 
Transcriptional alterations caused by CORM-2 are dependent on CO 
release 
Administration of any CO-RM produces some metabolite(s) along with the CO 
that is liberated. Therefore, we have determined whether the biological effect of a 
given CO-RM actually results from the liberated CO and not from any of its 
metabolites or the CO-RM’s molecular skeleton itself. The commercially available 
tricarbonyldichlororuthenium (II) dimer, [Ru(CO)3Cl2]2, also known as CORM-2 is, 
by far, the most tested CO-RM and we have reported its bactericidal activity [9]. 
The dimer complex is insoluble in aqueous media and its solubilisation, usually 
carried out in DMSO, entails a number of chemical transformations. According to 
Motterlini and co-workers [10], 23 min after dissolution three species are already 
formed, namely RuCl2(CO)3(DMSO) and two isomers of RuCl2(CO)2(DMSO)2. Of 
necessity, a certain amount of free CO is liberated into the DMSO solution and 
eventually lost to the atmosphere at an undetermined rate. More species appear 
upon standing or warming of the solution and further CO loss to give 
RuCl2(CO)(DMSO)3 and eventually RuCl2(DMSO)4 is to be expected since they are 
all synthetically interrelated in the presence of CO gas [27]. Nothing is presently 
known about the biological activity of any of these pure species in separate. 
However, the octahedral structure, the oxidation state as well as the ligands other 
than CO are retained along this series strongly supporting our choice of 
Ru(II)Cl2(DMSO)4 as a control for the bactericidal activity of the CO free 
Ru(II)Cl2(DMSO)x fragment. It must also be mentioned that, regardless of the 
species present in the DMSO solution of [Ru(CO)3Cl2]2, when an aliquot of this 
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solution is added to the cell culture medium no CO is released to the gas phase as 
previously reported [9]. We challenged E. coli with 500 µM of CO free 
Ru(II)Cl2(DMSO)4 and analysed the expression of several genes. Table 6.1-2 shows 
that no significant alteration in the transcription is observed when it is used a CO 
devoid compound, which allow to conclude that the main biological activity is due 
to the release of CO from CORM-2. 
 
Genes transcriptionally regulated in response to CORM-2, 
independently of oxygen  
The E. coli microarray data showed that upon exposure to CORM-2 the cells 
grown anaerobically exhibited a higher number of repressed genes than the cells 
grown aerobically. In particular, eight functional classes containing genes that 
were repressed by CORM-2 under anaerobic conditions were not detected in 
aerobically grown cells (Figure 6.1A-B). These results are in agreement with our 
previous observation that the decrease in cell viability caused by CO-RMs is higher 
for cells grown under anaerobic conditions [9]. However, a large set of genes were 
found in common between the two oxygen growth conditions and the fold of 
induction or repression generated by CORM-2 did not vary significantly between 
them (Table 6.3). There is also no example of a gene that was repressed under 
anoxic conditions and induced under aerobic conditions, and vice-versa. The major 
fold difference was observed for the heat shock protein ibpB, two hypothetical 
proteins (yncJ and ymgG), a flagellar repressor (lrhA) and an envelope stress 
induced periplasmic protein (spy). In all these cases, the genes showed a higher 
fold of CORM-2 dependent induction in aerobically grown cells than in cells 
cultured anaerobically (Table 6.3).  
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TABLE 6.3 Genes of E. coli differentially regulated by CORM-2 under both anaerobic 
and aerobic conditions. 
Gene 
Name 
Locus Gene Product 
Fold Change 
Anaerobic Aerobic 
 
Inorganic ion transport and metabolism 
alx b3088 Predicted inner membrane protein 12.3 3.3 
yheL b3343 Predicted intracellular sulfur oxidation protein 6.8 7.4 
exuT b3093 Hexuronate transporter 6.5 2.5 
chaA* b1216 Calcium/proton antiporter 6.0 8.4 
yqjH b3070 Predicted siderophore interacting protein 4.4 2.7 
metN b0199 D-methionine transport ATP-binding protein 4.3 9.9 
metI b0198 D-methionine transport system permease 4.0 6.5 
pspE b1308 Phage shock protein E precursor 2.4 7.0 
yegH b2063 Putative transport protein -2.4 -2.5 
apaG b0050 Protein associated with Co2+/Mg2+ efflux -3.6 -2.4 
 
Transcription 
lrhA b2289 DNA-binding transcriptional repressor of flagellar 15.5 4.6 
cpxP b4484 Periplasmic protein combats stress 14.0 12.2 
soxS b4062 DNA-binding transcriptional dual regulator 10.0 14.5 
frmR b0357 Regulator protein that represses frmRAB operon 8.5 6.7 
marA b1531 Multiple antibiotic resistance protein 7.3 9.5 
lexA b4043 LexA repressor 6.8 3.8 
zntR b3292 Zinc-responsive transcriptional regulator 5.1 6.1 
oxyR b3961 Hydrogen peroxide-inducible genes activator 4.5 4.1 
gadX b3516 DNA-binding transcriptional dual regulator -10.4 -4.3 
 
Posttranslational modification, protein turnover, chaperones 
ibpB b3686 16 kDa heat shock protein B 39.6 79.3 
ibpA b3687 16 kDa heat shock protein A 19.2 18.7 
hspQ b0966 DNA-binding protein, hemimethylated 7.7 4.8 
yeeD b2012 Predicted redox protein 7.4 3.3 
yggG b2936 Predicted peptidase 6.0 2.7 
hslO b3401 Hsp33-like chaperonin 4.6 5.4 
dnaJ b0015 Chaperone protein  3.7 4.1 
clpB b2592 Protein disaggregation chaperone 3.1 4.8 
 
Signal transduction mechanisms 
ydeH b1535 Hypothetical protein with DGC or GGDEF domain 17.5 23.5 
pspB b1305 Phage shock protein B 4.4 10.5 
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TABLE 6.3 Continuation. 
Gene 
Name 
Locus Gene Product 
Fold Change 
Anaerobic Aerobic 
 
Signal transduction mechanisms (continuation) 
pspG b4050 phage shock protein G 3.9 11.4 
narP b2193 Nitrate/nitrite response regulator protein 2.7 2.8 
ydiV b1707 C-di-GMP phosphodiesterase class I -3.7 -5.9 
 
Energy production and conversion 
frmA b0356 Alcohol dehydrogenase class III 15.8 8.1 
nemA b1650 N-ethylmaleimide reductase 3.1 3.6 
sucA b0726 2-oxoglutarate decarboxylase -9.1 -5.1 
 
Translation, ribosomal structure and biogenesis 
rrmJ b3179 Ribosomal RNA large subunit methyltransferase J 4.6 3.2 
hslR b3400 Ribosome-associated heat shock protein Hsp15 4.2 5.1 
miaA b4171 tRNA delta(2)-isopentenylpyrophosphate transferase 2.5 2.5 
 
Amino acid transport and metabolism 
ybaT b0486 Predicted transporter protein -3.4 -3.7 
gss b2988 Fused glutathionylspermidine amidase -3.5 -3.1 
 
Carbohydrate transport and metabolism 
tktB b2465 Transketolase -2.5 -2.9 
otsA b1896 Alpha-trehalose-phosphate synthase -4.9 -2.8 
 
Replication, recombination and repair 
fimE b4313 Tyrosine recombinase 5.6 3.9 
recN b2616 Recombination and repair protein 5.4 8.4 
 
Defence mechanisms 
rdoA b3859 Thr/Ser kinase implicated in Cpx stress response 2.8 3.5 
aidB b4187 Isovaleryl CoA dehydrogenase -2.6 -2.7 
 
Coenzyme transport and metabolism 
btuD b1709 Vitamin B12-transporter ATPase -3.1 -2.3 
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TABLE 6.3 Continuation. 
Gene 
Name 
Locus Gene Product 
Fold Change 
Anaerobic Aerobic 
 
Cell wall/membrane/envelope biogenesis 
btuD b1709 Vitamin B12-transporter ATPase -3.1 -2.3 
 
Secondary metabolites biosynthesis, transport and catabolism 
ybbA b0495 Hypothetical ABC transporter 7.7 7.1 
 
Intracellular trafficking, secretion, and vesicular transport 
spy b1743 Envelope stress induced periplasmic protein 16.0 30.0 
 
Cell cycle control, cell division, chromosome partitioning 
sulA b0958 Cell division inhibitor 9.5 5.4 
 
Hypothetical proteins 
yncJ b1436 Hypothetical protein 42.2 62.0 
yjfN b4188 Hypothetical protein 19.8 22.9 
ycfJ b1110 Hypothetical protein 18.0 13.5 
yebE b1846 Hypothetical protein 16.3 22.9 
ycfS b1113 Hypothetical protein 12.0 16.9 
yhdV b3267 Hypothetical protein 9.0 9.0 
yneM b4599 Hypothetical protein 8.4 6.2 
yqjA b3095 Hypothetical protein 8.0 5.7 
ypfG b2466 Hypothetical protein 6.7 8.6 
fxsA b4140 FxsA protein 6.7 13.8 
yaiY b0379 Hypothetical protein 6.5 5.8 
tqsA b1601 Predicted permease 6.3 9.1 
yeeE b2013 Predicted inner membrane protein 6.3 2.7 
ybeD b0631 Hypothetical protein 6.1 6.0 
yqaE b2666 Hypothetical protein 5.9 4.5 
ytfK b4217 Hypothetical protein 5.3 5.3 
ycjX b1321 Hypothetical protein 5.0 7.7 
ybfA b0699 Hypothetical protein 4.5 4.5 
bax b3570 BAX protein 4.3 3.3 
ymgG b1172 Hypothetical protein 4.2 16.0 
sraF b4448 Unknown RNA 3.5 2.5 
yrfG b3399 Predicted hydrolase 3.4 4.3 
ynfD b1586 Hypothetical protein 3.4 4.5 
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TABLE 6.3 Continuation. 
Gene 
Name 
Locus Gene Product 
Fold Change 
Anaerobic Aerobic 
 
Hypothetical proteins (continuation) 
yciS b1279 Hypothetical protein 3.3 3.2 
ycjF b1322 Hypothetical protein 3.2 10.0 
yhdN b3293 Hypothetical protein 3.1 4.3 
yciC b1255 Hypothetical protein 2.6 2.3 
slp b3506 Outer membrane protein Slp precursor -2.2 -4.1 
yahK b0325 
Predicted oxidoreductase, Zn-dependent and 
NAD(P)-binding 
-4.0 -3.6 
yciX b4523 Hypothetical protein -4.6 -8.0 
* strains mutated in the genes represented in bold were phenotipically analysed 
 
Phenotypic analysis of E. coli regulators induced by CORM-2 
To gain further insight into the function of the genes whose transcription was 
perturbed by treatment with CORM-2 we have analysed the phenotype of twelve E. 
coli mutant strains to test if the deleted gene has a role in the E. coli CORM-2 
response. The genes were chosen on the basis of their highest fold of induction or 
repression and by exhibiting variation in transcript abundance both in cells grown 
under aerobic or anaerobic conditions (see Table 6.3). Hence, genes encoding 
regulators (soxS, oxyR, zntR, metR, and gadX), a putative combat stress protein 
(cpxP), heat shock proteins (ibpA and ibpB), proteins involved in biofilm formation 
(ydgG (tqsA), ycfR (bhsA)), an antiporter protein (chaA), and genes involved in the 
methionine metabolism (metN, metI) were studied. However, the study of the E. 
coli single mutant strains deleted in the genes zntR, gadX and chaA revealed that 
the strains did not display a CORM-2 growth induced delay when compared to the 
parent strain (data not shown).  
Concerning soxS, whose transcription is controlled directly by SoxR, the gene 
showed a high fold of induction upon treatment with CORM-2, under aerobic and 
anaerobic conditions (Table 6.3). Together with SoxR, SoxS participates in the 
regulation of several genes involved in the response to oxidative stress [21]. 
However, with the exception of the marRAB operon, none of the other known 
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members of the SoxRS regulon was induced. A similar behaviour, which so far 
remains unexplained, was previously observed in other microarray experiments of 
E. coli grown in the presence of hydrogen peroxide and nitric oxide [28, 29]. The 
phenotypic study of the E. coli strain deficient in the soxS gene showed that the 
mutation leads to an increase of sensitivity to CORM-2 of the cells grown under 
aerobic (> 70 %) and anaerobic conditions (> 35 %) (Figure 6.3A-B).  
The oxyR gene, whose encoded protein participates in the regulation of genes 
involved in the response to oxidative stress [28], was up-regulated by CORM-2 
under aerobic and anaerobic conditions ( ≥ 4-fold) (Table 6.3). Under aerobic 
conditions and in the presence of CORM-2, the sensitivity of the oxyR mutant 
strain was found to be ~ 70 % higher than that of the wild type strain (Figure 
6.3C), while no differences were observed for growth performed under anaerobic 
conditions.  
The microarray data showed that in aerobically grown E. coli the transcription 
of metR was up-regulated by CORM-2. Analysis of the ΔmetR strain revealed that 
this mutant display a sensitivity ~ 80 % higher than that of the parental strain for 
cells grown aerobically (Figure 6.3F), while no effect was detected in anoxic 
conditions (data not shown). 
In all cases, the wild-type behaviour was restored upon expression of the 
genes from a plasmid containing SoxS, OxyR or MetR (Figure 6.3A1-C1 and 6.3F1), 
showing that these transcription factors have an important role in the E. coli 
regulatory mechanisms triggered by exposure to CORM-2. 
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FIGURE 6.3 Analysis of the sensitivity of several E. coli mutant strains to CORM-2. 
Parental E. coli strain (gray bars), and mutant strains (white bars), were grown aerobically (+O2; panels 
A, C and F) or anaerobically (-O2; panels B, D and E) and exposed to 150 µM or 100 µM of CORM-2, 
respectively. The E. coli ∆cpxP mutant and its parental strain were treated with 125 µM of CORM-2 
(panel E). In Panel F, the ∆metR (striped bars), ∆metI (light gray bars) and ∆metN (white bars) mutant 
strains were grown aerobically and treated with 150 µM of CORM-2. The error bars represent the 
standard error of the average values obtained from at least two independent biological samples 
performed in duplicate (*P <0.01, ** P <0.05). Panels A1-F1: complementation analysis of ΔsoxS (A1-
B1), ΔoxyR (C1), ΔibpAB (D1) and ΔmetR (F1) using the plasmids indicated in each panel. 
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Identification of other genes involved in the CORM-2 sensitivity of 
anaerobically grown E. coli cells 
A significant variation of the expression of ibpA and ibpB genes was measured 
in aerobically and anaerobically grown cells of E. coli submitted to CORM-2 (Table 
6.3). These genes encode two small heat shock proteins, IbpA and IbpB, that bind 
to protein aggregates and inclusion bodies formed during heterologous protein 
expression [30]. The two proteins are known to cooperate with ClpB and DnaK 
forming a functional triad of chaperones [17, 30]. Interestingly, the transcription of 
clpB and dnaK as well as that of genes coding for other chaperones like dnaJ, grpE 
and htpG, was also up-regulated anaerobically by CORM-2 (Table 6.A1). Actually, 
under anaerobic conditions, inactivation of the genes ibpAB led to an increase of 
the E. coli CORM-2 sensitivity of 45 % relative to the parental strain (Figure 6.3D), 
while no differences were observed under aerobic conditions (data not shown). As 
expected, complementation of ibpAB mutation induced the rescue of the wild type 
phenotype (Figure 6.3D1).  
The transcription of E. coli cpxP, which encodes a periplasmic protein 
putatively involved in combating extracytoplasmic protein-mediated toxicity [31], 
was up-regulated 12-14-fold in cells exposed to CORM-2 and cultured in both 
oxygen conditions. CpxP belongs to the E. coli Cpx system, which senses 
perturbations in the bacterial cell envelope and responds through the up-regulation 
of many gene products involved in protein folding and degradation [32].  In 
accordance, we verified that together with the induction of cpxP occurred a high 
number of transcriptionally modified genes involved in cell wall biogenesis and in 
protein folding, including heat shock proteins (ibpAB, hslJ, htpX), chaperones 
(dnaJ, htpG, clpB) and proteases (ftsH) (Table 6.A1), mainly under anaerobic 
conditions. These genes are under the control of rpoH factor ( 32) [33], a gene 
that was also found to be up-regulated by CORM-2 under anaerobic conditions. 
The study of the growth behaviour of the ΔcpxP mutant revealed that this strain is 
approximately 35 % more sensitive to CORM-2 than the parental type but only 
under anaerobic conditions (Figure 6.3E), not under aerobic conditions (data not 
shown). 
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CORM-2 interferes with methionine biosynthesis  
Addition of CORM-2 to aerobically grown cells of E. coli caused a marked 
increase in the transcription of several genes implicated in methionine biosynthesis 
and uptake, with metR being the gene that showed the highest induction (21-fold) 
(Table 6.A2). Apart from the genes presented in Table 6.A2, induction of the 
expression of genes metA (12.4-fold; P=0.0527) and metE (5.5-fold; P=0.0565) 
was also observed. To further clarify this issue, growth experiments were 
conducted aerobically in the presence of CORM-2 for the E. coli ∆metR, ∆metI and 
∆metN mutant strains. All mutant strains are hypersensitive to CORM-2 (80 %, 66 
%, and 40 %, higher, respectively) (Figure 6.3F). Furthermore, the 
complementation assay showed that E. coli ∆metR regains resistance to CO upon 
expression of the regulator MetR (Figure 6.3F1). These findings suggest that, under 
aerobic conditions, CORM-2 affects the E. coli metabolism of methionine.  
 
CORM-2 influences biofilm formation 
Previous microarray studies revealed that apart from the E. coli genes that 
are directly implicated in the process of biofilm formation such as tqsA, mqsR, 
bhsA, yceP (bssS) and yliH (bssR), genes involved in the response to stress 
conditions are also induced during biofilm formation, namely ibpAB, soxS, cpxP and 
spy [34, 35]. Many of these genes were also found to be transcriptionally modified 
when E. coli is exposed to CORM-2 (Tables 6.3 and 6.A6). In particular, 
comparison of the microarray data showed that approximately 40 % of the genes 
that are found to be transcriptionally modified during the formation of the E. coli 
biofilm [34] are in common with those altered by CORM-2 under anaerobic 
conditions, and 12 % of the common genes are observed when growth is 
performed aerobically (Table 6.A6). 
To evaluate the effect of CORM-2 in the process of biofilm formation, 
quantification of the total biofilm formed during aerobic growth in LB and in the 
presence of the compound was performed. The results showed that CORM-2 
increased by 1.6-fold the total biofilm of the E. coli wild type strain (Figure 6.4A). 
This indicates that E. coli produces higher biofilm content as a defensive response 
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against CORM-2, as previously observed for other stress conditions [22]. The E. 
coli gene related with biofilm formation, bhsA [22], was significantly induced under 
anaerobic conditions (26-fold). Although the ∆bhsA mutant showed an elevated 
resistance to CORM-2 anaerobically (Figure 6.4B), and the complementation 
experiment performed with a multiple-copy clone containing the bhsA regulatory 
region rescued the wild type behaviour (Figure 6.4B2), the values of total biofilm 
measured for the mutant strain exposed to CORM-2 matched those of the parental 
strain (Figure 6.4A).  
 
FIGURE 6.4 Effect of CORM-2 in 
biofilm formation and cell viability of 
E. coli ∆tqsA and ∆bhsA mutant 
strains. Biofilm was assayed in E. coli 
wild type and in ∆tqsA and ∆bhsA mutant 
strains, in the absence or in the presence 
of 250 µM of CORM-2. Cell viability of E. 
coli parental strain (gray bars), ∆tqsA 
(white bars) and ∆bhsA (black bars) 
mutants strains grown anaerobically (B) 
or aerobically (C) in the presence of 100 
µM or 180 µM of CORM-2, respectively. 
The number of colonies (cfu) was 
determined for at least two biological 
samples and in duplicate. Error bars 
represent the standard error of average 
values (*P <0.01, ** P <0.05). 
Complementation analysis of ∆tqsA and 
∆bhsA mutant strains (B1 and B2, 
anaerobic conditions), and ∆tqsA (C1, 
aerobic conditions) using the plasmids 
indicated in each panel. 
 
In E. coli, the tqsA  gene is proposed to encode a putative transport protein 
involved in biofilm formation [19]. The gene was up-regulated in aerobically and 
anaerobically grown CORM-2 treated cells with a 9- and 6-fold increase, 
respectively. Analysis of the E. coli ∆tqsA mutant revealed that deletion of tqsA 
yielded a strain with higher resistance to CORM-2 than the parental strain, either 
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under oxic or anoxic growth conditions (Figure 6.4B-C), and the phenotype of the 
tqsA mutant strain could be fully complemented by a clone containing the tqsA 
gene (Figure 6.4B1-C1). This result is in agreement with those obtained by 
Herzberg and co-workers, which show that inactivation of tqsA increases the 
resistance to several antibiotics [19]. Additionally, deletion of tqsA abolished the 
increase in biofilm formation observed in the wild type strain upon exposure to 
CORM-2 (Figure 6.4A).  
 
6.4 Conclusion 
In this study, we provide the first microarray analysis of a microorganism 
treated with the new bactericide CORM-2. The choice of E. coli was based on the 
fact that, besides being a model bacterium, this Gram-negative microorganism is 
able to live in aerobic environments and also adapts to anaerobic niches as part of 
its normal colonisation-transmission cycle within a host. Hence, it allowed us to 
compare the transcriptional response of a bacterium when treated with CORM-2 in 
both anaerobic and aerobic environments. The broad effect of the CORM-2 on 
gene expression levels is evident from the distribution of induced and repressed 
genes over the spectrum of all functional categories. In particular, the higher 
number of genes affected in anaerobically CORM-2-exposed cells illustrates 
fundamental differences between the way in which microbes control external 
stress under the two oxygen conditions, and highlights the importance of specific 
investigations to understand the different adaptation strategies.  
Although it has been assumed that CO targets are haem containing enzymes 
or proteins, they were not yet identified and little is known about the trigger event 
or mechanism that mediates the transfer of CO from the CO-RM to the haem 
target. The present data shows that the action of CO extends further beyond the 
action on haem proteins since a wide range of transcriptional modifications is 
observed in cells grown under fermentative conditions and exposed, aerobically or 
anaerobically, to CORM-2.  
The changes in the expression level of key transcription regulators together 
with the phenotypic analysis of the mutant strains reveals that CORM-2 triggers a 
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complex network of responses. Like all other microarray studies performed in E. 
coli cells submitted to toxic chemicals such as hydrogen peroxide and NO, 
exposure to CORM-2 increases the transcription of soxS regulator but it does not 
induce any of the genes of the regulon, a result that requires further studies to be 
clarified. A particular observation, common to all transcriptional studies, is the 
large representation of “unknown” genes, which leaves a wide field to be still 
explored, until the bacterial physiology is fully understood and indeed ready for the 
application of a systems biology approach. Nevertheless, the data provided by this 
study will certainly be valuable for guiding future research on the pharmacological 
application of CO-RMs. 
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TABLE 6.A1 E. coli genes differentially expressed following anaerobic exposure to 
CORM-2. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Amino acid transport and metabolism 
glnQ b0809 8.0 0.0350 Glutamine ABC transporter ATP-binding protein 
glnP b0810 6.4 0.0179 Glutamine ABC transporter permease protein 
cycA b4208 6.4 0.0024 D-alanine/D-serine/glycine transporter 
glnH b0811 3.6 0.0172 Glutamine ABC transporter periplasmic-binding protein 
aspA b4139 3.5 0.0167 Aspartate ammonia-lyase 
pepD b0237 -2.4 0.0029 Aminoacyl-histidine dipeptidase (peptidase D) 
dcp b1538 -2.4 0.0029 Dipeptidyl carboxypeptidase II 
hisB b2022 -2.4 0.0101 Imidazole glycerol-phosphate dehydratase 
potC b1124 -2.5 0.0462 Polyamine transporter subunit 
hisH b2023 -2.5 0.0034 Imidazole glycerol phosphate synthase subunit HisH 
hisF b2025 -2.6 0.0407 Imidazole glycerol phosphate synthase subunit HisF 
aroB b3389 -2.6 0.0030 3-dehydroquinate synthase 
gadC b1492 -2.6 0.0088 
Predicted glutamate:gamma-aminobutyric acid 
antiporter 
artI b0863 -2.6 0.0055 Arginine-binding periplasmic protein 1 precursor 
gcvP b2903 -2.8 0.0025 Glycine dehydrogenase; glycine decarboxylase  
aspC b0928 -2.9 0.0036 Aspartate aminotransferase PLP-dependent 
proC b0386 -2.9 0.0368 Pyrroline-5-carboxylate reductase, NAD(P)-binding 
leuB b0073 -3.0 0.0352 3-isopropylmalate dehydrogenase 
speD b0120 -3.0 0.0046 S-adenosylmethionine decarboxylase proenzyme 
solA b1059 -3.0 0.0147 N-methyltryptophan oxidase, FAD-binding 
gadB b1493 -3.3 0.0113 Glutamate decarboxylase B, PLP-dependent 
artJ b0860 -3.3 0.0240 Arginine transporter subunit 
ybaT b0486 -3.4 0.0323 Predicted transporter 
gss b2988 -3.5 0.0035 Fused glutathionylspermidine amidase/ synthetase 
gcvH b2904 -3.5 0.0032 Glycine cleavage system protein 
ansA b1767 -3.5 0.0113 Cytoplasmic asparaginase I 
artP b0864 -3.6 0.0141 Arginine transport ATP-binding protein 
dapB b0031 -3.8 0.0039 Dihydrodipicolinate reductase 
ybaS b0485 -3.8 0.0015 Glutaminase 
gcvT b2905 -4.1 0.0037 Glycine cleavage system aminomethyltransferase 
tppB b1634 -4.4 0.0009 Dipeptide/tripeptide permease  
pepN b0932 -4.6 0.0016 Aminopeptidase N 
aroG b0754 -4.6 0.0043 
3-deoxy-D-arabino-heptulosonate-7-phosphate 
synthase 
gadA b3517 -8.0 0.0027 Glutamate decarboxylase A, PLP-dependent 
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TABLE 6.A1 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Amino acid transport and metabolism (continuation) 
dadA b1189 -9.3 0.0483 D-amino acid dehydrogenase small subunit 
 
Transcription 
ygaV b2667 30.4 0.0041 Predicted DNA-binding transcriptional regulator 
lrhA b2289 15.5 0.0057 
DNA-binding transcriptional repressor of flagellar, 
motility and chemotaxis genes 
cpxP b4484 14.0 0.0088 Periplasmic protein combats stress  
marR b1530 13.8 0.0003 Multiple antibiotic resistance protein 
bssS b1060 13.0 0.0002 Biofilm formation regulatory protein 
soxS b4062 10.0 0.0036 Regulatory protein SoxS 
yqjI b3071 9.4 0.0052 Predicted transcriptional regulator 
frmR b0357 8.5 0.0020 Regulator protein that represses frmRAB operon 
marA b1531 7.3 0.0005 Multiple antibiotic resistance protein 
ydhM b1649 6.9 0.0044 Predicted DNA-binding transcriptional regulator 
lexA b4043 6.8 0.0076 LexA repressor  
ycfQ b1111 6.5 0.0019 Predicted DNA-binding transcriptional regulator 
rpoH b3461 6.1 0.0482 RNA polymerase sigma factor 
zntR b3292 5.1 0.0044 
DNA-binding transcriptional activator in response to 
Zn(II) 
oxyR b3961 4.5 0.0013 Hydrogen peroxide-inducible genes activator 
exuR b3094 4.0 0.0194 DNA-binding transcriptional repressor 
greA b3181 3.4 0.0017 Transcription elongation factor 
yhaJ b3105 3.1 0.0024 Predicted DNA-binding transcriptional regulator 
cspA b3556 2.8 0.0127 Major cold shock protein 
hdfR b4480 2.3 0.0289 DNA-binding transcriptional regulator  
appY b0564 -2.4 0.0040 DLP12 prophage 
chaB b1217 -2.7 0.0427 Cation transport regulator 
yheO b3346 -2.8 0.0043 Predicted DNA-binding transcriptional regulator 
cspC b1823 -2.8 0.0057 Cold shock-like protein 
gadE b3512 -3.2 0.0169 DNA-binding transcriptional activator 
yiiD b3888 -3.4 0.0108 Predicted acetyltransferase 
rnb b1286 -3.4 0.0018 Ribonuclease II 
yhgF b3407 -4.2 0.0434 Predicted transcriptional accessory protein 
csgD b1040 -4.4 0.0299 DNA-binding transcriptional activator  
putA b1014 -5.0 0.0057 Fused DNA-binding transcriptional regulator 
gadW b3515 -6.1 0.0358 DNA-binding transcriptional activator 
gadX b3516 -10.4 0.0075 DNA-binding transcriptional dual regulator 
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TABLE 6.A1 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Energy production and conversion 
frmA b0356 15.8 0.0215 Alcohol dehydrogenase class III  
ybdH b0599 3.7 0.0358 Hypothetical oxidoreductase 
yeaX b1803 3.1 0.0362 Predicted oxidoreductase 
nemA b1650 3.1 0.0262 N-ethylmaleimide reductase, FMN-linked 
rsxB b1628 2.9 0.0238 Predicted iron-sulfur protein 
sdhB b0724 -2.3 0.0049 Succinate dehydrogenase  
pntA b1603 -2.4 0.0076 NAD(P) transhydrogenase, subunit alpha 
nuoC b2286 -2.4 0.0143 NADH:ubiquinone oxidoreductase 
ppa b4226 -2.4 0.0087 Inorganic pyrophosphatase 
aceE b0114 -2.5 0.0177 Pyruvate dehydrogenase subunit E1 
gpsA b3608 -2.6 0.0024 
NAD(P)H-dependent glycerol-3-phosphate 
dehydrogenase 
ydfG b1539 -2.6 0.0124 L-allo-threonine dehydrogenase, NAD(P)-binding 
aceA b4015 -2.7 0.0133 Isocitrate lyase 
ackA b2296 -2.7 0.0193 Acetate kinase 
aceB b4014 -2.7 0.0132 Malate synthase 
nuoA b2288 -2.9 0.0024 NADH dehydrogenase subunit A 
hyaB b0973 -3.0 0.0040 Hydrogenase 1, large subunit 
nuoB b2287 -3.1 0.0040 NADH dehydrogenase subunit B 
ydiJ b1687 -3.6 0.0017 Predicted FAD-linked oxidoreductase 
fpr b3924 -3.6 0.0182 Ferredoxin-NADP reductase 
ppc b3956 -3.7 0.0366 Phosphoenolpyruvate carboxylase 
cybB b1418 -3.8 0.0009 Cytochrome b561 
hyaA b0972 -5.0 0.0030 Hydrogenase 1 
sucA b0726 -9.1 0.0049 2-oxoglutarate decarboxylase 
 
Posttranslational modification, protein turnover, chaperones 
ibpB b3686 39.6 0.0018 16 kDa heat shock protein B 
ibpA b3687 19.2 0.0009 16 kDa heat shock protein A 
htpX b1829 8.6 0.0018 Heat shock protein HtpX 
hspQ b0966 7.7 0.0176 DNA-binding protein, hemimethylated 
yeeD b2012 7.4 0.0179 Predicted redox protein 
hslJ b1379 6.1 0.0033 Heat shock protein  
yggG b2936 6.0 0.0015 Predicted peptidase 
hslO b3401 4.6 0.0029 Hsp33-like chaperonin 
ftsH b3178 4.0 0.0063 Protease, ATP-dependent zinc-metallo 
ybbK b0489 3.8 0.0231 Predicted protease 
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TABLE 6.A1 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Posttranslational modification, protein turnover, chaperones (continuation) 
dnaJ b0015 3.7 0.0038 Chaperone Hsp40, co-chaperone with DnaK.  
clpB b2592 3.1 0.0019 Protein disaggregation chaperone 
htpG b0473 2.5 0.0359 Heat shock protein 90 
hflC b4175 2.4 0.0164 
Modulator for HflB protease specific for phage λ cII 
repressor 
glnE b3053 -2.3 0.0064 Glutamate-ammonia-ligase adenylyltransferase  
sppA b1766 -2.5 0.0015 Protease IV (signal peptide peptidase) 
hchA b1967 -2.6 0.0177 Hsp31 molecular chaperone  
tpx b1324 -3.3 0.0108 Lipid hydroperoxide peroxidase 
grxB b1064 -3.4 0.0228 Glutaredoxin 2  
trxB b0888 -4.1 0.0453 Thioredoxin reductase, FAD/NAD(P)-binding 
cbpA b1000 -4.3 0.0496 Curved DNA-binding protein, DnaJ homologue  
cbpM b0999 -4.3 0.0103 Modulator of CbpA co-chaperone 
msrB  b1778 -4.7 0.0057 Methionine sulfoxide reductase B 
 
Inorganic ion transport and metabolism 
mgtA b4242 57.0 0.0112 Magnesium transporter 
ygaP b2668 17.7 0.0017 Predicted inner membrane protein 
alx b3088 12.3 0.0214 Predicted inner membrane protein, part of terminus 
yheL b3343 6.8 0.0010 Predicted intracellular sulfur oxidation protein 
exuT b3093 6.5 0.0433 Hexuronate transporter 
chaA b1216 6.0 0.0031 Calcium/sodium:proton antiporter 
yqjH b3070 4.4 0.0420 Predicted siderophore interacting protein 
metN b0199 4.3 0.0426 D-methionine transport ATP-binding protein  
ftnB b1902 4.3 0.0038 Ferritin-like protein 
metI b0198 4.0 0.0071 D-methionine transport system permease protein 
hcaE b2538 3.8 0.0261 3-phenylpropionate dioxygenase, large (alpha) subunit 
feoA b3408 2.8 0.0361 Ferrous iron transport protein A 
pspE b1308 2.4 0.0097 Phage shock protein E 
corA b3816 2.4 0.0041 Magnesium/nickel/cobalt transporter 
yegH b2063 -2.4 0.0301 Putative transport protein  
yheN b3345 -2.5 0.0130 Predicted intracellular sulfur oxidation protein 
ppx b2502 -2.8 0.0483 Exopolyphosphatase 
mdoG b1048 -2.9 0.0054 Glucan biosynthesis protein 
bcp b2480 -3.4 0.0092 bacterioferritin comigratory protein 
ftnA b1905 -3.5 0.0042 Ferritin iron storage protein 
bfr b3336 -3.5 0.0023 Bacterioferritin 
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Inorganic ion transport and metabolism (continuation) 
apaG b0050 -3.6 0.0103 
Uncharacterized protein associated with Co2+/Mg2+ 
efflux 
can b0126 -5.3 0.0100 Carbonic anhydrase. 
 
Nucleotide transport and metabolism 
gmk b3648 2.9 0.0087 Guanylate kinase 
cmk b0910 2.6 0.0043 Cytidylate kinase 
apt b0469 -2.3 0.0041 Adenine phosphoribosyltransferase 
thyA b2827 -2.5 0.0065 Thymidylate synthase 
pyrG b2780 -2.6 0.0035 CTP synthetase 
deoC b4381 -2.7 0.0129 2-deoxyribose-5-phosphate aldolase 
purE b0523 -2.8 0.0435 Phosphoribosylaminoimidazole carboxylase 
purD b4005 -2.8 0.0097 Phosphoribosylglycinamide synthetase 
purH b4006 -2.9 0.0428 Cyclohydrolase  
purK b0522 -3.1 0.0368 Phosphoribosylaminoimidazole carboxylase 
guaB b2508 -3.2 0.0019 Inositol-5-monophosphate dehydrogenase 
purB b1131 -3.3 0.0142 Adenylosuccinate lyase 
amn b1982 -3.8 0.0413 AMP nucleosidase 
carB b0033 -4.3 0.0105 Carbamoyl-phosphate synthase large subunit  
purU b1232 -4.4 0.0357 Formyltetrahydrofolate deformylase 
ndk b2518 -4.6 0.0038 Nucleoside diphosphate kinase 
pyrC b1062 -4.6 0.0249 Dihydroorotase 
prsA b1207 -4.9 0.0235 Ribose-phosphate pyrophosphokinase 
hinT b1103 -5.0 0.0181 Purine nucleoside phosphoramidase 
carA b0032 -8.3 0.0088 Carbamoyl-phosphate synthase small subunit 
codA b0337 -8.3 0.0265 Cytosine deaminase 
codB b0336 -9.7 0.0310 Cytosine transporter  
 
Cell wall/membrane/envelope biogenesis 
mltD b0211 3.7 0.0034 
Membrane-bound lytic murein transglycosylase D 
precursor  
yiaD b3552 3.0 0.0249 Predicted outer membrane lipoprotien 
lpxC b0096 2.5 0.0040 
UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine 
deacetylase  
amiC b2817 2.4 0.0082 N-acetylmuramoyl-L-alanine amidase  
tolA b0739 2.3 0.0258 
Membrane anchored protein in TolA-TolQ-TolR 
complex 
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Fold 
Change 
P value Gene Product 
 
Cell wall/membrane/envelope biogenesis (continuation) 
blc b4149 -2.3 0.0036 Outer membrane lipoprotein  
yncA b1448 -2.3 0.0038 
Predicted acyltransferase with acyl-CoA N-
acyltransferase domain  
mdoH b1049 -2.6 0.0031 Glucan biosynthesis: glycosyl transferase.  
 osmF b2131 -2.8 0.0181 Predicted transporter subunit 
rfaL b3622 -3.0 0.0311 O-antigen ligase 
rfaF b3620 -3.2 0.0216 ADP-heptose--LPS heptosyltransferase II 
galE b0759 -3.2 0.0072 UDP-galactose-4-epimerase 
lolC b1116 -3.3 0.0110 Outer membrane-specific lipoprotein transporter  
imp b0054 -3.3 0.0105 
Exported protein required for envelope biosynthesis 
and integrity 
lolB b1209 -3.9 0.0308 Chaperone for lipoproteins  
murF b0086 -4.1 0.0033 
UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-
diaminopimelate--D-alanyl-D-alanyl ligase 
yfdI b2352 -4.8 0.0056 
CPS-53 (KpLE1) prophage; predicted inner membrane 
protein 
murE b0085 -5.0 0.0013 
UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-
diaminopimelate ligase  
mdtE b3513 -5.4 0.0161 Multidrug resistance efflux transporter 
yfdH b2351 -6.2 0.0025 CPS-53 (KpLE1) prophage 
cfa b1661 -8.3 0.0295 Cyclopropane fatty acyl phospholipid synthase 
 
Carbohydrate transport and metabolism 
yhbE b3184 6.8 0.0062 Hypothetical transport protein 
yicI b3656 3.4 0.0350 Predicted alpha-glucosidase 
nadK b2615 -2.3 0.0063 Inorganic polyphosphate/ATP-NAD kinase 
ybjS b0868 -2.4 0.0211 Predicted NAD(P)H-binding oxidoreductase 
gnd b2029 -2.5 0.0222 6-phosphogluconate dehydrogenase 
pgk b2926 -2.5 0.0036 Phosphoglycerate kinase 
tktB b2465 -2.5 0.0102 Transketolase 2, thiamin-binding 
rpe b3386 -2.5 0.0133 Ribulose-phosphate 3-epimerase  
pgi b4025 -2.6 0.0046 Glucose-6-phosphate isomerase 
treA b1197 -2.7 0.0052 Periplasmic trehalase 
ptsN b3204 -2.7 0.0083 Sugar-specific enzyme IIA component of PTS 
tpiA b3919 -2.8 0.0188 Triosephosphate isomerase 
pykF b1676 -2.9 0.0384 Pyruvate kinase I 
nagB b0678 -3.2 0.0300 Glucosamine-6-phosphate deaminase  
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Carbohydrate transport and metabolism (continuation) 
amyA b1927 -3.2 0.0018 Cytoplasmic alpha-amylase 
pykA b1854 -3.5 0.0428 Pyruvate kinase 
talA b2464 -3.7 0.0007 Transaldolase A 
ybhC b0772 -4.0 0.0165 Predicted pectinesterase 
pgl b0767 -4.3 0.0151 6-phosphogluconolactonase 
otsA b1896 -4.9 0.0479 Trehalose-6-phosphate synthase 
 
Coenzyme transport and metabolism 
moaA b0781 -2.3 0.0042 Molybdenum cofactor biosynthesis protein A. 
sufB b1683 -2.3 0.0034 SufB protein; component of SufBCD complex 
pdxA b0052 -2.4 0.0251 4-hydroxythreonine-4-phosphate dehydrogenase 
sufC b1682 -2.5 0.0157 cysteine desulfurase ATPase component 
pta b2297 -2.7 0.0162 Phosphate acetyltransferase 
folD b0529 -2.7 0.0079 5,10-methylene-tetrahydrofolate dehydrogenase  
sufD b1681 -2.8 0.0096 Cysteine desulfurase activator 
pdxY b1636 -3.0 0.0386 Pyridoxine kinase  
btuE b1710 -3.1 0.0014 Vitamin B12 transport periplasmic protein 
btuD b1709 -3.1 0.0034 Vitamin B12-transporter ATPase 
sufA b1684 -3.5 0.0226 Iron-sulfur (Fe-S) cluster assembly scaffold protein 
poxB b0871 -3.7 0.0084 Pyruvate dehydrogenase 
lipA b0628 -3.9 0.0444 Lipoyl synthase 
pdxH b1638 -4.3 0.0020 Pyridoxamine 5'-phosphate oxidase 
bioB b0775 -4.4 0.0100 Biotin synthase 
serC b0907 -6.5 0.0264 Phosphoserine aminotransferase 
 
Replication, recombination and repair 
fimE b4313 5.6 0.0467 Tyrosine recombinase 
recN b2616 5.4 0.0137 Recombination and repair protein 
dinJ b0226 4.8 0.0007 Predicted antitoxin of YafQ-DinJ  
insL b0016 3.7 0.0203 Transposase 
dnaG b3066 3.0 0.0200 DNA primase 
priC b0467 2.6 0.0212 Primosomal replication protein N 
dnaA b3702 2.6 0.0171 Chromosomal replication initiator protein 
nudE b3397 2.6 0.0072 ADP-ribose diphosphatase 
nudJ  b1134 -2.3 0.0228 Thiamin pyrophosphate hydrolase  
nei b0714 -2.4 0.0106 Endonuclease VIII 
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Replication, recombination and repair (continuation) 
nudC b3996 -2.5 0.0476 NADH pyrophosphatase 
nfi b3998 -2.5 0.0078 Endonuclease V 
xthA b1749 -3.1 0.0129 Exonuclease III 
holA b0640 -3.1 0.0051 DNA polymerase III subunit delta 
uvrC b1913 -3.3 0.0242 Excinuclease ABC subunit C 
 
Signal transduction mechanisms 
ydeH b1535 17.5 0.0002 
Hypothetical protein with Diguanylate-cyclase (DGC) 
or GGDEF domain  
pspC b1306 4.6 0.0055 Phage shock protein C 
pspB b1305 4.4 0.0147 Phage shock protein B 
pspG  b4050 3.9 0.0290 Phage shock protein G 
uspG b0607 3.3 0.0065 Universal stress protein UP12 
narP b2193 2.7 0.0056 Nitrate/nitrite response regulator protein 
ybeZ b0660 -2.5 0.0224 
Predicted protein with nucleoside triphosphate 
hydrolase domain 
rstA b1608 -2.5 0.0054 
DNA-binding response regulator in two-component 
regulatory system with RstB 
ptsP b2829 -2.9 0.0121 
Phosphoenolpyruvate-protein phosphotransferase; 
fused PTS enzyme 
yebR b1832 -2.9 0.0080 Hypothetical protein; GAF domain 
yeaP b1794 -3.0 0.0192 Predicted diguanylate cyclase 
spoT b3650 -3.2 0.0093 
Guanosine-3',5'-bis pyrophosphate 3'-
pyrophosphohydrolase 
rseB b2571 -3.5 0.0100 Periplasmic negative regulator of sigmaE 
ydiV b1707 -3.7 0.0245 C-di-GMP phosphodiesterase class I  
 
Translation, ribosomal structure and biogenesis 
rttR b4425 15.9 0.0002 Regulatory sRNA 
rrmJ b3179 4.6 0.0061 23S rRNA methyltransferase 
deaD b3162 4.3 0.0012 ATP-dependent RNA helicase 
hslR b3400 4.2 0.0292 Ribosome-associated heat shock protein Hsp15.  
rprA b4431 4.1 0.0271 Regulatory sRNA  
miaA b4171 2.5 0.0330 tRNA delta(2)-isopentenylpyrophosphate transferase 
trmJ b2532 2.5 0.0151 Hypothetical tRNA/rRNA methyltransferase 
truA b2318 2.3 0.0138 tRNA pseudouridine synthase A 
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Translation, ribosomal structure and biogenesis (continuation) 
glyQ b3560 -2.2 0.0025 Glycyl-tRNA synthetase alpha subunit  
yeiP b2171 -2.4 0.0182 Elongation factor P 
rluE b1135 -2.5 0.0086 23S rRNA pseudouridine synthase 
rimN  b3282 -2.5 0.0310 Predicted ribosome maturation factor 
 
Defence mechanisms 
mdtA b2074 13.6 0.0449 Multidrug efflux system, subunit A 
acrD b2470 4.5 0.0227 Aminoglycoside/multidrug efflux system 
rdoA b3859 2.8 0.0054 Thr/Ser kinase implicated in Cpx stress response 
yefM b2017 2.4 0.0460 Antitoxin of the YoeB-YefM toxin-antitoxin system 
lolD b1117 -2.5 0.0391 Outer membrane-specific lipoprotein transporter 
aidB b4187 -2.6 0.0045 Isovaleryl CoA dehydrogenase 
katE b1732 -4.0 0.0015 Catalase 
 
Secondary metabolites biosynthesis, transport and catabolism 
macB b0879 9.6 0.0012 
Fused macrolide transporter subunits of ABC 
superfamily 
ybbA b0495 7.7 0.0047 Hypothetical ABC transporter  
yrbE b3194 4.2 0.0137 Predicted toluene transporter subunit 
yrbF b3195 3.8 0.0349 Predicted toluene transporter subunit 
yrbD b3193 2.4 0.0082 Predicted ABC-type organic solvent transporter 
ycaC b0897 -3.9 0.0421 Predicted hydrolase 
pptA b1461 -4.2 0.0220 4-oxalocrotonate tautomerase homolog 
 
Intracellular trafficking, secretion, and vesicular transport 
spy b1743 16.0 0.0002 Envelope stress induced periplasmic protein 
zraP b4002 10.4 0.0335 Zn-binding periplasmic protein 
secG b3175 2.5 0.0224 Preprotein translocase membrane subunit  
secF b0409 2.4 0.0021 SecYEG protein translocase auxillary subunit 
fimC b4316 -3.9 0.0493 Chaperone, periplasmic 
 
Lipid transport and metabolism 
fabI b1288 -2.3 0.0153 Enoyl-[acyl-carrier-protein] reductase 
ispD b2747 -2.8 0.0297 
2-C-methyl-D-erythritol 4-phosphate 
cytidylyltransferase 
yegS b2086 -3.2 0.0220 Phosphatidylglycerol kinase 
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Central intermediary metabolism 
appA b0980 -2.5 0.0375 Phosphoanhydride phosphorylase 
psiF b0384 -2.7 0.0127 Phosphate starvation-inducible protein.  
 
Cell cycle control, cell division, chromosome partitioning 
sulA b0958 9.5 0.0097 SOS cell division inhibitor 
yhdE b3248 -2.4 0.0056 Maf-like protein 
 
Phage-related functions and prophages 
lit b1139 -3.1 0.0218 Cell death peptidase (e14 prophage) 
ymfI b1143 -4.1 0.0023 e14 prophage 
 
Hypothetical proteins 
yncJ b1436 42.2 0.0086 Hypothetical protein 
yaaX b0005 42.2 0.0098 Hypothetical protein 
bhsA b1112 25.7 0.0115 Hypothetical protein 
yjfN b4188 19.8 0.0029 Hypothetical protein 
ycfJ b1110 18.0 0.0177 Hypothetical protein 
yebE b1846 16.3 0.0029 Hypothetical protein 
ycfS b1113 12.0 0.0165 Hypothetical protein 
yedX b1970 10.3 0.0069 Transthyretin-like protein precursor 
yhdV b3267 9.0 0.0191 Hypothetical protein 
ypfM b4606 8.8 0.0018 Hypothetical protein 
yneM b4599 8.4 0.0082 Hypothetical protein 
yqjA b3095 8.0 0.0023 Hypothetical protein 
yiiX b3937 6.9 0.0218 Predicted peptidoglycan peptidase 
ypfG b2466 6.7 0.0310 Hypothetical protein 
fxsA b4140 6.7 0.0032 Hypothetical membrane protein 
yqjB b3096 6.6 0.0426 Hypothetical protein 
yaiY b0379 6.5 0.0187 Hypothetical protein 
tqsA b1601 6.3 0.0331 Predicted permease 
yeeE b2013 6.3 0.0469 Predicted inner membrane protein 
ybeD b0631 6.1 0.0029 Hypothetical protein 
yqaE b2666 5.9 0.0015 Hypothetical protein 
mgrB b1826 5.8 0.0340 Hypothetical protein 
yhcN b3238 5.8 0.0014 Hypothetical protein 
ymgD b1171 5.5 0.0216 Hypothetical proteins 
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Hypothetical proteins (continuation) 
yebG b1848 5.4 0.0017 Conserved protein regulated by LexA 
bssR b0836 5.4 0.0192 Hypothetical protein 
ytfK b4217 5.3 0.0027 Hypothetical protein 
obgE b3183 5.2 0.0091 Hypothetical GTP-binding protein 
ves b1742 5.0 0.0278 Hypothetical protein 
ycjX b1321 5.0 0.0015 Hypothetical protein 
ybfA b0699 4.5 0.0182 Hypothetical protein 
rmuC b3832 4.4 0.0199 Predicted recombination limiting protein 
bax b3570 4.3 0.0342 Hypothetical protein;  ATP-binding protein 
ymgG b1172 4.2 0.0230 Hypothetical protein 
ygdR b2833 4.2 0.0203 Hypothetical protein 
ycbB b0925 3.7 0.0092 Predicted carboxypeptidase 
yfcO b2332 3.6 0.0159 Hypothetical protein 
ymgI b4593 3.6 0.0177 Hypothetical protein 
ydcH b1426 3.5 0.0470 Hypothetical protein 
yohN b2107 3.5 0.0033 Hypothetical protein 
sraF b4448 3.5 0.0140 Unknown RNA 
yrfG b3399 3.4 0.0253 Predicted hydrolase 
ynfD b1586 3.4 0.0284 Hypothetical protein 
yciS b1279 3.3 0.0274 Hypothetical protein 
rygB b4445 3.3 0.0028 Unknown RNA 
yebO b1825 3.2 0.0038 Hypothetical protein 
ycjF b1322 3.2 0.0093 Hypothetical protein 
rygA b4444 3.1 0.0347 Unknown RNA 
yhdN b3293 3.1 0.0076 Hypothetical protein 
ryeE b4438 2.9 0.0099 Unknown RNA 
nlpI b3163 2.8 0.0053 Lipoprotein, contains TPR repeats 
ybbJ b0488 2.7 0.0226 Hypothetical protein 
yifN b3776 2.7 0.0210 Hypothetical protein 
ytfP b4222 2.7 0.0195 Hypothetical protein 
sroF b4441 2.6 0.0119 Unknown RNA 
ybaJ b0461 2.6 0.0271 Hypothetical protein 
ydcY b1446 2.6 0.0052 Hypothetical protein 
yciC b1255 2.6 0.0044 hypothetical protein 
pgaD b1021 2.5 0.0111 Hypothetical protein 
yhhA b3448 2.5 0.0441 Hypothetical protein 
yjgQ b4262 2.4 0.0221 Conserved membrane protein 
lolA b0891 2.4 0.0084 Chaperone for lipoproteins 
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Hypothetical proteins (continuation) 
yrbB b3191 2.4 0.0030 
Hypothetical protein. Predicted NTP binding protein 
(contains STAS domain) 
b3022 b3022 2.3 0.0042 Predicted cyanide hydratase 
yjgP b4261 2.3 0.0023 Conserved membrane protein. Predicted permease 
yccJ b1003 -2.2 0.0034 Hypothetical protein 
yeaH b1784 -2.2 0.0352 Hypothetical protein 
slp b3506 -2.2 0.0068 Outer membrane lipoprotein. 
yfbT b2293 -2.3 0.0058 Predicted hydrolase or phosphatase 
wrbA b1004 -2.3 0.0166 Predicted flavoprotein in Trp regulation 
yciH b1282 -2.4 0.0066 Hypothetical protein 
ybiB b0800 -2.5 0.0304 Predicted transferase/phosphorylase 
ydhZ b1675 -2.5 0.0163 Hypothetical protein 
yabQ b0057 -2.5 0.0266 Hypothetical protein 
msyB b1051 -2.6 0.0052 Hypothetical protein 
ybeY b0659 -2.6 0.0126 Hypothetical protein 
yihI b3866 -2.6 0.0171 Hypothetical protein 
yehE b2112 -2.6 0.0247 Hypothetical protein 
yceK b1050 -2.6 0.0484 Predicted lipoprotein 
yoaC b1810 -2.6 0.0394 Hypothetical protein 
yigL b3826 -2.7 0.0033 Predicted hydrolase, phosphatase-like domain 
yobF b1824 -2.7 0.0310 Hypothetical protein 
yidA b3697 -2.7 0.0249 Predicted hydrolase 
ydbJ b4529 -2.7 0.0162 Hypothetical protein 
yjdJ b4127 -2.8 0.0206 Predicted acyltransferase 
ytjA b4568 -2.8 0.0411 Hypothetical protein 
yeaC b1777 -2.9 0.0086 Hypothetical protein 
yecN b1869 -2.9 0.0358 Hypothetical protein 
elaB b2266 -3.0 0.0076 Hypothetical protein 
bcsE b3536 -3.0 0.0223 Hypothetical protein 
yiiQ b3920 -3.0 0.0398 Hypothetical protein 
ycfM b1105 -3.0 0.0029 Predicted outer membrane lipoprotein 
envC b3613 -3.1 0.0024 Protease with a role in cell division 
yceF b1087 -3.4 0.0039 Hypothetical protein 
bcsF b3537 -3.5 0.0051 Hypothetical protein 
ybjT b0869 -3.5 0.0022 
Conserved protein with NAD(P)-binding Rossmann-fold 
domain 
ydiA b1703 -3.6 0.0076 Hypothetical protein 
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Hypothetical proteins (continuation) 
fklB b4207 -3.6 0.0491 
FKBP-type peptidyl-prolyl cis-trans isomerase 
(rotamase) 
ycfL b1104 -3.7 0.0171 Predicted lipoprotein 
rcsF b0196 -3.8 0.0423 Predicted outer membrane protein 
yahK b0325 -4.0 0.0036 Predicted oxidoreductase 
yjdI b4126 -4.4 0.0183 Hypothetical protein 
ydiZ b1724 -4.4 0.0031 Hypothetical protein 
ychJ b1233 -4.5 0.0008 Hypothetical protein 
gph b3385 -4.5 0.0020 Phosphoglycolate phosphatase 
yciX b4523 -4.6 0.0044 Hypothetical protein 
yhiD b3508 -5.1 0.0026 Predicted Mg2+ transport ATPase 
yiiS b3922 -5.3 0.0433 Hypothetical protein 
yhiM b3491 -6.9 0.0128 Hypothetical protein. 
yeeN b1983 -7.2 0.0238 Hypothetical protein 
ybgA b0707 -8.8 0.0334 Hypothetical protein 
 
ANNEXES 
_________________________________________________________________________ 
 182 
 
TABLE 6.A2 E. coli genes differentially expressed following aerobic exposure to CORM-2. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Inorganic ion transport and metabolism 
tauA b0365 19.4 0.0107 Taurine transporter subunit 
tauB b0366 17.7 0.0362 Taurine transport ATP-binding protein 
sbp b3917 10.7 0.0048 Sulfate transporter subunit 
metN b0199 9.9 0.0009 D-methionine transport ATP-binding protein  
tauC b0367 9.0 0.0019 Taurine transport system permease protein 
chaA b1216 8.4 0.0483 Calcium/sodium:proton antiporter 
yheL b3343 7.4 0.0016 Predicted intracellular sulfur oxidation protein 
pspE b1308 7.0 0.0438 
Phage shock protein E. Thiosulfate:cyanide 
sulfurtransferase (rhodanese) 
metI b0198 6.5 0.0005 D-methionine transport system permease protein 
cysA b2422 5.2 0.0373 Sulfate/thiosulfate transporter subunit 
ssuA b0936 4.7 0.0181 Alkanesulfonate transporter subunit 
cysW b2423 3.4 0.0368 Sulfate/thiosulfate transporter subunit 
alx b3088 3.3 0.0196 Predicted inner membrane protein, part of terminus 
yqjH b3070 2.7 0.0022 Predicted siderophore interacting protein 
exuT b3093 2.5 0.0418 Hexuronate transporter 
yqcE b2775 2.3 0.0124 Predicted transporter 
apaG b0050 -2.4 0.0229 
Uncharacterized protein associated with Co2+/Mg2+ 
efflux 
yegH b2063 -2.5 0.0146 Hypothetical protein. Putative transport protein  
cyaY b3807 -2.8 0.0289 Frataxin, iron-binding and oxidizing protein 
 
Energy production and conversion 
frmA b0356 8.1 0.0042 Alcohol dehydrogenase class III 
ldhA b1380 4.8 0.0150 Fermentative D-lactate dehydrogenase 
glpK b3926 3.7 0.0334 Glycerol kinase 
nemA b1650 3.6 0.0428 N-ethylmaleimide reductase, FMN-linked 
yqhD b3011 3.6 0.0319 Alcohol dehydrogenase, NAD(P)-dependent 
yfiD b2579 3.2 0.0015 Pyruvate formate lyase subunit 
fucO b2799 3.0 0.0231 L-1,2-propanediol oxidoreductase 
ssuD b0935 3.0 0.0054 Alkanesulfonate monooxygenase 
xdhD b2881 2.9 0.0087 hypoxanthine oxidase 
fdoH b3893 -2.6 0.0127 Formate dehydrogenase-O, Fe-S subunit 
sucB b0727 -2.7 0.0019 Dihydrolipoamide acetyltransferase 
lldD b3605 -3.2 0.0162 L-lactate dehydrogenase, FMN-linked 
gabD b2661 -3.6 0.0341 Succinate-semialdehyde dehydrogenase I 
fumA b1612 -3.9 0.0146 Fumarate hydratase (fumarase A) 
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Energy production and conversion (continuation) 
sucA b0726 -5.1 0.0318 2-oxoglutarate decarboxylase, thiamin-requiring 
sdhC b0721 -7.8 0.0133 Succinate dehydrogenase 
sdhD b0722 -8.7 0.0305 Succinate dehydrogenase 
 
Carbohydrate transport and metabolism 
uxuB b4323 6.1 0.0043 D-mannonate oxidoreductase, NAD-binding 
uxuA b4322 5.9 0.0043 Mannonate dehydratase 
yciM b1280 3.7 0.0427 Hypothetical protein 
uxaC b3092 3.2 0.0188 Uronate isomerase  
gntX b3413 3.1 0.0323 Gluconate periplasmic binding protein 
maa b0459 3.0 0.0283 Maltose O-acetyltransferase 
uhpT b3666 2.8 0.0367 Hexose phosphate transport protein  
srlE b2703 2.7 0.0236 Glucitol/sorbitol-specific enzyme  
rbsB b3751 2.7 0.0487 D-ribose transporter subunit 
uxaA b3091 2.5 0.0128 Altronate hydrolase 
fucI b2802 2.4 0.0065 L-fucose isomerase 
otsA b1896 -2.8 0.0059 Trehalose-6-phosphate synthase 
tktB b2465 -2.9 0.0413 Transketolase 2, thiamin-binding 
proP b4111 -3.1 0.0431 Proline/glycine betaine transporter 
ugpA b3452 -3.9 0.0067 Glycerol-3-phosphate transporter subunit 
tsgA  b3364 -4.2 0.0176 Predicted transporter 
 
Amino acid transport and metabolism 
metF b3941 17.9 0.0058 5,10-methylenetetrahydrofolate reductase 
metB b3939 4.5 0.0062 Cystathionine gamma-synthase, PLP-dependent  
prlC b3498 3.7 0.0441 Oligopeptidase A 
metL b3940 3.3 0.0246 Homoserine dehydrogenase II 
sdaA b1814 2.9 0.0327 L-serine deaminase I 
ilvG b4488 2.9 0.0427 Acetolactate synthase II, large subunit 
glpB b2242 2.7 0.0081 Glycerol-3-phosphate dehydrogenase 
ilvM b3769 2.6 0.0301 Acetolactate synthase II, small subunit 
gss b2988 -3.1 0.0248 Fused glutathionylspermidine amidase 
lysP b2156 -3.2 0.0482 Lysine transporter 
yeaS b1798 -3.3 0.0176 Neutral amino-acid efflux system 
ybaT b0486 -3.7 0.0074 Predicted transporter 
ygjG b3073 -5.9 0.0279 Putrescine: 2-oxoglutaric acid aminotransferase 
aroH b1704 -7.0 0.0421 2-dehydro-3-deoxyphosphoheptonate aldolase 
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TABLE 6.A2 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Transcription 
metR b3828 20.5 0.0053 DNA-binding transcriptional activator 
soxS b4062 14.5 0.0251 Regulatory protein SoxS 
cpxP b4484 12.2 0.0455 Periplasmic protein combats stress 
marA b1531 9.5 0.0096 Multiple antibiotic resistance protein 
frmR b0357 6.7 0.0442 Regulator protein that represses frmRAB operon 
zntR b3292 6.1 0.0045 
DNA-binding transcriptional activator in response to 
Zn(II) 
araC b0064 5.0 0.0083 Arabinose operon regulatory protein 
lrhA b2289 4.6 0.0180 
DNA-binding transcriptional repressor of flagellar, 
motility and chemotaxis genes 
oxyR b3961 4.1 0.0059 Hydrogen peroxide-inducible genes activator 
lexA b4043 3.8 0.0160 LexA repressor 
lsrR b1512 3.0 0.0186 lsr operon transcriptional repressor 
cspG b0990 -3.2 0.0231 Cold shock-like protein 
gadX b3516 -4.3 0.0143 DNA-binding transcriptional dual regulator 
 
Posttranslational modification, protein turnover, chaperones 
ibpB b3686 79.3 0.0266 16 kDa heat shock protein B 
ibpA b3687 18.7 0.0022 16 kDa heat shock protein A 
hslO b3401 5.4 0.0096 Hsp33-like chaperonin 
hspQ b0966 4.8 0.0026 DNA-binding protein, hemimethylated 
clpB b2592 4.8 0.0378 Protein disaggregation chaperone 
dnaJ b0015 4.1 0.0014 Chaperone Hsp40, co-chaperone with DnaK.  
yeeD b2012 3.3 0.0023 Predicted redox protein 
ybbN b0492 2.9 0.0373 Predicted thioredoxin domain-containing protein 
yggG b2936 2.7 0.0444 Predicted peptidase 
dnaK b0014 2.6 0.0105 Chaperone Hsp70, co-chaperone with DnaJ 
 
Signal transduction mechanisms 
ydeH b1535 23.5 0.0122 Hypothetical protein with diguanylate-cyclase 
pspG b4050 11.4 0.0352 Phage shock protein G  
pspB b1305 10.5 0.0045 Phage shock protein B 
uspF b1376 3.8 0.0207 Stress-induced protein, ATP-binding protein  
narP b2193 2.8 0.0487 Nitrate/nitrite response regulator protein 
apaH b0049 -2.8 0.0394 diadenosinetetraphosphatase 
ydiV b1707 -5.9 0.0360 C-di-GMP phosphodiesterase class I  
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TABLE 6.A2 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Replication, recombination and repair 
phr b0708 -2.6 0.0316 Deoxyribodipyrimidine photolyase, FAD-binding 
ruvA b1861 2.5 0.0438 Component of RuvABC resolvasome 
fimE b4313 3.9 0.0156 Tyrosine recombinase 
mutM b3635 6.0 0.0282 Formamidopyrimidine-DNA glycosylase 
recN b2616 8.4 0.0302 Recombination and repair protein 
 
Defence mechanisms 
mdtB b2075 19.0 0.0312 Multidrug efflux system, subunit B 
marB b1532 6.9 0.0049 Multiple antibiotic resistance protein 
rdoA b3859 3.5 0.0184 Thr/Ser kinase implicated in Cpx stress response 
pmrD b2259 2.8 0.0325 Polymyxin B resistance protein 
aidB b4187 -2.7 0.0373 Isovaleryl CoA dehydrogenase 
 
Translation, ribosomal structure and biogenesis 
hslR b3400 5.1 0.0010 Ribosome-associated heat shock protein Hsp15 
micF b4439 4.1 0.0291 Regulatory antisense sRNA affecting ompF expression 
rrmJ b3179 3.2 0.0166 23S rRNA methyltransferase 
miaA b4171 2.5 0.0151 tRNA delta(2)-isopentenylpyrophosphate transferase 
 
Cell motility 
ydeS b1504 3.2 0.0218 Predicted fimbrial-like adhesin protein 
flgA b1072 -2.6 0.0153 
Assembly protein for flagellar basal-body periplasmic 
P ring  
cheA b1888 -2.9 0.0453 Sensory histidine kinase/signal sensing protein 
 
Intracellular trafficking, secretion, and vesicular transport 
spy b1743 30.0 0.0043 Envelope stress induced periplasmic protein  
secA b0098 3.4 0.0065 Preprotein translocase subunit, ATPase 
 
Lipid transport and metabolism 
sbmA b0377 3.2 0.0260 Predicted transporter 
yihG b3862 -2.7 0.0270 Predicted endonuclease 
 
Nucleotide transport and metabolism 
guaC b0104 -2.2 0.0167 GMP reductase 
sthA b3962 -5.0 0.0069 Soluble pyridine nucleotide transhydrogenase 
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TABLE 6.A2 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Secondary metabolites biosynthesis, transport and catabolism 
ybbA b0495 7.1 0.0084 Hypothetical ABC transporter 
ybbP b0496 6.5 0.0154 Predicted inner membrane protein 
 
Cell wall/membrane/envelope biogenesis 
osmB b1283 3.1 0.0394 Osmotically inducible lipoprotein B 
amiC b2817 2.4 0.0154 N-acetylmuramoyl-L-alanine amidase 
 
Coenzyme transport and metabolism 
thiC b3994 -2.3 0.0080 Thiamin (pyrimidine moiety) biosynthesis protein 
btuD b1709 -2.3 0.0111 Vitamin B12-transporter ATPase 
 
Cell cycle control, cell division, chromosome partitioning 
sulA b0958 5.4 0.0232 SOS cell division inhibitor 
 
Hypothetical proteins 
yncJ b1436 62.0 0.0191 Hypothetical protein 
yjfN b4188 22.9 0.0030 Hypothetical protein 
yebE b1846 22.9 0.0056 Hypothetical protein 
ycfS b1113 16.9 0.0064 Hypothetical protein 
ymgG b1172 16.0 0.0312 Hypothetical protein 
fxsA b4140 13.8 0.0135 Hypothetical membrane protein 
ycfJ b1110 13.5 0.0390 Hypothetical protein  
ycjF b1322 10.0 0.0151 Hypothetical protein 
tqsA b1601 9.1 0.0461 Predicted permease  
yhdV b3267 9.0 0.0063 Hypothetical protein 
ypfG b2466 8.6 0.0319 Hypothetical protein 
ycjX b1321 7.7 0.0223 Hypothetical protein  
yodA b1973 6.6 0.0117 Conserved metal-binding protein 
yneM b4599  6.2 0.0438 Hypothetical protein 
ybeD b0631 6.0 0.0020 Hypothetical protein 
yaiY b0379 5.8 0.0109 Hypothetical protein 
ydeT b1505 5.7 0.0017 Hypothetical protein 
yqjA b3095 5.7 0.0100 Hypothetical protein 
ryeD b4437 5.6 0.0125 Unknown RNA 
ytfK b4217 5.3 0.0023 Hypothetical protein 
ycgK b1178 4.9 0.0338 Hypothetical protein 
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TABLE 6.A2 Continuation. 
Gene 
Name 
Locus 
Fold 
Change 
P value Gene Product 
 
Hypothetical proteins (continuation) 
yqaE b2666 4.5 0.0145 Hypothetical protein 
ybfA b0699 4.5 0.0023 Hypothetical protein  
ynfD b1586 4.5 0.0385 Hypothetical protein 
ydjM b1728 4.4 0.0043 Predicted inner membrane protein 
yedY b1971 4.3 0.0035 Predicted reductase 
yrfG b3399 4.3 0.0104 Predicted hydrolase 
yhdN b3293 4.3 0.0341 Hypothetical protein 
eptB b3546 4.0 0.0315 Predicted metal dependent hydrolase 
yobB b1843 4.0 0.0060 Predicted amidohydrolase  
bax b3570 3.3 0.0284 ATP-binding protein 
yciS b1279 3.2 0.0134 Hypothetical protein  
ldrB b4421 3.1 0.0481 Toxic polypeptide, small 
yeeE b2013 2.7 0.0183 Predicted inner membrane protein 
ybjK b0846 2.6 0.0076 Predicted DNA-binding transcriptional regulator 
sraF b4448 2.5 0.0109 Unknown RNA 
yciC b1255 2.3 0.0298 Hypothetical protein 
ucpA b2426 2.3 0.0056 Predicted oxidoredutase 
yeiB b2152 -2.2 0.0138 Conserved inner membrane protein 
yqcC b2792 -2.3 0.0102 Hypothetical protein 
yaeB b0195 -2.7 0.0059 Hypothetical protein 
yrdB b3280 -2.8 0.0138 Hypothetical protein 
ygfJ b2877 -2.9 0.0288 Hypothetical protein 
yafK b0224 -3.0 0.0098 Hypothetical protein 
yahK b0325 -3.6 0.0290 Predicted oxidoreductase 
ybaK b0481 -3.9 0.0269 Hypothetical protein 
slp b3506 -4.1 0.0200 Outer membrane lipoprotein 
yciX_2 b4523 -8.0 0.0152 Hypothetical protein 
yagU b0287 -10.4 0.0226 Conserved inner membrane protein 
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TABLE 6.A3 Oligonucleotides used in this study. 
Oligonucleotides Sequence (5’ – 3’) 
RT_yncJ_up GGACAACTCATGGCAGGGC 
RT_yncJ_low GCTCGCGCAAACCTTCC 
RT_marA_up GGACTGGATCGAGGACAACC 
RT_marA_low CGCCCTGCATATTGGTCAT 
RT_soxS_up GACCAGCCGCTTAACATTGA 
RT_soxS_low CGATAATCGCTGGGAGTGC 
RT_lrhA_up CGCGTGAGTTCGGTTTATCC 
RT_lrhA_low CTGCGCAGTACCAGTGTGTTG 
RT_ibpB_up CGCCGTACAACATTGAGAAA 
RT_ibpB_low CGGGACGTTCGCTGATAG 
RT_frmA_up CCGGCGTTGTGGTTGAAGT 
RT_frmA_low TCGCGCCAAGACCAAACAC 
RT_gadX_up CGCTTTCATTATTTCTCCCGA 
RT_gadX_low CACGGTTCGACAATCTCTGC 
RT_metR_up TCTGCGCATTGCCATTGAG 
RT_metR_low GGCGTACAGTCGGCTCCAC 
RT_bhsA_up GTAAAAACCCTCATCGCTGC 
RT_bhsA_low TGCTGTTCCATGGAGGGTAT 
RT_sucA_up GGCGTTTAACCCGTCTCACC 
RT_sucA_low GCGTCGCCACTTTTTCCTG 
Comp_ibpAB_HindIII ATCGTGGGTGTAAGCTTGATGAGTT 
Comp_ibpAB_XbaI CAGTCGAAATCTAGAGCATTGTTGAG 
Comp_metR_HindIII TCGTACCAAGCTTAATCGCCCACC 
Comp_metR_ XbaI GCTGGTAAACCTGTCTAGATGGCAC 
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TABLE 6.A4 Bacterial strains used in this study. 
E. coli Strains Description Reference 
MG1655 Wild type 
Laboratory 
stock 
∆metR MG1655 metR::Kanr CGSC*, [13] 
∆metI MG1655 metI::Kanr CGSC, [13] 
∆metN MG1655 metN::Kanr CGSC, [13] 
SA29 MC4100 ∆oxyR::Kanr [14] 
∆oxyR 
P1 transduction of SA29 to 
MG1655 
This study 
GC4468 Parental strain [15] 
BW831 GC4468 soxS3::Tn10 [15] 
MC4100 Parental strain [16] 
JGT10 MC4100 ∆ibpAB::Kanr [17] 
PAD282 Parental strain [18] 
PAD488 PAD282 cpxP::Kanr [18] 
BW25113 Parental strain [19] 
∆tqsA BW25113 tqsA::Kanr [19] 
∆bhsA BW25113 bhsA::Kanr [22] 
*CGSC - Coli Genetic Stock Center 
 
 
 
TABLE 6.A5 E. coli plasmids used in this study. 
Plasmid Description Reference 
pUC-19 Cloning vector (Ampr) Laboratory stock 
pibpAB pUC-19 containing ibpAB This study 
pmetR pUC-19 containing metR This study 
pAQ17 pUC-19 containing oxyR [20] 
pBR322 Cloning vector (Ampr) [21] 
pWB31 pBR322 containing soxS [21] 
pCA24N Cloning vector (Cmr) [19] 
pCA24NydgG+ pCA24N containing ydgG [19] 
pCA24NycfR+ pCA24N containing ycfR [22] 
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TABLE 6.A6 Comparison of CORM-2- and biofilm-regulated genes. 
Gene 
Name 
Locus 
Fold Change 
Anaerobic 
CORM-2 
Aerobic 
CORM-2 
Biofilm* 
ibpB b3686 40 79 32 
bhsA b1112 26 - 12 
ibpA b3687 19 19 4 
bssS b1060 13 - 5 
soxS b4062 10 15 49 
tqsA b1601 6 9 6 
bssR b0836 5 - 3 
ybaJ b0461 3 - 36 
yefM b2017 2 - 3 
b3022 b3022 2 - 8 
yceK b1050 -3 - -8 
artI b0863 -3 - -6 
yobF b1824 -3 - -7 
artP b0864 -4 - -6 
gabD b2661 - -4 -8 
hyaA b0972 -5 - -6 
yhiD b3508 -5 - -5 
yhiM b3491 -7 - -6 
* Adapted from [34] 
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7.1 New insight into the role of S. aureus flavohaemoglobin 
S. aureus is an opportunist pathogen that due to its high virulence and 
antibiotic resistance has high impact on human health and is responsible for 
several serious infections such as toxic shock syndrome and septicemia [1]. 
Macrophages and neutrophils are key components of the human innate 
immune system that provide defence against invading microorganisms. Nitric oxide 
is one of the most powerful antimicrobial products generated within phagocytic 
cells and has been shown to afford protection against S. aureus since the inhibition 
of nitric oxide synthase or its gene deletion leads to an increase of mice 
susceptibility to S. aureus infections [2, 3].  
Microbes have developed several strategies to detoxify NO (Chapter 1) but the 
mechanisms by which S. aureus resist to nitrogen reactive species remain 
essentially unknown. Among the known NO-detoxifiers (see 1.2.2), S. aureus 
genome only encodes a flavohaemoglobin-like gene.  
Flavohaemoglobins are important enzymes regarding the scavenging of NO 
[4-6]. In this thesis, the role of flavohaemoglobin in S. aureus protection against 
nitrosative stress was addressed. S. aureus Hmp exhibits 30 % amino acid 
sequence identity with E. coli Hmp, and is constituted by a high spin haem b and a 
flavin domain. Its biochemical characterisation revealed that it has all the typical 
features of the canonical flavohaemoglobins. Modeling studies, using the three-
dimensional structure of the E. coli Hmp, predicted that S. aureus Hmp has a 
overall folding similar to that of the E. coli enzyme. In particular,  the His85 residue 
(considering the residue numbering of the S. aureus amino acid sequence), that 
links the haem to the polypeptide chain, and the residues that control the 
interaction with ligands (Tyr29 and Gln53) are conserved (Figure 7.1) [7]. In 
addition, the residues that interact with phopholipids are conserved (Figure 7.1), 
which suggest that S. aureus Hmp may also bind lipids and detoxify toxic 
hydroperoxides [8, 9].  
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* * * * * *
Saureus M L T E Q E K D I I K Q T V P L L K E K G T E I T S I F Y P K M F K A H P E L L N M F N Q T N Q K R G M Q S S A L A Q A :60
Ecoli M L D A Q T I A T V K A T I P L L V E T G P K L T A H F Y D R M F T H N P E L K E I F N M S N Q R N G D Q R E A L F N A :60
Aeutropha M L T Q K T K D I V K A T A P V L A E H G Y D I I K C F Y Q R M F E A H P E L K N V F N M A H Q E Q G Q Q Q Q A L A R A :60
Scerevisae M L A E K T R S I I K A T V P V L E Q Q G T V I T R T F Y K N M L T E H T E L L N I F N R T N Q K V G A Q P N A L A T T :60
*
Saureus V M A A A V N I D N L S V I K P V I M P V A Y K H C A L Q V Y A E H Y P I V G K N L L K A I Q D V T G L E E N D P V I Q :120
Ecoli I A A Y A S N I E N L P A L L P A V E K I A Q K H T S F - Q K P E Q Y N I V G E H L L A T L D E M F S - - P G Q E V L D :117
Aeutropha V Y A Y A E N I E D P N S L M A V L K N I A N K H A S L G V K P E Q Y P I V G E H L L A A I K E V L G N A A T D D I I S :120
Scerevisae V L A A A K N I D D L S V L M D H V K Q I G H K H R A L Q I K P E H Y P I V G E Y L L K A I K E V L G D A A T P E I I N :120
Saureus A WA K A Y G V I A D V F I Q I E K E I Y D Q M M - - - - - W I G F K P F K I T N I K Q E S E D I K S F T V E T - - - - :171
Ecoli A WG K A Y G V L A N V F I N R E A E I Y N E N A S K A G G WE G T R D F R I V A K T P R S A L I T S F E L E P - - - - :173
Aeutropha A WA Q A Y G N L A D V L M G M E S E L Y E R S A E Q P G G WK G WR T F V I R E K R P E S D V I T S F I L E P - - - - :174
Scerevisae A WG E A Y Q A I A D I F I T V E K K M Y E E A L - - - - - WP G WK P F D I T A K E Y V A S D I V E F T V K P K F G S :175
Saureus - E E Y D F S E F T P G Q Y I T V D V S - - S D K L P Y R A K R H Y S I V S G - E K N H L T F G V K R D V T T E H - - E :225
Ecoli V D G G A V A E Y R P G Q Y L G V WL K - - P E G F P H Q E I R Q Y S L T R K P D G K G Y R I A V K R E E G G Q - - - - :227
Aeutropha A D G G P V V N F E P G Q Y T S V A I D - - V P A L G L Q Q I R Q Y S L S D M P N G R T Y R I S V K R E G G G P Q - P P :231
Scerevisae G I E L E S L P I T P G Q Y I T V N T H P I R Q E N Q Y D A L R H Y S L C S A S T K N G L R F A V K M E A A R E N F P A :235
Saureus G E V S T I L H D E I K E G D M I N L A A P V G G F V L - - - - - E N T T E P Q L F L G S G I G V T P L V A M Y E A A S :280
Ecoli - - V S N WL H N H A N V G D V V K L V A P A G D F F M A - - - - V A D D T P V T L I S A G V G Q T P M L A M L D T L A :281
Aeutropha G Y V S N L L H D H V N V G D Q V K L A A P Y G S F H I D - - - - V D A K T P I V L I S G G V G L T P M V S M L K V A L :287
Scerevisae G L V S E Y L H K D A K V G D E I K L S A P A G D F A I N K E L I H Q N E V P L V L L S S G V G V T P L L A M L E E Q V :295
Saureus A K G L D T - - Q M V Q V A E N E Q H L P F K D N F N S I A S H H D N A K L Y T H L K - - - - - - - - - - - - D K Q G Y :326
Ecoli K A G H T A Q V N WF H A A E N G D V H A F A D E V K E L G Q S L P R F T A H T WY R Q P S E A D R A K G Q F D S E G L :341
Aeutropha Q A - P P R Q V V F V H G A R N S A V H A M R D R L R E A A K T Y E N L D L F V F Y D Q P L P E D V Q G R D Y D Y P G L :346
Scerevisae K C N P N R P I Y WI Q S S Y D E K T Q A F K K H V D E L L A E C A N V D K I I V H T - - - - - - - - - - - - D T E P L :343
Saureus I G A E E L Q - V F L A N K P E I Y I C G G T K F L Q S M I E A L K S L N Y D M D R V H Y E T F I P R L S V A V :381
Ecoli M D L S K L E G A F S D P T M Q F Y L C G P V G F M Q F T A K Q L V D L G V K Q E N I H Y E C F G P H K V L :396
Aeutropha V D V K Q I E K S I L L P D A D Y Y I C G P I P F M R M Q H D A L K N L G I H E A R I H Y E V F G P D L F A E :403
Scerevisae I N A A F L K - E K S P A H A D V Y T C G S L A F M Q A M I G H L K E L E H R D D M I H Y E P F G P K M S T V Q V :399
 
FIGURE 7.1 Amino acid sequence alignment of flavohaemoglobins. S. aureus, E. coli, A. 
eutrophus and S. cerevisiae flavohaemoglobins. Asterisks refer to amino acid residues involved in 
ligation to the phospholipids in the A. eutrophus enzyme. 
 
We showed that S. aureus Hmp metabolises NO, under aerobic and anaerobic 
conditions, with activity values that are within the range of values measured to 
homologous proteins [10-12]. However, as the anaerobic activity of E. coli 
flavohaemoglobin is much lower than the aerobic one, it has been considered that 
flavohaemoglobins have a major role under aerobic conditions [13]. Yet, Hmp was 
reported to afford NO-protection to S. typhimurium under low levels of dioxygen, 
since the hmp deficient mutant showed high susceptible to GSNO under anaerobic 
conditions [14]. Similar results were describded for S. cerevisiae, underlining the 
potential protective role of flavohaemoglobins under anaerobic conditions [15]. Our 
results also demonstrated the anaerobic ability of S. aureus Hmp to detoxify nitric 
oxide since the over-expression of S. aureus Hmp in the E. coli flavorubredoxin-
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mutant, a strain that display high susceptibility to nitric oxide anaerobically, is able 
to protect E. coli cells against nitrosative stress (Figure 3.3F). 
Richardson and co-workers, have also analysed the role of flavohaemoglobin 
in S. aureus COL strain [16]. However, in this work, only the aerobic protection 
afforded by Hmp was explored exhibiting the S. aureus hmp null mutant higher 
susceptibility to nitrosative stress when compared to the wild type. Furthermore, 
the growth phenotypes were analysed after a long period of incubation (~ 12 h) 
and using a high S-nitroso-N-acetylpenicillamine concentration (5 mM), which is 
well above the estimated intracellular NO levels (µM range) [16, 17].  
On contrary, all our results reinforce the proposal that S. aureus Hmp has a 
major role under low levels of dioxygen. In fact, the highest induction of S. aureus 
hmp expression is triggered by the limitation of dioxygen in bacterial growth 
conditions (Figure 3.2), and the deletion of the hmp gene generates a S. aureus 
strain sensitive to nitrosative stress but only under microaerobic conditions (Figure 
3.3C-D). Therefore, S. aureus Hmp functions as a NO denitrosylase. Although this 
mechanism has already been proposed by Hausladen et al. as the one operative 
for flavohaemoglobin under physiological conditions (discussed 1.5.2), this was the 
first time that supportive experimental data was obtained. 
Hmp is required for full virulence in mice as a S. aureus hmp-deleted strain 
was not able to induce mortality of infected mice, which highlights the importance 
of Hmp in S. aureus defence against nitrosative stress [16]. Nevertheless, since the 
S. aureus NO consuming activity is not completely abolished in the hmp mutant, 
the contribution of other enzymes to the S. aureus NO metabolism needs to be 
considered [16]. Recently, we have identified a bifunctional nitroreductase that, in 
addition to its nitroreductase activity, displays GSNO reductase activity. The 
enzyme affords protection to GSNO-treated S. aureus as the deletion of the 
nitroreductase gene increases the susceptibility of S. aureus to GSNO [18]. 
The importance of NO detoxifying systems is increased in S. aureus, since NO 
is also produced endogenously via the activity of NO synthase, which was reported 
to generate nitric oxide in response to methanol [19]. Although several bacteria 
contain NO synthase homologues, their biological function remains to be 
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elucidated. Recent studies suggest that bacterial NO synthase may increase the 
resistance to a broad spectrum of antibiotics as B. subtilis and S. aureus strains 
deleted in the NO synthase gene display higher susceptibility to antibiotics like 
acriflavine and pyocyanin [20]. The mechanisms by which NO-mediated antibiotic 
resistance include chemical modification of the antibiotic, and induction of the 
expression of genes involved in oxidative stress detoxification [20]. 
Interestingly we found that, on contrary, flavohaemoglobin confers antibiotic 
susceptibility to S. aureus. During the investigation of the ability of S. aureus Hmp 
to coordinate azoles antibiotics, that inhibit S. aureus Hmp NO denitrosylase 
activity, we observed that, the deletion of hmp gene increases the resistance of S. 
aureus to azole antibiotics (see Chapter 4), both in the absence and presence of 
NO. 
Azoles are synthetic compounds that were initially used to treat fungal 
infections and its main target is the lanosterol 14 -demethylase, an essential 
enzyme in the biosynthesis of ergosterol [21]. Nowadays, it is well established that 
azoles are also active against bacteria, particularly Gram-positive species, but its 
cellular targets remain unknown [22, 23]. 
This work showed that S. aureus is susceptible to imidazoles like miconazole, 
sulconazole, clotrimazole, and ketozonazole, but not to triazoles such as 
fluconazole and itraconazole. The lack of S. aureus sensitivity to triazoles seems to 
result from the inability of these compounds to coordinate to Hmp. 
To assed the mechanism by which flavohaemoglobin potentiates the 
antimicrobial action of imidazoles, it was first analysed the ability of the imidazole 
to bind the purified S. aureus Hmp. By UV-Visible, EPR and resonance Raman it 
was shown that miconazole coordinates S. aureus Hmp haem as a sixth ligand in 
both ferric and ferrous state given rise to low spin species (Figure 4.3 and Table 
4.1). The miconazole binds tightly to the Hmp ferric haem with an association 
constant of 1.7 x 106 M-1. More importantly, when provided with an electron donor 
(NADH), an increase of superoxide production by Hmp was observed (Figure 4.4B). 
In accordance, a high level of reactive oxygen species is detected in S. aureus cells 
expressing hmp and the deletion of hmp increases the resistance of S. aureus to 
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imidazoles by ~ 60 % for miconazole, 56 % for sulconazole and clotrimazole and ~ 
40 % for ketoconazole. 
Several studies have already reported that Hmp has the ability of reducing 
dioxygen and the production of superoxide results from the binding of dioxygen to 
the protein haem [24-27]. However, in the presence of imidazoles, the haem site is 
occupied by the antibiotic molecule and the superoxide reduction can only occur at 
the flavin domain. Hence, we proposed that Hmp transfers electrons directly from 
flavin to dioxygen, which would be in agreement with other’s results showing that 
when haem is blocked (e.g. CO) Hmp transfers electrons to several external 
electron acceptors [28]. 
Concerning the generation of reactive oxygen species related to the azole 
action, previous studies in C. albicans and S. cerevisiae reported a similar 
occurrence. However, a completely different mechanism is operating as ROS 
production results from inhibition of ROS-detoxification enzymes like catalase and 
peroxidase [21, 29]. Hence, the presented data revealed a novel mode of action of 
the imidazoles antibiotics. Nevertheless, the existence of other cellular targets that 
contribute to the imidazole-ROS generation in S. aureus cannot be excluded. In 
fact, antibiotic treated hmp deleted strains still contain a non-contemptible amount 
of reactive oxygen species.  
Regarding other potential imidazole targets that may contribute to the 
generation of ROS, an early study reported that S. aureus exposed to miconazole 
has decreased levels of vitamin K2 and increased levels of octaprenyl diphosphate, 
which was proposed to be relating with the inhibition of MenA, the sixth enzyme in 
menaquinone (vitamin K2) biosynthesis. Since menaquinones are involved in the 
electron transport in the respiratory chain, the inhibition of its synthesis might 
potentiate the increase of intracellular reactive oxygen species [30].  
We also observed that the increase of S. aureus susceptibility to imidazole, 
and consequent increase of reactive oxygen species, was not dependent on the 
presence of NO as the survival of miconazole-treated S. aureus strains is strongly 
reduced in LPS- and INF-γ-activated macrophages (producing NO) as well as in 
macrophages in which the generation of NO was inhibited by L-NMMA.  
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Therefore, the simultaneous presence of NO and imidazoles will both 
contribute to the killing of S. aureus by: i) increasing the ROS production; and ii) 
decreasing the S. aureus ability to detoxify NO due to the impairment of NO 
binding to the haem when in the presence of the antibiotic.  
It is interesting to note that in S. cerevisiae the simultaneous treatment with 
miconazole and NO increases the susceptibility of yeast to an extension similar to 
that occurring when S. cerevisiae hmp-mutant in exposed only to NO, thus 
suggesting that the increase of miconazole-sensitivity is related with the inhibition 
of Hmp NO denitrosylase activity [31]. 
In candida species, a synergistic effect between NO and imidazoles was 
reported, although the mechanism whereby the simultaneous treatment with NO 
and imidazoles enhances candida killing was not investigated. Our results, together 
with the observation that candida species (e.g. C. albicans, C. tropicalis and C. 
dubliniensis) containing a flavohaemoglobin show higher sensitivity to azole 
treatment and lower susceptibility to NO than candida strains lacking a hmp 
homologue gene (e.g. C. krusei and C. glabrata), we can speculate that the 
antifungal activity of azole also depends on flavohaemoglobin. Hence, in addition 
to the lanosterol 14 -demethylase, Hmp may constitute an important target of 
azole derivatives on fungal species [32]. 
The knowledge of microbial defence mechanisms to resist inside phagocytes 
is very important to design new strategies to combat pathogens. The work present 
in Chapter 3 provides evidences that S. aureus utilises Hmp to defend itself against 
nitrosative stress, and therefore inhibitors of its activity are good candidates for 
antibiotic development. The work described in Chapter 4 allowed the identification 
of a mechanism by which imidazoles are able to inhibit the growth of S. aureus 
that also involves Hmp. It was demonstrated that by ligating to flavohaemoglobin, 
imidazoles increase the S. aureus intracellular ROS production, which leads to the 
decrease of S. aureus survival. Hence, imidazoles both inhibit the NO denitrosylase 
activity of Hmp and potentiate the ROS formation constituting a good alternative 
treatment for S. aureus infections. 
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7.2 Carbon monoxide as antimicrobial agent 
 
7.2.1 The bactericidal action of CO-releasing molecules  
Carbon monoxide is produced in the human body by the activity of haem 
oxygenase enzymes, which also generates ferrous iron and biliverdin. However the 
relevance of the endogenous production of CO remains, so far, to be fully 
understood. In addition, the potential of utilising the “poisoning ability” of CO was 
until now never addressed. In this thesis, it was analysed, for the first time, the 
effect of CO on bacteria viability using two sources of CO: CO gas and CO-RMs. It 
was found that CO and, in particular, CO-RMs are indeed able to kill bacteria like E. 
coli and S. aureus, under oxic and anoxic conditions.  
Although similar studies have never been performed, an early investigation 
reported the influence of different packing systems on meat preservation. 
Curiously, the authors observed that packages to which CO had been added 
exhibited less bacterial growth [33]. These results can now be explained based on 
the data presented in Chapter 5, which show that the treatment of cells with CO 
causes bacterial growth inhibition. 
The CO released by CO-RMs elicits a more pronounced decrease of bacteria 
viability and the reason behind this difference is not yet clear. Nevertheless, we 
can speculate that the low solubility of CO gas in aqueous solutions may contribute 
to its reduced effectiveness and that the ability of CO-RMs to accumulate inside 
bacterial cells, as demonstrated by the increase of the metal content in E. coli cells 
after being treated with the CO-RMs (Table 7.1), may be responsible for its higher 
efficacy. 
TABLE 7.1 E. coli metal content after the treatment with CO-RMs. 
 
[Metal] 
(µmol/g cell) 
CORM-2 ALF 021 ALF 062 
- + - + - + 
[Ru] 0.001 26     
[Mn]   0.2 20   
[Mo]     0.04 2 
- E. coli cells untreated; + E. coli cells treated with CO-RM  
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Our results revealing that the antimicrobial action of CO-RMs is higher under 
low levels of dioxygen may be explained considering the preferential binding of CO 
to the ferrous form of haem proteins, which are present predominantly under 
anoxic conditions. This observation is not negligible since pathogen colonisation 
occurs in nearly-anaerobic environments. On the other hand, the type of bacterial 
cell wall seems not to interfere with the function of CO-RMs, as a similar decrease 
of cell viability was observed for E. coli and S. aureus, which are consider as 
prototypes of Gram-negative and Gram-positive bacteria, respectively. 
Importantly, the addition of haemoglobin to the bacterial cultures abolishes 
the antimicrobial action of CO-RMs, suggesting that the antibacterial effect is 
dependent on the CO-released. Neither iCORM-2 nor an inactivated solution of ALF 
062 shows any antimicrobial effect. Furthermore, the decomposition products of 
ALF 062, (tetraethyl ammonium bromide and sodium molybdate) are also 
innocuous toward bacterial growth. Hence, the bactericidal activity of CO-RMs is 
not due to the molecular skeleton of the compound but related to its ability of 
releasing CO. 
An early study reported that the exogenous treatment of macrophages with 
CO gas enhances the phagocytic clearance of E. coli [34]. Since the authors 
measured the macrophages phagocytosis ability and did not evaluate the bacterial 
viability, the CO activity was only associated with the increase of surface 
expression of Toll-like receptor 4 of macrophages via the p38 MAPK pathway [34]. 
However, the results presented in this thesis suggest that the increase of bacteria 
clearance in macrophages also relates to the ability of CO gas to kill E. coli.  
After our work, Chung and co-workers analysed the importance of HO-1 on 
microbial sepsis [35]. It was shown that HO-1 deficient mice display enhanced 
susceptibility to polymicrobial infections, while the over-expression of HO-1 has 
remarkable beneficial effects, enhancing bacterial clearance by increasing 
phagocytosis, which leads to the reduction of the number of viable bacteria in mice 
blood and organ homogenates. The beneficial effects of HO-1 on microbial sepsis 
are attributed to CO since the administration of CORM-2 to mice decreases the 
number of bacterial counts in blood, lungs, liver and spleen, and rescues the HO-1-
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deficient mice from sepsis-induced lethality [35]. However, the data acquired with 
HO-1-deficient mice only demonstrate the antibacterial effect of the exogenous 
administration of CO-RMs and not of the endogenous production of CO since HO-1 
produces, in addition to CO, bilirubin and ferrous iron, therefore not allowing to 
exclude the contribution of these other products of the HO-1 activity.  
More recently, Desmard and co-workers showed that CO gas and CORM-3 are 
also able to decrease P. aeruginosa growth, and the antimicrobial effect of CORM-3 
was correlated with the inhibition of the respiratory chain as the CORM-3 
treatment impairs dioxygen consumption of P. aeruginosa cultures. Interestingly, 
CORM-3 exhibits bactericidal effect on P. aeruginosa cultures at concentrations 
lower than those required to kill E. coli and S. aureus. However, these results are 
most probably due to the use of a much lower number of P. aeruginosa cells when 
compared to those utilised in the E. coli and S. aureus experiments. In addition, 
while CORM-3 was added to the beginning of the E. coli exponential cell phase, the 
addition of CORM-3 to P. aeruginosa occurred at the lag phase [36, 37].  
Importantly, Desmard et al. also reported that the prior administration of 
CORM-3 to mice followed P. aeruginosa infection prolongs its survival, being 
observed a decrease of the bacterial counts in the spleen of immunocompetent 
and immunosuppressed mice [36]. This indicates that carbon monoxide 
contributes, together with the stimulation of bacterial phagocytosis by the host, to 
the bacterial clearance, as previously proposed by Otterbein et al. and Chung and 
co-workers [34-36]. 
The present work and the subsequent studies reported above strongly 
suggest that the exogenous administration, whether in the form of CO gas or CO-
RMs, has the potential to treat several bacterial infections. In particular, our results 
indicate that CO-RMs can be considered as a promising pharmaceutical tool for 
eradication of both Gram-positive and Gram–negative microorganisms. It is also 
important to refer that the bactericidal effect of CO-RMs occurs at concentrations 
not cytotoxic to eukaryotic cells, as the treatment of macrophages or smooth 
muscle cells with CO-RMs at concentrations up to 500 µM was reported to promote 
a non-significant cytotoxicity [36, 38, 39]. Furthermore, the administration of CO-
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RMs to rats (5-20 µmol/Kg) does not increase carboxy-haemoglobin to dangerous 
levels (COHb levels < 10 %) [38, 40, 41]. In particular, the intravenous 
administration of 100 µM CORM-3 to mice only raised the COHb level to ~ 0.5 % 
[36]. Since the first symptoms of CO poisoning in humans appear in a range of 15 
– 20 % COHb, it is not predictive significant side effects of CO-RMs therapy [36, 
42].  
 
7.2.2 On the search of bacterial targets of CO-releasing 
molecules 
In humans, the biological activity of CO has been considered mainly due to its 
interaction with iron haem proteins. However, CO may bind to almost all transition 
metals-containing proteins, altering their structure and activity. Therefore, there 
are a large number of intracellular targets that may be responsible for the toxic 
effects of CO on bacteria.  
To identify the potential bacterial CO targets, the transcriptional response of 
E. coli to CORM-2 was analysed by DNA microarray experiments (Chapter 6). 
Microarray studies allow the simultaneous examination of the expression levels of 
thousands of genes being consider an essential tool since it provides a global 
picture of the metabolic pathways that are affected by an external stimulus. The 
choice of E. coli was based on the fact that, besides being a model bacterium with 
the genome fully sequenced and annotated, this Gram-negative bacterium is a 
facultative anaerobic that grows in oxygenated as well as in anoxic environments 
during its normal colonisation-transmission cycle within the host. Therefore, it 
allows to compare the transcriptional response to CORM-2 under both anaerobic 
and aerobic conditions. 
To confirm that the expression profile of E. coli cells exposed to CORM-2 was 
indeed due to the CO liberated by the molecule, quantitative Real-Time RT-PCR 
experiments were conducted in E. coli cells grown with the iCORM-2, a molecule 
depleted of all CO groups. In fact, it was observed that this CO-free molecule does 
not cause significant alterations in the transcription of the genes that are regulated 
by CORM-2. 
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Based on the results acquired, phenotypic studies were designed and 
performed for more than ten E. coli mutant strains that are deleted in genes whose 
expression was found to be significantly changed by CORM-2. In this way, insights 
into the biological function of CORM-2-regulated genes could be obtained. 
In general, the microarray results demonstrated that for E. coli cells grown 
under aerobic conditions the main target of CORM-2 is the aerobic respiration. This 
was an expected result, since CO is known to be an inhibitor of cytochrome 
oxidase, the terminal electron acceptor of the aerobic respiratory chain. Although 
the transcription of cytochrome oxidase was not altered by CORM-2, the 
transcription of genes encoding enzymes of the citric acid cycle (e.g. sdhCD, fumA, 
and sucB) were found to be repressed. Interesting, all the above mentioned genes 
encode proteins that contain and/or utilise metals for their biological activity. SdhC 
and SdhD are the large and the small subunits, respectively, of the succinate 
dehydrogenase, a cytochrome b556-containing protein. Fumarase (FumA) contains 
a [4Fe-4S] cluster, and SucB a subunit of 2-oxoglutarate dehydrogenase uses Mg2+ 
as co-factor. Therefore, the inhibition of citric acid cycle enzymes may result either 
from the binding of CO to the cytochrome oxidase which impairs the re-oxidation 
of NADH or from the direct binding of CO to these enzymes. 
Results acquired for E. coli grown aerobically revealed that CORM-2 also 
strongly affects the transcription of genes involved in the methionine biosynthesis 
process, up-regulating the expression of metNI and metBLF operons. The deletion 
of metR, a regulator of several genes involved in methionine biosynthesis, and of 
metN and metI, encoding two methionine transporters, were found to increase the 
susceptibility of E. coli to CORM-2. Altogether, the data suggest that methionine 
protects E. coli cells against CORM-2 through a mechanism that needs to be 
elucidated. 
Interestingly, E. coli showed to be more affected by the CORM-2 treatment 
when grown anaerobically, as judged by the higher number of repressed genes in 
comparison to those altered under aerobic conditions. In fact, these results are in 
agreement with the higher susceptibility of anaerobic E. coli cells exposed to CO-
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RMs thus showing that the CO-RM action goes far beyond the impairment of 
aerobic respiratory chain.  
Exposure of E. coli cells grown under anaerobic conditions to CORM-2 has a 
high impact on the glucose catabolic process. In particular, CORM-2 inhibits the 
transcription of several genes encoding glycolic enzymes, such as pyruvate kinase 
and phosphoglycerate kinase, both participate in the generation of ATP at the level 
of glycolysis. Interestingly, the two enzymes utilise Mg2+ as co-factor. Since in cells 
grown anaerobically the major fraction of ATP is generated glycolytically, the 
inhibition of those enzymes conduct to the depletion of ATP which probably 
contributes to the higher susceptibility that E. coli cells display upon treatment with 
CORM-2 under anaerobic conditions.  
Another work reported that the exposure of aerobically grown of E. coli cells 
to CO decreased the thymine uptake and reduced the ATP levels. The authors 
could not observed alteration in thymine incorporation and ATP concentration in 
cells grown under anaerobic conditions in the presence of CO [43, 44]. However, 
the present results do suggest that ATP level is indeed altered in E. coli cells grown 
anaerobically since among the four genes encoding glycolytic enzymes that were 
repressed by CORM-2, two of them are involved in ATP formation (pgk and pykF 
encoding phosphoglycerate kinase and pyruvate kinase, respectively).  
In addition, a significant number of genes found to be regulated by CORM-2 
in E. coli cells grown anaerobically encode proteins involved in folding, namely, 
heat-shock proteins, chaperones and proteases. The analysis of the deletion of 
cpxP and ibpAB genes, which have been induced under both conditions of growth 
in the presence of CORM-2, give rise to strains that display elevated sensitivity to 
CORM-2. CpxP is a periplasmic combat stress protein that belongs to the Cpx 
system which is involved in the sensing of perturbations occurring at the bacterial 
cell envelope and responds through the up-regulation of several gene products 
involved in protein folding and degradation [45]. IbpA and IbpB are two heat-
shock proteins that bind to protein aggregates and inclusion bodies formed during 
heterologous protein expression and contributes to the reduction of protein 
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disaggregation and degradation [46]. Hence, under anaerobic conditions CORM-2 
affects the protein homeostasis.  
The comparison of the microarray results obtained for E. coli cells grown 
aerobically with those acquired anaerobically reveals that a larger number of genes 
are regulated by CORM-2 independently of the presence of dioxygen (Table 6.6). 
The transcription of several genes encoding regulators was up-regulated by CORM-
2 aerobically and anaerobically, namely soxS, frmR, zntR, oxyR, and narP (see 
Table 6.6 for the function of these regulators) whereas, the expression of gadX 
was repressed. The phenotypic analysis of E. coli strains lacking OxyR and soxS, 
two of the genes that participate in the oxidative stress response, revealed that the 
soxS null mutant exhibits high sensitivity to CORM-2 both under aerobic and 
anaerobic conditions, while oxyR mutant only displays elevated susceptibility to 
CORM-2 under aerobic conditions. These results suggest that CORM-2 increases 
the reactive oxygen species, which, under aerobic conditions, may be link to the 
inhibition of the respiration. Nevertheless, the increase of soxS transcription as well 
as the enhanced sensitivity displayed by the soxS mutant anaerobically needs to be 
rationalised. 
CORM-2 also affects the expression of genes involved in biofilm formation, as 
jugged by the high number of CORM-2-regulated genes that were found in 
common with those whose expression was altered during the E. coli biofilm 
formation (see Table 6.A6). Hence, the total biofilm was measured in E. coli cells 
after being exposed to CORM-2. CORM-2 increases the biofilm production in E. coli 
as it also happens in the presence of several other stress agents like hydrogen 
peroxide, acid, low-temperature, and heavy metal stresses [47]. Given that 
bacterial biofilms display high resistance to antimicrobial agents by restricting 
penetration, slowing the bacterial growth owing to nutrient limitation and inducing 
the expression of genes involved in the general stress response, it is possible that 
E. coli cells exposed to CORM-2 trigger the production of biofilm as a defensive 
response [48]. 
Regarding the role of specific genes, phenotypic analysis of one of the 
biofilm-related genes, bshA, a gene that was highly induced in E. coli cells grown 
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anaerobically and treated with CORM-2, revealed that its deletion increases the 
resistance of E. coli to CORM-2, suggesting that BshA contribute to the 
susceptibility of E. coli to CORM-2 when grown under anaerobic conditions. BshA is 
reported to be a multiple stress resistance protein due to its relation with the 
increase of E. coli resistance to hydrogen peroxide, heat, acid, and cadmium. BshA 
is also proposed to be involved in the biofilm formation elicited by these stress 
agents [47]. However, we did not detect differences in the biofilm formation in 
ΔbshA cells exposed to CORM-2, when compared to the wild type, and hence 
concluded that BshA does not mediate the formation of biofilm elicited by CORM-2.  
The expression of tsqA was induced by CORM-2 treatment and the study of 
the mutant strain revealed that the deletion of this gene increases the resistance 
of E. coli to CORM-2 and abolishes the increase of biofilm-induced by CORM-2. 
TsqA is proposed to export the quorum-sensing signal autoinducer-2 and is 
involved in the bacterial susceptibility to several antibiotics, namely streptomycin 
[49]. Our results demonstrate that TqsA not only increases the E. coli sensitivity to 
CORM-2, but also participates in the biofilm formation trigged by the presence of 
CORM-2 and suggest that TsqA may potentiate the entry of CORM-2 in E. coli cells. 
The effect of CORM-3 in E. coli transcriptome was analysed by Davidge et al. 
[42]. In that study, E. coli cells grown aerobically in defined media with glycerol, 
and anaerobically in LB media supplemented with casamino acids using fumarate 
as terminal electron acceptor were treated with 30 µM and 100 µM CORM-3, 
respectively. As expected, the authors reported that the addition of CORM-3 to E. 
coli cells grown aerobically, down-regulates genes encoding proteins that form the 
aerobic respiratory complexes, namely the operon cyoABCDE encoding the 
cytochrome bo’ haem-copper terminal oxidase. On the other hand, CORM-3 up-
regulates many genes involved in zinc homeostasis, such as yodA and znuA, two 
genes that encode Zn-binding proteins. These genes were also induced in the 
microarray of the E. coli cells grown anaerobically together with zraP, a gene that 
also codes for a zinc-binding protein. 
Comparing the transcriptional response of E. coli to CORM-2 and CORM-3, 
some genes were found to be regulated in common by the two CO-RMs. For 
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example, under aerobic conditions most of the genes involved in citric acid cycle 
were repressed by CORM-2 and CORM-3, while metF, involved in methionine 
metabolism and mdtB, a multidrug efflux system, were found to be induced. Under 
anaerobic conditions, ftnA, an iron storage protein was repressed whereas zraP, a 
zinc-binding periplasmic protein and mdtA, a multidrug efflux system, were found 
to be induced by the two CO-RMs. Interestingly, the genes spy, a envelope stress 
induced periplasmic protein and cpxP, whose function was mentioned above, were 
induced in the two microarray experiments and under both growth conditions, 
suggesting that CO-RMs affect the integrity of cell envelope proteins.  
The most striking difference between the two microarray studies was that 
only CORM-3 seems to interfere with zinc homeostasis. However, Davidge and co-
workers did not found any alteration in the total amount of intracellular zinc 
content after exposing E. coli cells to CORM-3 [42]. 
The differences that are detected between the two microarray experiments 
are most probable due to the different experimental conditions used regarding the 
growth media, the type and the concentration of CO-RM, and the compound used 
in control samples. Nevertheless, the two microarray studies revealed several 
potential targets for CO-RMs action that required further investigation.  
Although CO is usually considered as a relatively inert molecule, its reactivity 
is significant with transition metals. Indeed, the data presented in this thesis 
indicate that CO is able to interfere with several genes revealing that targets other 
then haem iron need to be considered to account for the CO action. 
Taking into consideration that CO also displays anti-inflammatory activity 
(Chapter 2) by inhibiting the expression of pro-inflammatory cytokines [50-52], 
and the pro-inflammatory action, by limiting sepsis [34], the function of CO may 
appear as paradoxal. In fact, as it happens with NO, the dosage of CO seems to 
control the balance between the pro- and anti-inflammatory action during 
infection. In this work, we started by showing that the exogenous administration of 
CO gas and CO-RMs efficiently kill bacteria and the role of the endogenous 
production of CO on bacteria needs now to be explored. As mentioned before, the 
results obtained, by Chung et al., in mice deleted in HO-1 and in mice over-
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expressing the enzyme, suggest that the products of HO activity are important in 
the control of the microbial sepsis. However, they do not prove the direct 
involvement of endogenous CO production in the killing of the pathogens since HO 
activity generates apart from CO, ferrous iron and bilirubin [35]. 
The emergence and spread of drug resistance bacteria, which reveals the 
ineffectiveness of currently available antibiotics, makes the search for new 
molecules to fight pathogens of great importance. The work developed during this 
thesis reveals novel strategies to improve bacterial clearance. In particular, it is 
described a novel class of antibiotics, the CO-releasing molecules and the potential 
mechanisms by which they mediate their bactericidal action, namely by causing 
alteration at the level of aerobic respiration, methionine metabolism, regulation of 
the transcription, protein homeostasis and biofilm formation. 
Future work needs to be developed to understand how CO-RMs deliver CO to 
bacteria and why CO-RMs appear to be more effective than CO gas, as 
antimicrobial agent. The data acquired so far suggest that CO-RMs can form the 
basis for developing a novel therapeutic strategy against several pathogens. 
Nevertheless, novel CO-releasing molecules are needed, with different chemical 
characteristics to improve the bactericidal effectiveness of CO-RMs at lower 
concentrations, and to facilitate the delivery of CO to humans in a safe and more 
controlled way.  
 
7.3 References 
[1] Madigan, M.T., Martinko, J.M. and Parker, J. (2000) Biology of Microorganisms. Prentice-Hall, Inc, 
New Jersey. 
[2] McInnes, I.B., Leung, B., Wei, X.Q., Gemmell, C.C. and Liew, F.Y. (1998) Septic arthritis following 
Staphylococcus aureus infection in mice lacking inducible nitric oxide synthase. J. Immunol. 160, 308-
315. 
[3] Sasaki, S., Miura, T., Nishikawa, S., Yamada, K., Hirasue, M. and Nakane, A. (1998) Protective role 
of nitric oxide in Staphylococcus aureus infection in mice. Infect. Immun. 66, 1017-1022. 
[4] Gardner, P.R., Gardner, A.M., Martin, L.A. and Salzman, A.L. (1998) Nitric oxide dioxygenase: an 
enzymic function for flavohemoglobin. Proc. Natl. Acad. Sci. U S A 95, 10378-10383. 
[5] Membrillo-Hernandez, J., Coopamah, M.D., Anjum, M.F., Stevanin, T.M., Kelly, A., Hughes, M.N. and 
Poole, R.K. (1999) The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a 
 
General discussion 
____________________________________________________________________________________ 
 211 
"Nitric oxide Releaser," and paraquat and is essential for transcriptional responses to oxidative stress. J. 
Biol. Chem. 274, 748-754. 
[6] Svensson, L., Marklund, B.I., Poljakovic, M. and Persson, K. (2006) Uropathogenic Escherichia coli 
and tolerance to nitric oxide: the role of flavohemoglobin. J. Urol. 175, 749-753. 
[7] Ilari, A., Bonamore, A., Farina, A., Johnson, K.A. and Boffi, A. (2002) The X-ray structure of ferric 
Escherichia coli flavohemoglobin reveals an unexpected geometry of the distal heme pocket. J. Biol. 
Chem. 277, 23725-23732. 
[8] Nobre, L.S., Goncalves, V.L. and Saraiva, L.M. (2008) Flavohemoglobin of Staphylococcus aureus . 
Methods Enzymol. 436, 203-216. 
[9] Ermler, U., Siddiqui, R.A., Cramm, R. and Friedrich, B. (1995) Crystal structure of the 
flavohemoglobin from Alcaligenes eutrophus at 1.75 A resolution. Embo J. 14, 6067-6077. 
[10] Gardner, P.R. (2005) Nitric oxide dioxygenase function and mechanism of flavohemoglobin, 
hemoglobin, myoglobin and their associated reductases. J. Inorg. Biochem. 99, 247-266. 
[11] Kim, S.O., Orii, Y., Lloyd, D., Hughes, M.N. and Poole, R.K. (1999) Anoxic function for the 
Escherichia coli flavohaemoglobin (Hmp): reversible binding of nitric oxide and reduction to nitrous 
oxide. FEBS Lett. 445, 389-394. 
[12] Poole, R.K. and Hughes, M.N. (2000) New functions for the ancient globin family: bacterial 
responses to nitric oxide and nitrosative stress. Mol. Microbiol. 36, 775-783. 
[13] Gardner, A.M. and Gardner, P.R. (2002) Flavohemoglobin detoxifies nitric oxide in aerobic, but not 
anaerobic, Escherichia coli. Evidence for a novel inducible anaerobic nitric oxide-scavenging activity. J. 
Biol. Chem. 277, 8166-8171. 
[14] Crawford, M.J. and Goldberg, D.E. (1998) Role for the Salmonella flavohemoglobin in protection 
from nitric oxide. J. Biol. Chem. 273, 12543-12547. 
[15] Liu, L., Zeng, M., Hausladen, A., Heitman, J. and Stamler, J.S. (2000) Protection from nitrosative 
stress by yeast flavohemoglobin. Proc. Natl. Acad. Sci. U S A 97, 4672-4676. 
[16] Richardson, A.R., Dunman, P.M. and Fang, F.C. (2006) The nitrosative stress response of 
Staphylococcus aureus is required for resistance to innate immunity. Mol. Microbiol. 61, 927-939. 
[17] MacMicking, J., Xie, Q.W. and Nathan, C. (1997) Nitric oxide and macrophage function. Annu. Rev. 
Immunol. 15, 323-350. 
[18] Tavares, A.F., Nobre, L.S., Melo, A.M. and Saraiva, L.M. (2009) A novel nitroreductase of 
Staphylococcus aureus with S-nitrosoglutathione reductase activity. J. Bacteriol. 191, 3403-3406. 
[19] Hong, I.S., Kim, Y.K., Choi, W.S., Seo, D.W., Yoon, J.W., Han, J.W., Lee, H.Y. and Lee, H.W. 
(2003) Purification and characterization of nitric oxide synthase from Staphylococcus aureus . FEMS 
Microbiol. Lett. 222, 177-182. 
[20] Gusarov, I., Shatalin, K., Starodubtseva, M. and Nudler, E. (2009) Endogenous nitric oxide protects 
bacteria against a wide spectrum of antibiotics. Science 325, 1380-1384. 
[21] François, I.E.J.A., Cammue, B.P., Borgers, M., Ausma, J., Dispersyn, G.D. and Thevissen, K. (2006) 
Azoles: Mode of Antifungal Action and Resistance Development. Effect of Miconazole on Endogenous 
 
Chapter 7 
____________________________________________________________________________________ 
 212 
Reactive Oxygen Species Production in Candida albicans. Anti-Infective Agents in Medicinal Chemistry 5, 
3-13. 
[22] Van Cutsem, J.M. and Thienpont, D. (1972) Miconazole, a broad-spectrum antimycotic agent with 
antibacterial activity. Chemotherapy 17, 392-404. 
[23] Rautelin, H., Vaara, M., Renkonen, O.V., Kosunen, T.U. and Seppala, K. (1992) In vitro activity of 
antifungal azoles against Helicobacter pylori. Eur. J. Clin. Microbiol. Infect. Dis. 11, 273-274. 
[24] Wu, G., Corker, H., Orii, Y. and Poole, R.K. (2004) Escherichia coli Hmp, an "oxygen-binding 
flavohaemoprotein", produces superoxide anion and self-destructs. Arch. Microbiol. 182, 193-203. 
[25] Orii, Y., Ioannidis, N. and Poole, R.K. (1992) The oxygenated flavohaemoglobin from Escherichia 
coli: evidence from photodissociation and rapid-scan studies for two kinetic and spectral forms. 
Biochem. Biophys. Res. Commun. 187, 94-100. 
[26] Poole, R.K., Rogers, N.J., D'Mello R, A., Hughes, M.N. and Orii, Y. (1997) Escherichia coli 
flavohaemoglobin (Hmp) reduces cytochrome c and Fe(III)-hydroxamate K by electron transfer from 
NADH via FAD: sensitivity of oxidoreductase activity to haem-bound dioxygen. Microbiology 143 ( Pt 5), 
1557-1565. 
[27] Membrillo-Hernandez, J., Ioannidis, N. and Poole, R.K. (1996) The flavohaemoglobin (HMP) of 
Escherichia coli generates superoxide in vitro and causes oxidative stress in vivo. FEBS Lett. 382, 141-
144. 
[28] Wu, G., Wainwright, L.M. and Poole, R.K. (2003) Microbial globins. Adv. Microb. Physiol. 47, 255-
310. 
[29] De Nollin, S., Van Belle, H., Goossens, F., Thone, F. and Borgers, M. (1977) Cytochemical and 
biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob. Agents Chemother. 11, 
500-513. 
[30] Bossche, H.V., Lauwers, W., Willemsens, G., Marichal, P., Cornelissen, F. and Cools, W. (2006) 
Molecular basis for the antimycotic and antibacterial activity of N-substituted imidazoles and triazoles: 
The inhibition of isoprenoid biosynthesis Pesticide Science 15, 188-198. 
[31] Helmick, R.A., Fletcher, A.E., Gardner, A.M., Gessner, C.R., Hvitved, A.N., Gustin, M.C. and 
Gardner, P.R. (2005) Imidazole antibiotics inhibit the nitric oxide dioxygenase function of microbial 
flavohemoglobin. Antimicrob. Agents Chemother. 49, 1837-1843. 
[32] McElhaney-Feser, G.E., Raulli, R.E. and Cihlar, R.L. (1998) Synergy of nitric oxide and azoles 
against candida species in vitro. Antimicrob. Agents Chemother. 42, 2342-2346. 
[33] Brashears, M.M. and Brooks, M.M. (2006) Effect of meat packaging technologies on the safety and 
spoilage-indicating characteristics of ground beef - phase 1: safety characteristics. 
[34] Otterbein, L.E., May, A. and Chin, B.Y. (2005) Carbon monoxide increases macrophage bacterial 
clearance through Toll-like receptor (TLR)4 expression. Cell Mol. Biol. (Noisy-le-grand) 51, 433-440. 
[35] Chung, S.W., Liu, X., Macias, A.A., Baron, R.M. and Perrella, M.A. (2008) Heme oxygenase-1-
derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J. Clin. 
Invest. 118, 239-247. 
 
General discussion 
____________________________________________________________________________________ 
 213 
[36] Desmard, M., Davidge, K.S., Bouvet, O., Morin, D., Roux, D., Foresti, R., Ricard, J.D., Denamur, E., 
Poole, R.K., Montravers, P., Motterlini, R. and Boczkowski, J. (2009) A carbon monoxide-releasing 
molecule (CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival 
in an animal model of bacteraemia. Faseb J. 23, 1023-1031. 
[37] Nobre, L.S., Seixas, J.D., Romao, C.C. and Saraiva, L.M. (2007) Antimicrobial action of carbon 
monoxide-releasing compounds. Antimicrob. Agents Chemother. 51, 4303-4307. 
[38] Motterlini, R., Clark, J.E., Foresti, R., Sarathchandra, P., Mann, B.E. and Green, C.J. (2002) Carbon 
monoxide-releasing molecules: characterization of biochemical and vascular activities. Circ. Res. 90, 
E17-24. 
[39] Motterlini, R., Mann, B.E. and Foresti, R. (2005) Therapeutic applications of carbon monoxide-
releasing molecules. Expert. Opin. Investig. Drugs 14, 1305-1318. 
[40] Foresti, R., Bani-Hani, M.G. and Motterlini, R. (2008) Use of carbon monoxide as a therapeutic 
agent: promises and challenges. Intensive Care Med. 34, 649-658. 
[41] Vera, T., Henegar, J.R., Drummond, H.A., Rimoldi, J.M. and Stec, D.E. (2005) Protective effect of 
carbon monoxide-releasing compounds in ischemia-induced acute renal failure. J. Am. Soc. Nephrol. 16, 
950-958. 
[42] Davidge, K.S., Sanguinetti, G., Yee, C.H., Cox, A.G., McLeod, C.W., Monk, C.E., Mann, B.E., 
Motterlini, R. and Poole, R.K. (2009) Carbon monoxide-releasing antibacterial molecules target 
respiration and global transcriptional regulators. J. Biol. Chem. 284, 4516-4524. 
[43] Weigel, P.H. and Englund, P.T. (1975) Inhibition of DNA replication in Escherichia coli by cyanide 
and carbon monoxide. J. Biol. Chem. 250, 8536-8542. 
[44] Cairns, J. and Denhardt, D.T. (1968) Effect of cyanide and carbon monoxide on the replication of 
bacterial DNA in vivo. J. Mol. Biol. 36, 335-342. 
[45] Danese, P.N. and Silhavy, T.J. (1998) CpxP, a stress-combative member of the Cpx regulon. J. 
Bacteriol. 180, 831-839. 
[46] Lethanh, H., Neubauer, P. and Hoffmann, F. (2005) The small heat-shock proteins IbpA and IbpB 
reduce the stress load of recombinant Escherichia coli and delay degradation of inclusion bodies. 
Microb. Cell Fact. 4, 6. 
[47] Zhang, X.S., Garcia-Contreras, R. and Wood, T.K. (2007) YcfR (BhsA) influences Escherichia coli 
biofilm formation through stress response and surface hydrophobicity. J. Bacteriol. 189, 3051-3062. 
[48] Ito, A., Taniuchi, A., May, T., Kawata, K. and Okabe, S. (2009) Increased antibiotic resistance of 
Escherichia coli in mature biofilms. Appl. Environ. Microbiol. 75, 4093-4100. 
[49] Herzberg, M., Kaye, I.K., Peti, W. and Wood, T.K. (2006) YdgG (TqsA) controls biofilm formation in 
Escherichia coli K-12 through autoinducer 2 transport. J. Bacteriol. 188, 587-598. 
[50] Kim, H.P., Ryter, S.W. and Choi, A.M. (2006) CO as a cellular signaling molecule. Annu. Rev. 
Pharmacol. Toxicol. 46, 411-449. 
[51] Otterbein, L.E., Bach, F.H., Alam, J., Soares, M., Tao Lu, H., Wysk, M., Davis, R.J., Flavell, R.A. and 
Choi, A.M. (2000) Carbon monoxide has anti-inflammatory effects involving the mitogen-activated 
protein kinase pathway. Nat. Med. 6, 422-428. 
 
Chapter 7 
____________________________________________________________________________________ 
 214 
[52] Morse, D., Pischke, S.E., Zhou, Z., Davis, R.J., Flavell, R.A., Loop, T., Otterbein, S.L., Otterbein, 
L.E. and Choi, A.M. (2003) Suppression of inflammatory cytokine production by carbon monoxide 
involves the JNK pathway and AP-1. J. Biol. Chem. 278, 36993-36998. 
 
 
